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SUMMARY 
The aim of this work was to investigate immune modulation with a particular focus on 
airway inflammation and allergic pathogenesis.  This was probed in a model of pathogen 
driven immunomodulation (B. pertussis), and two models of therapeutic intervention namely 
immunisation (attenuated B. pertussis, BPZE1) or using a candidate cell therapy approach 
(mesenchymal stem cells, MSC).  
This work demonstrated that, in contrast to virulent B. pertussis, an attenuated, 
candidate vaccine strain of B. pertussis, BPZE1, did not enhance but rather reduced allergen-
driven airway pathology supporting findings that suggest allergic asthma is linked not just to 
a CD4
+
 T cell profile, but also to the degree of airway damage at the time of priming.  The 
second approach sought to ascertain whether a candidate stem cell therapy could modulate 
immunity in vivo to a degree that was sufficient to suppress allergic lung inflammation.  The 
work presented here demonstrated that adult bone marrow-derived allogeneic MSC actively 
prevent the induction of allergen driven pathology in a murine model.  Prior stimulation of 
MSC with IFN-γ increased their protective effect.  An increase in IL-10 as a result of MSC 
delivery suggested a role for MSC in Treg induction.  The immune mechanisms by which 
MSC confer protection in this model were probed and demonstrated that MSC generate the 
expansion of Treg subsets, CD4
+
FoxP3 and CD8
+
 γ/δ T cells, in the lung.  Moreover, 
expansion of Treg was proven to exert a functional effect as depletion of these cells resulted in 
a negation of the protective effect of MSC.  In an experimental asthma model, where mice 
devoid of naturally occurring Treg, delivery of MSC fails to impair the development of 
allergic airway pathology and class switching to IgE.   
A reduction in airway eosinophilia in the absence of regulatory T cells suggested an 
alternative mechanism of protection employed by MSC.  Pre-incubation with MSC inhibited 
the expression of important adhesion markers on eosinophils which most likely affected their 
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ability to migrate as demonstrated by the inhibitory effect on their chemotactic migration. 
These data suggests a critical role for soluble factor secretion by MSC contributing to the 
reduction of airway eosinophilia.  Collectively, these data provides a fundamental insight into 
novel therapeutic approaches that can profoundly influence the allergic airway response. 
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1.1 THE CAPACITY TO ADAPT: THE EVOLUTIONARY BENEFIT CONFERRED BY  
MAMMALIAN IMMUNITY 
 Adaptation is the hallmark of mammalian and vertebrate immunity.  A 
combination of exquisite specificity and powerful immunological memory distinguishes 
adaptive immunity from non-vertebrate defence based on the innate responses (Burnet, 
1968).  Adaptive immunity confers a powerful selective advantage allowing protection 
against pathogens and the opportunity for protective immunisation (Baumgarth, 2005).  
To achieve this within the coding capacity of the mammalian genome requires clonal 
selection and an elegant gene recombination system first predicted by Dreyer and Bennett 
(Dreyer, 1965) and shown by Tonegawa in 1976 (Hozumi, 1976).  The drawback, 
however, is such that an approach requires an editing and selection system that limits the 
possibility for autoimmunity, allergy or transplant rejection (Sakaguchi, 1995).  
Consequently, control or modulation of immunity is a central feature of the adaptive 
immune response.  A variety of inhibitory mechanisms and pathways are employed to 
control both the innate and adaptive immune response as well as to ensure immune 
tolerance and homeostasis (Fehervari, 2004).  In a broad sense, such inhibitory pathways 
appear to be highly specialised and compartmentalised (Hori, 2003).  However, this 
complexity presents both opportunities and challenges in targeting these pathways in the 
treatment of immune-mediated diseases.  The development of clinically applicable 
strategies to harness the potency of inhibitory pathways for therapeutic purposes remains 
a major challenge.  The purpose of this work was to employ novel non-chemotherapeutic 
approaches in an attempt to disrupt the pathogenesis of an inappropriate immune response 
(allergic asthma) and to understand the underlying mechanisms of efficacy.  
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1.1.1 THE INTERPLAY BETWEEN IMMUNE PROTECTION AND REGULATION 
The adaptive immune system is composed of many interdependent processes and cell 
types which collectively protect the body from viral, parasitic, bacterial and fungal infections.  
It links specific antigen recognition to innate effector systems and provides provision for 
immunological memory.  Although protection against infection is the prime benefit of 
immunity (Ahmed, 1996), pathologies are also associated with misdirected immune 
responses against antigens.  Abnormal immune responses in the absence of infection occur in 
allergy or hypersensitivity, (where the antigen may be an innocuous foreign substance), in 
autoimmune disease, (where the response is to self antigen), or in graft rejection, (where the 
antigen is the non-autologous cell).  In order to induce desirable and specific responses, 
immunisation is critical.  This may invoke antibody-mediated immunity that links to effector 
functions such as complement activation, neutralisation or opsonisation (van de Winkel, 
1991) and/or  the cell-mediated response where host cells present antigenic epitopes via 
polymorphic MHC molecules to induce cytotoxicity (via CD8
+
 cytotoxic T lymphoctes 
(CTL)) and coordination functions via CD4
+
 helper T cells.  As the coordination function of 
the T cell is central to the appropriateness and efficacy of adaptive immunity, it is this 
response which will be a major focus of this work.  
 
1.1.2 CD4
+
 T HELPER CELLS: CONDUCTING THE IMMUNE ORCHESTRA 
Early discoveries of acquired immune-deficiencies induced by HIV have dramatically 
shown the important co-ordinating function of CD4
+
 T cells in adaptive immunity (Koup, 
1994).  Antigen presentation by antigen presenting cells (APC, such as DC) to CD4
+
 T cells 
results in activation and differentiation of these cells into several specific functional subsets 
(Mosmann, 1986).  Each subset is defined by its‟ specific cytokine secretion profile and the 
functional effects they direct (summarised in Table 1.1).  Th1 cells orchestrate protection 
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from intracellular pathogens and are defined by the production of IFN-γ, IL-2, TNF-α, TNF-β 
and lymphotoxin (Mosmann, 1989).  They are the principle effector of pro-inflammatory 
reactions, delayed-type hypersensitivity and cell-mediated immunity against intracellular 
pathogens such as Mycobacterium tuberculosis and Listeria sp.  In contrast, Th2 cells are 
characterized by the production of IL-4, IL-5, and IL-13 and mediate protection from 
extracellular parasites (Mosmann, 1989; Medoff, 2008).  Unlike Th1 immunity, the Th2 
response is often associated with humoral responses which produce high levels of pathogen-
specific immunoglobulin generated to neutralise foreign organisms.  Consequently, Th2 
responses are important for resistance against extracellular pathogens such as helminths 
(Sher, 1992).  
Th17 cells are a more recently described subset.  These cells are characterised by the 
production of IL-17 and are associated with the clearance of extracellular bacteria and fungi 
(Bettelli, 2007; Bettelli, 2008).  They are responsible for, or participate in, the induction of 
many organ-specific autoimmune diseases.  These cells have critical roles in host defence 
against extracellular bacteria and also play pivotal roles in the pathogenesis of autoimmune 
disease.  Th17 cells produce a range of cytokines including TNF, IL-17A, IL-17F, IL-21 and 
IL-22.  Recent advancements in T cell biology have also discovered a variety of suppressive 
or regulatory T cell (Treg) subsets that either develop as a normal part of the immune response 
(naturally occurring Treg) or in response to antigenic stimulation (adaptive Treg) (Bluestone, 
2003).  Naturally-occurring Treg constitutively express high levels of surface CD25.  These 
cells are characterized by the expression of IL-10 and TGF-β and can actively suppress 
proliferation and cytokine production from other effector T cells (Fehervari, 2004).  They 
owe their suppressive phenotype, in part, to the expression of high levels of forkhead 
transcription factor FoxP3, as removal of FoxP3 diminishes their ability to suppress, whilst 
addition of FoxP3 to CD25 negative effector T cells confers suppressive function upon them 
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(Fontenot, 2003; Hori, 2003; Wan, 2007).  Recent studies have shown that TGF-β, in the 
presence of IL-4 re-programmes Th2 differentiation and leads to the development of a new 
population of Th9 cells that produce IL-9 and IL-10 (Dardalhon, 2008).  Th9 cells lack 
suppressive function and promote tissue inflammation.  Adoptive transfer of Th9 cells into 
recombination-activating gene 1-deficient mice induced colitis and peripheral neuritis 
(Dardalhon, 2008).  Follicular helper T cells (Tfh) cells can develop independently of other 
effector T cell subsets but almost certainly also derive from T cell types such as Th1, Th2 or 
Th17 cells. Tfh cells provide help to B cells and support antibody class switching in germinal 
centres and are mostly defined by their follicular localisation, which is dictated by the 
expression of CXC chemokine receptor 5 (CXCR5).   
Although classically viewed as distinct lineages, studies have called into question 
whether helper CD4
+
 T cell subsets are really distinct lineages, and if so how plastic are they 
in modifying their committed state (O‟Shea, 2010).  There are now abundant examples of this 
flexibility in terms of cytokine production (Zhou, 2009).  For example, IL-10 was first 
recognised as a Th2-type cytokine; however, it is known that Th1, Th17 and Treg can all 
produce IL-10.  Similarly, T cells that express FoxP3 and RORγt, transcription factor 
associated with Th17 cell differentiation, have also been described.  FoxP3
+
Treg that become 
IL-17 producers can express the Th1 cell-associated transcription factor Tbet or make IFN-γ 
(Xu, 2007).  Table 1.1 summarises each CD4 T helper cell and their functions. 
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Table 1.1 Summary of T cell subsets. 
 
T cell 
subset 
Cytokines produced Transcription 
factor 
Polarising 
Signals  
Effector Function 
Th1 IFN-γ, IL-2, LTα Tbet/Stat4 IL-12, IFN-γ Macrophage activation, 
autoimmunity 
Th2 IL-4, IL-5, IL-13, 
IL-25, Amphiregulin 
GATA-3/Stat5 IL-4, IL-2 Extracellular parasites, 
allergy and asthma 
Treg TGF-β, IL-35, IL-10 FoxP3/Stat5 TGF-β, IL-2 Immune tolerance, 
regulation of immune 
responses, lymphocyte 
homeostasis 
Th17 IL-21, IL17a, IL-17, 
IL-22 
RORγt/Stat3 TGF-β (IL-1), 
IL-6, IL-21, IL-
23 
Extracellular bacteria, fungi 
Autoimmunity 
Th9 IL-9, IL-10 Not known TGF-β, IL-4 Tissue inflammation 
 
Tfh IL-21, IL-6 BCL6 CXCR5, IL-6, 
IL-21 
Autoimmunity 
Th22 IL-22, TNF-α, IL-13 RORC IL-6, TNF-α Inflammatory skin disorders 
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1.2 INFLAMMATION, REMODELLING AND REPAIR IN THE AIRWAYS 
At the exposed external surfaces of the body such as the airways, the epithelium and 
immune system interact to defend against the numerous potentially harmful physical, 
chemical and biological agents present in the environment (Eder, 2006).  The human lung is 
comprised of a large surface area for gas exchange, and is forty times the surface of the next 
largest epithelial organ, the skin (Warburton, 1998).  It presents an estimated area of 100m
2
 
that comes into contact with approximately 10,000L of environmental air during normal 
breathing each day (Elad, 2008).  The bronchial epithelium acts as a semi-permeable barrier 
between the external environment and the inner bronchus, and is, therefore, particularly 
vulnerable to damage.  There exists an array of cellular defences designed to limit the 
continual and inevitable threat of damage arising from the interaction between insult, and the 
tissue‟s molecular and cellular components.  The cells of the innate, adaptive immune system 
and epithelium produce mediators that constitute airway inflammation (Holgate, 2000; 
Hackett, 2007).   
Insult or disruption to the mature airway epithelium, as a result of inhaled particles, 
pathogens or inflammatory respiratory disease, must be repaired without delay.  In the 
absence of repair, extensive changes in the architecture of the airway walls occur.  Damaged 
cells are shed into the airway lumen, and the basement membrane becomes exposed.  
Epithelial cells at the edge of the “wound” or damaged area proliferate, flatten and migrate 
over the denuded basement membrane in order to protect the exposed airway (Erjefalt, 1997; 
Sacco, 2004).  This process, termed “remodelling” of the epithelial structure is accompanied 
by goblet cell hyperplasia, immune cell recruitment, proliferation of fibrocytes (fibrosis) and 
proliferation of smooth muscle cells which leads to extracellular matrix (ECM) deposition.  
These processes all function to „seal‟ the exposed site of injury (Erjefalt, 1997), re-establish 
21 
 
epithelial integrity and eventually restore normal airway function (Sacco, 2004) if 
appropriately controlled. 
The airway epithelium is not inert in this process however.  In asthma, the airway 
epithelium is a major source of cytokines and chemokines that are strongly implicated in 
maintaining asthmatic inflammation including IL-5, RANTES, eotaxin, macrophage 
chemotactic peptides and TSLP which are all potent stimuli for polarising the immune 
response towards Th2 (Bals, 2004), thus demonstrating how the epithelium can provide a 
microenvironment to sustain ongoing Th2-like inflammation (Bals, 2004).  Following injury 
of the lung epithelium, the regeneration and repair process begins rapidly where damage 
recruits the cells involved in regeneration, inducing their proliferation, differentiation and 
recruitment to the site of injury (Sacco, 2004). The repairing epithelium sees a transitory 
squamous metaplasia followed by progressive re-differentiation in order to restore a 
pseudostratified and mucociliary epithelium (McDowell, 1979).  During chronic 
inflammatory diseases, restoration of the epithelial tissue architecture by the above 
mechanism is diminished.  It is suggested that the „normal‟ epithelial repair processes may be 
overwhelmed and alternatively contribute to the pathogenesis of inflammatory airway disease 
(Erjefalt, 1997).  Increased ECM deposition, immune cell infiltration, fibroblast and airway 
smooth muscle cell components, airway obstruction and a decrease in airway function are all 
common clinical pathophysiological features found in many inflammatory lung diseases 
including asthma, pulmonary fibrosis and adult respiratory distress syndrome (Holgate, 
2000).  These abnormal pathophysiologies remain unresolved, and may result in permanent 
loss of airway function and chronic disease. 
 
1.2.1 ASTHMA AND ALLERGIC DISEASE 
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Asthma is one of the most common chronic inflammatory diseases and affects an 
estimated 300 million people worldwide (Galli, 2008).  The pathogenesis of allergic asthma 
remains unclear; however, the current understanding is that allergic asthma involves two 
components: an aberrant remodelling response and the expansion of CD4
+
 Th2 allergen 
driven inflammation.  Genetic predisposition, coupled with environmental influences, 
appear to affect the regular suppression of Th2-mediated responses (Holgate, 2008).  It has 
been hypothesised that abnormalities in the maturation of the lung during foetal and 
neonatal development may also render the airways more susceptible to environmental 
allergens, favouring polarisation towards the Th2 phenotype and thus, predisposing the 
individual to atopy and asthma (Holgate, 2000; Wark, 2005).  Allergen-driven production of 
IL-4, IL-5 and IL-13 are typical of allergic pathologies and the secretion of such Th2-
cytokines initiates isotype class-switching of B cells towards IgE and recruitment of 
eosinophils to the airways (Holgate, 2008).  An important and consistent feature of chronic 
asthma is the production of excess mucus that blocks peripheral airways and is difficult to 
expectorate.  The pathophysiology of asthma is complex and influenced by several factors, 
including genetic susceptibility (Finkelman, 2010), the nature of the antigen that initiates 
the response and the possible co-exposure with bacteria or viruses which stimulate the 
innate immune response (Wenzel, 2006). 
 
1.2.2 THE PATHOLOGY ASSOCIATED WITH ASTHMA 
Histopathological studies in asthmatic patients have established that asthma is a 
disease involving the central and peripheral airways (Saetta, 2001).  The process includes 
structural (remodelling, thickening of airway wall) and cellular changes (inflammation at 
the airway wall).  There is considerable overlap between the airway remodelling, and 
airway inflammation.  Airway remodelling encompasses numerous alterations to the 
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airways including epithelium detachment (Naylor, 1962), an increase in the mass of airway 
smooth muscle, goblet cell and submucosal gland enlargement (Carroll, 1993), airway 
fibrosis, decreased cartilage integrity (Haraguchi, 1999), proliferation in blood vessels and 
airway edema (Sumi, 2007).  These all contribute to a thickening of the airway wall.  Goblet 
cell metaplasia involving the conducting airways (Ordenez, 2001) is common, however in 
chronic persistent disease, goblet cells also spread down to the more peripheral airways 
where they normally do not exist (Shimura, 1996).  In addition, submucosal glands are 
larger and contain a greater proportion of mucin compared with serous cells (Green, 2010).  
These changes are linked to an ongoing chronic inflammatory process that involves the 
differentiation of CD4
+
 T cells leading to the migration and activation of eosinophils, 
neutrophils and mast cells (Swain, 1990; Metcalfe, 1997).  Recent data suggest that airway 
remodelling is not a direct effect of Th2 cytokine secretion, but due to abnormal injury and 
repair mechanisms arising from a genetic susceptibility to innocuous environmental 
allergens (Holgate, 2000; Wark, 2005; Holgate, 2007).  The epithelial-mesenchymal trophic 
unit (EMTU) is thought to become reactivated due to over-expression of TGF, EGF and 
other nerve growth factors, thus accounting for airway remodelling.  This has sparked 
debate over whether development of allergic asthma is due to a primary abnormality or 
whether it is acquired later in life. 
Airway hyperresponsiveness (AHR) refers to the exaggerated response of the airways 
to external stimuli and is a key feature of asthma, although it is not exclusive to asthma, as 
AHR can present in other chronic airway diseases including cystic fibrosis  (van Haren, 
1995) and chronic obstructive pulmonary disorder (Postma, 1998).  AHR is measured by 
assessing the lung response to inhaled stimuli, such as histamine or methacholine.  The 
development of AHR is still poorly understood.  Airway remodelling and inflammation 
contribute to AHR however none are directly implicated in its‟ onset (Wilder, 1999).   
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Airway inflammation is a multicellular process where an overabundance of 
eosinophils is the most striking feature (Kay, 2005).  Eosinophils contribute to the allergic 
response by selective migration to specific sites within inflamed tissue through interactions 
between adhesion molecules on their surface and counter-ligands on tissue structures.  
Following accumulation at sites of inflammation, activated eosinophils degranulate to 
release cationic proteins and lipid mediators associated with local tissue damage and 
airway hyperreactivity (Gleich, 1988; Djukanovic, 1990).  Ultrastructural studies have 
demonstrated extensively degranulated eosinophils in the airway tissue during active 
disease (Djukanovic, 1990; Erjefalt, 1998).  The release of mediators such as histamine 
and cysteinyl leukotrienes from eosinophils and mast cells, trigger bronchoconstriction, 
airway oedema and mucus secretion, collectively contributing to the chronic inflammatory 
response which is fundamental to asthma pathogenesis (Holgate, 2008). 
 
1.2.3 THE IMMUNE RESPONSE IN ASTHMA 
A fundamental feature of asthma is the ability to recognise innocuous environmental 
allergens and respond to this by generating Th2 cytokines.  The dominant type of T-cell 
present in asthmatic airways is Th2 (Anderson, 2002), and it is the secretion of Th2 cytokines 
that results in the recruitment of mast cells, basophils and eosinophils.  These cell types 
collectively contribute to the persistent chronic inflammatory response.  This results from 
engagement of T cells with allergen-loaded antigen presenting dendritic cells (DC) (Mellman, 
2001).  A network of DC are located under the airway epithelium where they can survey the 
airways for invading pathogens and inhaled antigens (Holt, 1990; Huh, 2003).  This process 
is intensified by IgE bound to high affinity receptors on the surface of antigen-presenting 
cells (Kitamura, 2007) including basophils which are now seen as key APC in this condition 
(Maddur, 2009; Sokol, 2009).  When sufficiently stimulated, airway APC such as DC 
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migrates to the draining lymph node to induce T cell responses (de Jong, 2005).   The skew 
towards the production of Th2 lymphocytes largely depends on the secretion of IL-12 by DC.   
IL-12 has an essential role in Th1 development and has therefore also been considered as a 
potential therapy for asthma (Kuipers, 2004).  However, whilst IL-12 can counteract Th2 
sensitisation, it can also contribute to maximal expression of allergic airway disease post-
sensitisation phase, exhibiting enhanced recruitment of CD4
+ 
T cells and eosinophils 
combined with upregulation of Th2 cytokines (Meyts, 2006).  Once sensitised, T cells 
migrate back to the airways to the site of antigen presentation under the influence of 
chemokines including CCL11, CCL24, CCL26, CCL7, CCL13, CCL17 and CCL22, where 
they secrete a range of inflammatory cytokines such as IL-4, IL-5, IL-6, IL-9 and IL-13 (Kay 
2006).  Macrophages, dendritic cells, smooth muscle and epithelial cells produce IL-1β and 
CD4
+
 T cells further enhance antigen induced T cell proliferation through the production of 
IL-2 (Anderson, 2002; Schmitz, 2003; Dragon, 2006). 
It is thought that adjuvant signals from airway epithelium, generated in response to 
inhaled stimuli, influence the migration and maturation state of DC and T cells, and helps 
determine whether a particular antigen will trigger a T cell-mediated inflammatory response 
(Herrick, 2003; Huh, 2003; Piggott, 2005).  After the initial sensitisation to an allergen, re-
exposure results in a rapid exacerbation of allergic airway inflammation.  Inhaled allergen 
binds to preformed IgE and IgG in the airways and stimulates mast cells and macrophages to 
release histamine and produce leukotrienes, TNF, and Th2 cytokines (Djukanovic, 1990).  
Not only are cytokines involved in maintaining the chronic inflammatory process, they are 
also responsible for the initiation of the early stages of this process.  It is not simple to 
classify the numerous cytokines that are potentially involved in asthma because of their 
pleiotropic nature and overlapping properties. The early-phase of an asthmatic reaction is 
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initiated within minutes, and is subsequently followed several hours later by a late-phase 
reaction characterised by an influx of eosinophils and memory T cells into the airways.   
 
1.2.4 T CELL SUBSETS IN ASTHMA - BEYOND TH2 
Depending on the nature of the stimulus, naïve T cells differentiate into Th1, Th2, 
Th17, the recently discovered Th9 effector cells or indeed regulatory cells.  The role of Th2 
cells in controlling and perpetuating chronic inflammation in asthma has received much 
attention and has been described above.  Zhao et al have recently suggested a link between 
Th17 cells and the pathogenesis of allergic asthma (Zhao, 2010) where increasing levels of 
these cells correlated with increasing severity of the disease in asthmatic patients.  Levels of 
IL-17 mRNA were increased in the sputum of asthmatics (Bullens, 2006), whilst an increase 
in the production of IL-17 in allergic asthmatic individuals was also observed in response to 
allergic stimuli (Barczyk, 2003, Hashimoto, 2005, Molet, 2001).  Similar results have been 
seen in mice, where sensitisation induced a strong Th17 response in combination with airway 
inflammation, thus demonstrating a role for IL-17 in allergic airway inflammation (He, 
2009).  However, a dual effect of IL-17 in allergic asthma has also been demonstrated which 
shows that it is essential during sensitisation in order to establish disease, but negatively 
regulates established allergic responses via inhibition of DC and chemokine synthesis 
(Schnyder-Candrian, 2006).  Mucosal
 
IL-17 administration inhibited asthma by reducing the 
production of IL-5 and the chemokines TARC and eotaxin, which
 
control eosinophil 
recruitment and asthma (Schnyder-Candrian, 2006).  The potential role of regulatory T cells 
in asthma is discussed below. 
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Figure 1.2 Inflammatory cells involved in allergic asthma. Repeated chronic allergen 
exposure leads to bronchial inflammation, lung remodelling and hyperreactivity. Following 
allergen uptake and processing by antigen-presenting cells (APC), allergen peptides are 
presented via MHC class II to Th2 T cells contributing to the secretion of Th2 cytokines. This 
leads to the activation of mast cells by allergen-specific IgE and the migration of eosinophils 
through the bloodstream to the lung mucosa, where they induce bronchial epithelium damage via 
the secretion of cytotoxic by-products. Th2 cytokine-dependent inflammation and epithelial 
activation results in airway remodelling, characterized by thickening of the basement membrane, 
mucus hypersecretion and smooth muscle cell proliferation. 
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1.3 THERAPEUTIC INTERVENTION IN ASTHMA 
 Asthma cannot be cured by any current medication; however symptoms can be 
suppressed and alleviated.  Pharmacotherapy remains the cornerstone of treatment (British 
Thoracic Society, 2008) but once the drug is discontinued, the disease manifestations are 
likely to return (Guilbert, 2006).  Table 1.2 provides an overview of the medications currently 
used in the management of asthma.  Inhaled corticosteroids (ICS) are general anti-
inflammatory agents that specifically target airway inflammation, whereas β-agonists are 
bronchodilators with a different but complementary mechanism of action that target 
bronchoconstriction of the airway smooth muscle (Lulich, 1988).  Short-acting β-agonists 
provide immediate symptom relief, whilst long-acting β-agonists provide more sustained 
respite and are generally used in combination with ICS therapy Leukotriene modifiers 
block the leukotriene pathway (proinflammatory lipid mediators that promote airway smooth 
muscle contraction, among other inflammatory activities) and demonstrate both anti-
inflammatory and broncho-dilating activity.  Omalizumab, a recombinant humanised 
monoclonal anti-IgE antibody binds specifically to free IgE blocking the subsequent 
downstream cascade of inflammatory events (Hanania, 2008).  However, long-term usage of 
pharmaco or chemotherapies does not appear to induce fundamental changes in immune 
responsiveness or alter the natural history of asthma (Bisgaard, 2006; Guilbert, 2006).  
Therefore, the need to develop strategies to permanently reverse immunologic reactivity and 
chronic airway inflammation has become increasingly important. 
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1.3.1 IMMUNOTHERAPY 
 Specific-immunotherapy (allergen-SIT) has been used as a desensitising therapy 
for almost a century.  The first study to inhibit grass pollen allergy by subcutaneous 
injection of grass pollen extract was demonstrated in 1911 (Noon, 1911).  Allergen-SIT 
involves the administration of repeated and increasing doses of the sensitising allergen.  
Continuous treatment establishes a state of anergy in peripheral T cells.  This T cell 
tolerance is characterised by the generation of allergen-specific Treg cells which can 
suppress proliferative and cytokine responses (Francis, 2003; Akdis, 2006) which 
represents an essential step in the healthy immune response to allergen.  Peripheral T cell 
tolerance is initiated by the increased autocrine effect of allergen-specific Treg that produce 
high levels of anti-inflammatory cytokines IL-10 and TGF-β (Akdis, 1998; Jutel, 2003).  
Novel and promising SIT vaccines use recombinant proteins, peptides and hybrid allergens 
in an effort to improve efficacy and safety.  The use of short peptide epitopes that do not 
allow for IgE cross-linking work to bypass the typical IgE-binding process, targeting 
instead pinocytic and phagocytic antigen uptake mechanisms in dendritic cells and 
macrophages (Akdis, 2001).  This induces T cell tolerance involving Treg without the 
effector cell degranulation effect that occurs as a result of IgE-facilitated antigen 
presentation.  As a result, this allows higher doses of allergen to be administered without 
the risk of anaphylaxis (Akdis, 2001). 
 
1.3.2 INFECTION AND ASTHMA:  THE HYGIENE HYPOTHESIS 
The reasons for the increasing prevalence of allergic respiratory diseases in developed 
countries and in undeveloped countries that develop a Western lifestyle remain unclear (Eder, 
2006).  However, the reported increase in atopy inversely correlates with a steady decline in 
the extent to which people in Western societies are exposed to infectious diseases such as 
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whooping cough, measles, tuberculosis, and influenza (Cookson, 1997).  Allergic diseases 
appear to increase with advancing socioeconomic development and occur more frequently in 
industrialized countries than in developing areas (Eder, 2006).  Whereas, a higher level of 
exposure to pathogens associated with an agricultural lifestyle prevent the development of 
allergic disorders in children (Von Ehrensetin, 2000).  The lack of stimulation of Th1 cells in 
response to viral or bacterial infection with a subsequent deviation to Th2 immune responses 
founded the biological basis of the hygiene hypothesis, first theorised by Strachan in 1989, 
suggesting an association between an increasing prevalence of allergic diseases with 
decreased exposure to infectious agents in early childhood (Strachan, 1998).  The reduced 
exposure to infection was linked to numerous variants including; a reduction in family size, 
less exposure to pets, and “higher standards of personal cleanliness”.   
Viral but not all bacterial respiratory infections precipitate reactive airway symptoms 
(Johnston, 1995).  Lipopolysaccharide (LPS) or endotoxin is a major component of the outer 
membrane of ubiquitous gram-negative bacteria.  Gram-negative infections constitute a 
significant proportion of clinical respiratory tract infections among children in early life, thus, 
there is ongoing and chronic environmental exposure to gram-negative organisms and their 
products.  Gereda et al reported the first direct in vivo evidence that environmental exposure 
to LPS early in life (i.e. before polarised Th cell responses are established) protects against 
allergen sensitisation (Gereda, 2000).  This study found significantly lower concentrations of 
LPS in the homes of allergen-sensitised infants when compared to those of non-sensitised 
infants and that this reduction was associated with a decrease in IFN-γ-producing Th1 cells.  
Since CD4
+
 Th2 cells co-ordinate some allergies, it was suggested that the induction of 
counterbalancing responses might prevent the subsequent development of atopic disease 
(Strachan, 2000; Romagnani, 2004).  LPS was suggested as a potential regulator of the 
allergic response.  Microbial exposure activates innate immune pathways that alter Th1, Th2 
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and Treg responses.  This results in the suppression of T helper 2 cell expansion, and a 
consequent inhibition of isotype switching to IgE.  Thus, the triggering of normal postnatal 
maturation through exposure to infections and/or commensal microbial stimuli, particularly 
in the gastrointestinal tract (Sudo, 1997), helps to skew the immune response away from 
allergic phenotype and towards the normal non-atopic immune response (Liu, 2001).  
                                
1.3.3 ASTHMA AS A DISEASE OF ABSENT REGULATION  
 Regulatory T cells have been recognised as playing a major role in asthma (Suto, 
2001; Strickland, 2006). The primary function of regulatory T cells (Treg) is to control 
immune responsiveness.  Sakaguchi et al demonstrated that depletion of CD4
+
CD25
+
 T cells 
in mice resulted in the development of autoimmune pathology, which was prevented by the 
re-introduction of this cell type (Sakaguchi, 1995).  Treg are active in several disease models 
and have been shown to reverse established inflammation (Akbari, 2002; Najafian, 2003; 
Kearly, 2008).  Naturally occurring Treg are thymic-derived and are thought to play an 
important part in immune tolerance (Sakaguchi, 2005).  A second population of CD4
+
CD25
+
 
Treg can be induced and expanded both in vitro and in vivo through antigenic stimulation 
(Bluestone, 2003).  Both subsets have been shown to regulate immune response through IL-
10 and TGF-β-dependent mechanisms (Jutel, 2003).  The role of Treg in asthma remains 
controversial with conflicting reports (Suto, 2001; Jaffar, 2004), however the general 
consensus is that expansion of Treg is inversely related to lung inflammation and disease 
progression (Sakaguchi, 2007).  In the final phase of chronic inflammation, the induction of 
antibody production by B cells occurs; eosinophils, neutrophils, mast cells and macrophages 
become activated and exert individual effector functions; airway remodelling, loss of cell 
function and apoptosis.  As all of these events require the activation of effector T cells, 
peripheral tolerance is considered vital for a healthy immune response and represents a 
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mechanism to overcome chronic inflammation mediated by these T-cell subsets (Parijs, 
1998).   
The precise function and mechanism of action of each regulatory T cell subset has yet 
to be determined, however major subsets of Treg including CD4
+
CD25
+
 Foxp3 Treg, 
CD8
+TCRγδ and IL-10-producing Treg have demonstrated protective effects in models of 
allergic airway inflammation.  There is also evidence that the numbers or function of these 
subsets may be deficient in patients with atopic allergic disease (Grindbacke, 2004; Ling, 
2004; Isogai, 2007), suggesting that these T cells have the potential to suppress pathogenic 
Th2 responses and that this suppression may be defective or overridden in asthmatic patients.    
Animal models have also allowed specific mechanisms of suppression by Treg in allergic 
asthma to be identified (Lloyd, 2001).  Transfer of antigen-specific Treg from DO11.10 T cell-
receptor transgenic mice into sensitised BALB/c mice prevented the development of airway 
hyperresponsiveness and Th2-mediated inflammation (Kearly, 2005).  This suppression of 
allergic airway responses was dependent on IL-10 production from recipient T cells, but not 
from the transferred CD4
+
CD25
+
 Treg.  IL-10 is a cytokine with well-documented anti-
inflammatory and immunoregulatory activities that acts to inhibit the synthesis of pro-
inflammatory cytokines, chemokines (Fiorentino 1991) and eosinophils (Takanaski, 1994).  
In sensitised animals, IL-10 is effective in suppressing the inflammatory response to allergen 
(Zuany-Amorim, 1995).   
 Little is known about CD8
+
 regulatory T cells.  However, several studies have 
suggested that CD8
+γδ T cells may be influential in the CD8+ T cell-mediated regulation of 
airway inflammation (Lahn, 1999; Isogai, 2007).  These cells show tropism for mucosal 
epithelial cells, which is of potential importance in the epithelial repair process observed in 
chronic inflammatory conditions such as asthma (Wisnewski, 2001).  Lahn et al found that 
while a deficiency in γδ T cells was associated with a reduction in inflammation within the 
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lungs, TCR-δ-/- mice develop a higher level of AHR in response to antigen challenge than 
wild-type controls (Lahn, 1999).  This indicates that these regulatory cells exert their effects 
downstream of AHR as opposed to acting at the level of inflammation.  CD8
+
 γδ T cells from 
naïve donor rats adoptively transferred into sensitised animals reduced BAL Th2 cytokine 
levels and were accompanied by a reduction in late-phase AHR and eosinophilia, partly via 
an IFN-γ- dependent pathway (Isogai, 2003; Isogai, 2007).  These findings suggest the 
possibility that altered or defective CD8
+γδ T cell function may be a partial contributor to 
some forms of atopic asthma. 
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Figure 1.3 Treg and the asthmatic airway. Treg exert effects on multiple manifestations of 
allergic airway inflammation by regulating the activities of effector Th2 cells.  Treg secrete 
IL-10 and TGF-β which directly suppress IgE production and inhibit effector cells including 
eosinophils, mast cells and basophils. Also, Th2 cells are suppressed by Treg, thus inhibiting 
the production of cytokines including IL-4, IL-5 and IL-13.  These cytokines play critical 
roles in the differentiation and survival of mast cells, eosinophils and mucus-producing 
goblet cells.  Green line indicates stimulation, red line indicates suppression. 
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1.3.4 MURINE MODELS OF ASTHMA 
Animal models are useful in defining immunological mechanisms of asthma and 
allergic diseases.  Mice do not spontaneously develop asthma, but using different exposure 
models certain features concordant with allergic asthma can be induced (Taube, 2004).  
Induction of disease by systemic immunisation with allergen in combination with adjuvant, 
e.g. aluminium hydroxide, leading to allergen-specific Th2 immunity, is the most common 
method used in mouse models (Takeda, 1997).  Sensitised animals can then be exposed to 
respiratory challenge, via inhalation, intranasal or intratracheal routes, with allergen which 
results in an initial, but transient neutrophilic inflammatory response (Taube, 2003).  This is 
followed by sustained lung eosinophilic infiltration, elevated levels of antigen-specific serum 
IgE, mucus hypersecretion and inflammation, increased airway hyperreactivity and an 
increase in Th2 cytokine levels which are all hallmarks of the human disease.  Mouse models 
mimic clinically important human disease and allow the investigation of cellular and soluble 
mediators that can modulate the allergic immune response.  
 
1.3.5 VACCINATION AND ASTHMA 
The association between vaccination and the risk of atopic disease was first proposed 
by Odent et al in 1994 (Odent, 1994).  Since then, studies have suggested that immunisation 
can play both protective and inflammatory roles, depending on the type of vaccine and the 
age at which it is administered (Farooqi, 1998; Martignon, 2005; Bernsen, 2003; Destefano, 
2002; Garcia-Marcos, 2005; Gruber, 2008).  There is a consensus that common vaccines 
including tetanus, diphtheria and pertussis are protective against airway hyperresponsiveness 
and allergen-induced sensitisation.  Grüber et al demonstrated that vaccination of mice with a 
combined dose of diphtheria and tetanus prior to ovalbumin sensitisation, exhibited a 
statistically significant decrease in airway inflammation, and also in the production of 
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allergen-induced IgE.  Further, Martignon et al demonstrated a reduced risk of atopic disease 
in those vaccinated against diphtheria, tetanus and pertussis compared with a control proband 
(Martignon, 2005).  These findings concur with those of other investigators where a weak 
protective effect against asthma after pertussis vaccination was observed (Gruber, 2006).  
One particular study, Nilsson et al, demonstrated an 8% reduction in the risk of atopic disease 
in a randomised trial.  Further studies (Henderson, 1999; Destefano, 2002) showed no 
significant difference in the incidence of early wheezing or later onset wheezing as a result of 
whole cell pertussis vaccination in the first 6 months of life.  Two independent population-
based studies published in 2005 reported a possible atopy-protective effect of immunization 
(Garcia-Marcos, 2005; Martignon, 2005).  B. pertussis infection has been shown to 
exacerbate airway pathology in a murine model of allergen driven-inflammation despite 
induction of Th1 immunity (Ennis 2004).  In contrast, systemic immunisation with Th1-
inducing whole-cell pertussis vaccines inhibits allergic airway responsiveness (Ennis, 2005).  
Similarly, the acellular pertussis vaccine protects against B. pertussis-induced exacerbation of 
allergic asthma, but does induce IL-13 both at a systemic and local level (Ennis, 2005).   
 
1.4 BORDETELLA PERTUSSIS, A WELL ADAPTED HUMAN RESPIRATORY PATHOGEN 
B. pertussis is a Gram-negative bacteria and the causative agent of whooping cough, a 
severe respiratory disease that remains responsible for significant morbidity and mortality in 
infants worldwide (He, 2008).  The illness begins with colonisation of the respiratory tract, 
followed by the catarrhal stage.  This is the most contagious phase where infected individuals 
present with conjunctival irritation and a slight cough.  After 7-10 days, the paroxysmal stage 
ensues and can last from 2 to 6 weeks (Heininger, 2001).  It consists of the characteristic 
cough where a series of rapid forced expirations is followed by an inspiratory gasp, or 
“whoop”.  In neonates and young infants, the disease may present with apnoea and cyanosis 
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rather than coughing.  The disease is most severe and life-threatening at this age with more 
recurrent complications, including pneumonia, seizures, encephalopathy and secondary 
respiratory infections (Smith, 2000).  In non-fatal cases, mucus hypersecretion is a common 
pathological characteristic.  The pathology from post-mortem observations includes epithelial 
and ciliary damage, bronchopneumonia and pulmonary edema. 
 
1.4.1 VIRULENCE FACTORS OF B. PERTUSSIS AND IMMUNOMODULATION 
Bordetella pertussis colonises the respiratory tract using numerous antigenic 
components, which are involved in the pathogenicity of the bacterium.  Bordetella produces 
protein toxins, including pertussis toxin (PT), adenylate cyclase toxin (ACT), filamentous 
hemagglutinin (FHA), dermonecrotic toxin (dnt), and non-protein toxins, such as endotoxin 
and tracheal cytotoxin (TCT) which are fragments of the Bordetella peptidoglycan (Locht 
1999).  In addition, it produces numerous adhesion factors whose function is to attach the 
bacteria to the ciliated epithelium of the upper and lower respiratory tract.  FHA is primarily 
involved in mediating this adherence to host cells (Babu, 2001).  It also triggers several 
immune modulatory responses including the secretion of both inflammatory and anti-
inflammatory cytokines by macrophages (McGuirk, 2000) as well as promoting the 
generation of regulatory T cells that suppress protection Th1 responses during infection 
(McGuirk, 2000).  FHA exhibits a number of binding activities, including carbohydrate, 
heparin sulphate and integrin binding (Locht, 1993).  However, more recent studies have 
suggested the contribution of multiple factors to the binding process, including ACT.  
Secreted ACT modifies a heparin-inhibitable carbohydrate binding domain of FHA which 
ultimately enhances its‟ binding ability to cultured lung epithelial cells (Perez, 2006).  ACT is 
required to initiate infection; however, pertussis toxin is required for bacterial colonisation 
(Khelef, 1994).  Comparable to PT, ACT has two distinct domains which possess different 
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functions.  The first conducts enzymatic action, whilst the second has the ability to haemolyse 
red blood cells (Zaretzky, 2002).  ACT binds to, and penetrates host cells which suppress 
their bactericidal functions by converting cellular ATP to cAMP.  This uncontrolled cAMP 
signalling can also drive immature dendritic cells into a semi-mature state, which may hijack 
them to shape the local adaptive immune response towards tolerance of the pathogen 
(Vojtova, 2006).  ACT-deficient mutants of B. pertussis are more efficiently phagocytosed by 
human neutrophils (Mobberly-Schuman, 2005) and achieve lower bacterial loads in a mouse 
model of infection when compared to wild-type strains (Carbonetti, 2005).  ACT can 
suppress anti-bactericidal activity through inhibition of chemotactic migration, phagocytosis 
and the production of pro-inflammatory cytokines including TNF-α and IL12p70 (Ross, 
2004; Boyd, 2005; Spensieri, 2006).  This results in the promotion of bacterial colonisation.  
Recently, it has been shown that ACT can interfere with DC functionality, reducing 
protective Th1 immunity and triggering a polarisation towards a Th17 response (Fedele, 
2010). 
Both tracheal cytotoxin and dermonecrotic toxin, described below, contribute to the 
toxic effects observed during the disease.  Tracheal cytotoxin is responsible for destroying the 
ciliated tracheal epithelial host cells through the production of IL-1α and nitric oxide (Flak, 
2000).  It also exerts deleterious effects on neutrophils (Cundell, 1994).  It is therefore 
believed to be involved in the bouts of coughing which is characteristic of the disease.  PT 
has long been associated with the systemic responses related with pertussis infection, 
including lymphocytosis, hypoglycemia and histamine sensitivity (Munoz, 1981).  It is 
produced exclusively by B. pertussis and ADP-ribosylates several heterodimeric G proteins 
in mammalian cells, inhibiting many cell signalling events through G protein coupled 
receptors.  Infection with PT-deficient mutants of B. pertussis did not lead to airway infection 
demonstrating its‟ significant contribution to bacterial growth in the respiratory tract and 
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inhibition of resident airway macrophages (Carbonetti, 2004; Carbonetti, 2007; Carbonetti, 
2003).  PT also inhibits early neutrophil influx to the airways after infection by suppressing 
the early production of the neutrophil-attracting chemokines KC, LIX and MIP-2 by airway 
macrophages and epithelial cells (Andreasen, 2008).  This toxin exerts numerous 
immunosuppressive effects including the inhibition of serum antibody responses to B. 
pertussis antigens following infection (Mielcarek, 1998; Carbonetti, 2004), reduction of 
MHC class II molecules on the surface of monocytes and the modulation of surface markers 
on DC (Martino, 2006).  Therefore, it has been suggested that PT promotes and prolongs B. 
pertussis infection by multiple mechanisms, exerting effects on both innate and adaptive 
immunity.   
 
1.4.2 PERTUSSIS VACCINES 
To date, two specific types of pertussis vaccines have been employed in infant 
immunisation programmes.  Whole-cell pertussis vaccine (Pw) is composed of a suspension 
of killed B. pertussis cells.  Pertussis infection rates decreased dramatically with the 
introduction of Pw in combination with diphtheria and tetanus toxoid.  It has demonstrated an 
efficacy of ~80% and has been effective in markedly reducing the incidence rates in countries 
with good immunisation coverage (Burton, 2009).  However, due to fact that undesirable 
components such as endotoxin cannot be eliminated during whole-cell vaccine production, an 
acceptable level of potency is inevitably associated with a greater incidence of adverse effects 
(Manclark, 1984).  Fever, redness, swelling and pain at the site of injection are common. 
More severe complications including encephalopathy and permanent brain damage led to 
safety concerns.  Therefore, in spite of conferring good, long-lasting immunity, the degree of 
reactogenicity associated with it prompted the development of acellular pertussis vaccines 
(Pa) (Deloria, 1995) which was as efficacious as the whole-cell vaccine but had a much better 
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profile as far as the mild-to moderate adverse reactions were concerned.  The acellular 
vaccine contains purified, detoxified pertussis antigens, typically including those extracted 
from B. pertussis organisms, as well as those produced by genetic recombinant technology 
(Singh, 2006).  Four antigens were identified as suitable for inclusion in such vaccines: PT, 
FHA, pertactin, and fimbrial antigens serotype 2 and 3.  The vaccine may contain one or all 
of the above components.    Repeated administration of Pa can cause extensive swelling at the 
site of injection (Rennels, 2003).  In approximately 5 % of the cases, this swelling involves 
almost the entire limb and lasts for more than a week.  Although the mechanism of this 
swelling has not been characterised yet, it has been proposed to be due to an Arthus 
hypersensitivity reaction caused by high antibody levels induced by the primary 
immunisation (Robbins, 2005).  Whilst the replacement of first generation whole-cell 
vaccines by new acellular pertussis vaccine in many countries has significantly reduced the 
systemic adverse reactions observed with whole-cell vaccines, it has not abolished the need 
for repeated vaccination to achieve protection. 
 
1.4.3 AN ATTENUATED B. PERTUSSIS VACCINE, BPZE1 
Recently, a genetically-attenuated live vaccine against B. pertussis, BPZE1, has been 
developed as a candidate neonatal vaccine (Mielcarek, 2006).  This live recombinant B. 
pertussis strain induces strong local and systemic immune responses upon intranasal delivery.  
Administration via the nasal route mimics natural infection and promotes long-lasting 
immunity in children from 1 month of age (Mascart, 2003).  Three virulence factors have 
been targeted for attenuation; pertussis toxin, tracheal cytotoxin and dermonecrotic toxin.  
Attenuated BPZE1 lacks the dnt gene, reduced tracheal cytotoxin and produces inactive 
pertussis toxin.  Genes encoding these toxins were deleted or replaced with genetically 
inactivated analogues in order to induce protection, without the severe pathology associated 
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with wild-type infection (Mielcarek, 2006).  As described in Section 1.4.1, TCT is 
responsible for the destruction of ciliated cells in the trachea of infected hosts.  The gene, 
AmpG, is responsible for internalising TCT into the cell wall of the bacteria where it is used 
in its‟ biosynthesis.  B. pertussis AmpG was replaced with E. coli AmpG, resulting in a strain 
that expressed less than 1 % residual TCT activity.  PT is a major virulence factor in the 
pathogenesis of B. pertussis infection; however it is composed of an enzymatically active 
moiety, S1, which is also a critical protective antigen.  Therefore, PT was replaced with a 
mutated version, coding for an enzymatically inactive toxin.  Finally, allelic exchange was 
used in order to delete DNT, a virulence factor produced
 
by bacteria belonging to the genus 
Bordetella (Babu, 2001). 
 
1.4.4 MURINE MODELS OF PERTUSSIS 
The most commonly used animal model for pertussis infection is the mouse aerosol 
induction model.  This model has been used extensively for studies of Bordetella pertussis 
immunity and pathogenesis (Mills, 1997; Mills, 1998; Ennis, 2004; Skerry, 2009).  One 
limitation of this particular model is the lack of the characteristic cough observed in the 
human condition.  However, several important human infection manifestations are 
reproduced in this model including multiplication and clearance of the bacteria, confinement 
of the infection to the respiratory tract and an increased severity of disease in young animals.  
The newborn pig model of  B. pertussis infection offers several advantages over murine 
challenge including laboured breathing, nasal discharges and bronchopneumonia (Elahi, 
2005), however the practicality of large-scale studies make the mouse model more useful in 
the assessment of protective immune responses elicited by B. pertussis infection and 
vaccination (Mills, 2001).  In addition, this model of B. pertussis infection in combination 
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with the OVA model of allergic airway inflammation has been well-characterised in previous 
studies (Ennis, 2004; Ennis, 2005a; Ennis, 2005b).   
 
1.5.  NOVEL IMMUNOMODULATORY THERAPIES & ASTHMA 
As the immunopathology of asthma has become better defined, novel targets have 
been identified and agents developed for the treatment of asthma and allergic diseases.  These 
include strategies involved in specifically inhibiting inflammatory mediators or attempting to 
alter the Th1-Th2 inflammatory balance.  Stem cells represent great promise as a therapeutic 
tool in many diseases where they have been shown to slow or even block their progression.  
The capacity of stem cells to repair tissue creates huge potential for use in this area.   
Stem cells and progenitor cells from adult tissues represent important potential for 
therapeutic intervention in a number of pathological conditions.  Stem cells have the capacity 
for self-renewal and in the case of adult stem cells, can maintain their differentiation potential 
throughout the life of the organism.  Adult stem cells were first identified in tissues where a 
high rate of cell turnover exists, such as bone marrow.  The bone marrow is a complex mix of 
cell types including those from haematopoietic, mesenchymal and endothelial origin.  Their 
primary role is the maintenance and repair and this capacity has offered extensive 
opportunities in a regenerative medicine setting.  For instance, adult haematopoietic stem 
cells have been successfully used to reconstitute bone marrow following transplants for over 
30 years (Bryder, 2006).   
 
1.5.1 MESENCHYMAL STEM CELLS (MSC) 
Mesenchymal stem cells (MSC) are non-haematopoietic, pluripotent, adult stem cells.  
Following transplantation of MSC into the bone marrow of non-obese diabetic-severe 
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combined immunodeficiency (NOD-SCID) mice, they have demonstrated the ability to 
differentiate into osteoblasts, myofibroblasts, pericytes, endothelial cells and bone-marrow 
stromal cells, all of which constitute the functional components of the haematopoietic stem 
cell niche (Muguruma, 2006).  In this way, the MSC contribute to the maintenance of 
haematopoiesis through active interaction with haematopoietic cells.  They are also 
fundamental for maintaining haematopoietic stem cells in a quiescent state in the bone 
marrow, until appropriately stimulated to differentiate and become released into the vascular 
system (Benvenuto, 2007; Dazzi, 2005).  
Most MSC reside in the bone marrow, where they constitute 0.01- 0.001% of cells.  
However, they have been found in virtually all post-natal organs and tissues in the body, 
including the liver, adipose tissue, heart and synovium (da Silva Meirelles, 2006).  Unlike 
haematopoietic cells, MSC are adherent cells and are easily expandable in culture.  They are 
characterised based on their ability to differentiate into mesenchymal lineage cells including 
bone, fat, cartilage and smooth muscle cells (Krampera, 2003).  Although no one specific cell 
marker has been identified, MSC do express CD44, CD29, CD105, CD73 and CD166.  The 
absence of CD45, CD34, CD31, CD116, CD19 and glycosporin A distinguishes MSC from 
haematopoietic cells, endothelial cells, endothelial progenitors, monocytes, B cells and 
erythroblasts respectively (Stagg, 2007).  Despite possessing various multi-lineage 
differentiation abilities, the main therapeutic application of MSC has been immune 
modulation.  Unlike other stem cell types, MSC can not only evade immune response but also 
have the ability to mediate active suppression (Glennie, 2005; Corcione, 2006; Uccelli, 
2006). 
 
1.5.2 INFLUENCE OF MSC ON IMMUNE CELLS 
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MSC possess the unique ability to suppress immune responses, both in vitro and in 
vivo.  It is for this reason that MSC have broad implications for therapy in chronic 
inflammatory diseases.  MSC can indirectly inhibit various immune responses through the 
activation of Treg (Augello, 2007; Selmani, 2008) and the inhibition of DC maturation (Chen, 
2007; Ramasamy, 2007).  MSC have also exhibited regulatory effects on a broad range of 
immune cells including T cells, B cells and NK cells (Glennie, 2005; Keating, 2006).  The 
proliferative function of T cells stimulated with allogeneic splenocytes, peripheral blood 
mononuclear cells and mitogens including concanavalin A and anti-CD3 (Rasmusson, 2005; 
Ryan, 2007; English, 2008) is inhibited by MSC.  This inhibitory effect is not MHC-
restricted as it occurs in the presence of both autologous and allogeneic MSC.  Studies have 
shown that MSC can induce a state of T-cell anergy, where T cells cannot proliferate or 
release cytokines in response to antigen presentation demonstrating direct control over T cell 
cycle division (Zappia, 2005).  MSC have also exhibited inhibitory effects on cytotoxic T 
cells (Rasmusson, 2003).  DC play a critical role in the initiation of an immune response, and 
have thus sparked interest as a potential target for suppression of these immune responses to 
alleviate/prevent allogeneic tissue rejection.  During maturation, immature DC acquire the 
expression of co-stimulatory markers.  MSC have been shown to inhibit the maturation of 
monocytes into DC in vitro (Jiang, 2005).  They are also capable of inhibiting upregulation of 
CD1a, CD40, CD80, CD86 and HLA-DR during DC maturation, thereby maintaining DC in 
an immature state (Zhang, 2004).  Similar studies investigated the effect by co-culturing 
allogeneic human MSC with LPS and demonstrated a 50 % inhibition of tumour necrosis 
factor (TNF-α) production by DC (Aggarwal, 2005).  MSC can also induce regulatory 
antigen-presenting cells expressing IL-10 (Gur-Wahnon, 2007) indicating a polarisation of 
DC maturation towards a suppressor or inhibitory phenotype.  In addition, MSC can affect 
the degree of respiratory burst of neutrophils and delay the spontaneous apoptosis of resting 
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and activated neutrophils via IL-6 production (Raffaghello, 2008).  These data suggest the 
putative potent anti-inflammatory and immunoregulatory effect of MSC in vivo. 
The precise mechanisms by which MSC exert their immunosuppressive effect are not 
clear, however both contact-dependent and soluble factor secretion mechanisms are thought 
to collaborate in the immunosuppression.  Several soluble factors, (outlined in Table 1.2) 
have been reported to be involved in MSC-mediated immune regulation, including nitric 
oxide, indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2 (PGE2).  IFN-γ, either alone 
or in combination with TNF-α, IL-1α or IL-1-β, stimulates the production by MSC of nitric 
oxide synthase and of chemokines that attract T cells.  T cell proliferation is inhibited through 
the subsequent production of nitric oxide (Ren, 2008). MSC also express IDO which breaks 
down tryptophan, an important amino acid required for T cell proliferation.  A partial role for 
IL-10 had been suggested by Beyth and colleagues in human MSC inhibition of alloresponses 
(Beyth, 2005).  Other examples of soluble factors constitutively expressed by MSC including 
transforming growth factor-β (TGF-β), hepatocyte growth factor (HGF), IL-10 and IL-6, 
contribute to the regulatory function of MSC.  HGF has recently been shown to negatively 
regulate allergic airway inflammation and hyperresponsiveness in a murine model (Ito, 2007) 
via direct attenuation of eosinophil chemotactic function.   
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Table 1.3 (below) Soluble factors and enzymes secreted by MSC and putatively linked to 
immunomodulation. 
 
Soluble factors/Enzymes Study 
Hepatocyte growth factor (HGF) (Nicola, 2002)  
Prostaglandin E2 (Chen, 2007) 
TGF-β (Nicola, 2002), (Ryan, 2007) 
Indoleamine 2,3 dioxygenase (IDO) (Meisel, 2004) 
Nitric oxide (Ren, 2008), (Sato, 2007) 
 
1.5.3 CLINICAL APPLICATIONS OF MSC 
MSC therapies to date have mainly focused on their ability to promote engraftment of 
haematopoietic stem cells, to block graft-versus-host-disease (GvHD) and to help promote 
structural repair of damaged tissues.  Despite transplantation of very few MSC in vivo (<1%), 
MSC have exhibited significant improvement in the acute GvHD score (i.e. extent of damage 
ranging from rash to persistent nausea, vomiting, and anorexia), supporting their possible use 
as a therapy for immune-mediated disease.  The ability of MSC to modulate immune 
responses in vivo was first investigated by Bartholomew et al, who demonstrated that 
administration of allogeneic MSC could prolong skin-graft survival in primates 
(Bartholomew, 2004).  Since then, several studies have targeted MSC as a therapeutic tool in 
animal models of lung injury, myocardial infarction, graft-versus-host disease, kidney 
disease, diabetes and also some neurological disorders.  Selective localisation of systemically 
delivered MSC has been demonstrated in models of kidney failure (Ezquer, 2008), 
myocardial infarction (Quevedo, 2009), and neurological injury (Bouchez, 2008).  MSC 
possess the ability to roll and adhere in endothelial cells in a P-selectin and vascular cells 
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adhesion molecule-1-dependent manner allowing the migration into organs such as the lung, 
liver and spleen (Sackstein, 2008).  Ortiz et al have shown significantly augmented 
engraftment of MSC in a pulmonary fibrosis model of lung injury in mice when compared to 
engraftment in the lung of normal mice (Ortiz, 2003).  Likewise, Wu and co-workers 
demonstrated vigorous migration of MSC to the site of allograft rejection in a rat model, 
further highlighting their putative role in tissue repair during chronic rejection (Wu, 2003).  A 
rat model of Parkinson‟s disease showed significant improvement in behaviour upon 
engraftment of rat MSC by intra-striatal injection (Bouchez, 2008).  MSC also promoted the 
endogenous repair of pancreatic islet cells and renal glomeruli in a mouse model of 
streptozotocin-induced diabetes (Lee, 2006).  Co-infusion of MSC and bone marrow cells 
inhibited the proliferation of β-cell-specific T lymphocytes from diabetic pancreas in a mouse 
model and this effect was not due to the reconstitution of the damaged islet cells (Urban, 
2008).  It is noteworthy that many of these studies demonstrated beneficial effects of MSC in 
the absence of engraftment and transdifferentiation.  This suggests that the multi-potentiality 
of MSC is not critical for their immunosuppressive effect.  
An increasing number of studies have demonstrated a functional role for MSC in 
animal models of acute lung injury.  Systemic administration of MSC in a mouse model of 
bleomycin-induced pulmonary fibrosis decreased lung collagen accumulation and the level of 
matrix metalloproteinases (Ortiz, 2003).  Further studies identified IL-1 receptor antagonist, 
expressed by MSC, as the mediator of this effect (Ortiz, 2007).  This and numerous other 
studies suggest that MSC can have significant immunomodulatory effects in the lung, 
although the mechanisms by which they achieve this remain unclear.   
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Table 1.4 Effect of MSC therapy in animal models of disease 
 
Disease model Model Outcome Reference 
Acute lung injury 
 
Mouse Syngeneic intrapulmonary murine MSC decrease the 
severity of endotoxin-induced acute lung injury and 
improve survival in mice 
(Gupta, 2007) 
Myocardial infarction Rat Syngeneic rat MSC demonstrated an anti-
inflammatory role in ischemic heart disease 
(Orlic, 2001) 
Heart transplantation Rat Allogeneic rat MSC injected intravenously migrated 
to the heart during chronic rejection 
(Wu, 2003) 
Arthritis 
 
Mouse Allogeneic murine MSC prevented irreversible 
damage to bone and cartilage via Treg generation 
(Augello, 2007) 
Chronic lung injury Mouse Syngeneic murine-MSCs protect lung tissue from 
bleomycin-induced injury with anti-inflammatory 
effect 
(Ortiz, 2007) 
Graft-versus-host 
disease 
Rat Allogeneic rat-MSCs prevent lethal GVHD 66 (Ikehara, 2003) 
Renal failure 
 
Rat Inhibition of pro-inflammatory cytokine production 
and induction of anti-apoptotic and trophic factors 
(Imberti, 2007) 
Multiple sclerosis (EAE) 
 
Mouse Syngeneic murine MSC reduced inflammatory 
infiltrates, demyelination and axonal loss 
(Zappia, 2005; 
Gerdoni, 2007) 
Diabetes 
 
Mouse Human MSC grafted kidney and pancreas in STZ 
NOD-SCID mice ameliorating diabetes and kidney 
disease 
(Urban, 2008) 
Retinal degeneration 
 
Rat Decreased retinal degeneration through anti-apoptotic 
and trophic molecules 
(Inoue, 2007) 
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Table 1.5 Clinical trials using mesenchymal stem cells 
Clinical trial Condition Site/sponsor Status 
MSC Transplantation in 
Decompensated Cirrhosis 
Cirrhosis University of 
Tehran 
Recruiting 
Safety Study of Adult 
Mesenchymal Stem Cells (MSC) to 
Treat Acute Myocardial Infarction 
Myocardial 
infarction 
Osiris Therapeutics, 
U.S. 
Ongoing, but not 
recruiting 
Phase I Clinical Trial of the 
Treatment of Crohn’s Fistula by 
Adipose Mesenchymal Stem Cell 
Transplantation 
Crohn‟s disease “La Paz” University 
Hospital, Madrid, 
Spain 
Ongoing, but not 
recruiting 
Autologous Mesenchymal Stem 
Cells From Adipose Tissue in 
Patients With Secondary 
Progressive Multiple Sclerosis 
Multiple 
sclerosis 
Fundacion Progreso y 
Salud, Spain 
Recruiting 
Safety and Efficacy Study 
of Allogenic Mesenchymal 
Stem Cells to Treat 
Extensive Chronic Graft 
Versus Host Disease 
GVHD Guangdong General 
Hospital 
Not yet open for 
participant recruitment 
Prochymal® (Human 
Adult Stem Cells) 
Intravenous Infusion 
Following Acute 
Myocardial Infarction 
(AMI) 
Myocardial 
infarction 
Osiris Therapeutics Recruiting 
Prochymal® phase III Clinical 
Trial for the treatment of Steroid-
Refractory Acute GvHD  
GvHD Osiris Therapeutics Active, not recruiting 
Prochymal® Phase iii Clinical 
Trial for the Treatment of Newly 
Diagnosed Acute GvHD  
GvHD Osiris Therapeutics Completed 
Prochymal® Phase III Crohn's 
Disease 
Crohn‟s disease Osiris Therapeutics Active, not recruiting 
OTI-010 for Graft-
Versus-Host Disease 
Prophylaxis in Treating 
Patients Who Are 
Undergoing Donor 
Peripheral Stem Cell 
Transplantation for 
Hematologic Malignancies 
GvHD National Cancer 
Institute (NCI) 
Ongoing, but not 
recruiting 
Donor Mesenchymal Stem 
Cell Infusion in Treating 
Patients With Acute or 
Chronic Graft-Versus-
Host Disease After 
Undergoing a Donor Stem 
Cell Transplant 
GvHD National Cancer 
Institute (NCI) 
Ongoing, but not 
recruiting 
Mesenchymal Stem Cells 
in Multiple Sclerosis 
(MSCIMS) 
Multiple 
sclerosis 
University of 
Cambridge 
Ongoing, but not 
recruiting 
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1.6 AIMS & OBJECTIVES 
 
This chapter has presented the evidence that the adaptive immune system plays a 
central role in protecting the organism against infections (such as B. pertussis) but can also be 
detrimental in conditions such as asthma.  The control or modulation of immunity is therefore 
critical to the normal homeostasis of the organism but can also be exploited by infectious 
agents, or therapeutic intervention (immunisation or cell therapy).  The overall goal of the 
work presented in this thesis was to investigate immune modulation with a particular focus on 
airway inflammation and allergic pathogenesis.  This was probed in a model of pathogen 
driven immunomodulation (B. pertussis), and two models of therapeutic intervention namely 
immunisation (BPZE1) or using a candidate cell therapy approach (MSC).  These were 
captured in the following specific aims:   
i) To determine whether a candidate live, attenuated, neonatal vaccine modulated 
allergic airway pathology and how this compared to virulent infection with particular focus 
on immune modulatory mechanisms (Chapter 3). 
ii)  To determine the immunomodulatory effect of a potential cell therapy based on 
mesenchymal stem cells.  This focused specifically on the establishment of an experimental 
system to confidently deliver reliable and reproducible MSC populations for use in vivo 
(Chapter 4). 
iii)  To ascertain whether a candidate MSC therapy could modulate immunity in vivo 
sufficient to suppress allergic lung inflammation (Chapter 5). 
iv) To elucidate the immune mechanisms by which MSC confer protection (if any) in this 
model (Chapter 6). 
In this way, a greater understanding of allergic disease and the factors that affect it may be 
obtained to provide fundamental insight to the hygiene hypothesis and novel therapeutic 
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approaches to treat asthma.  Examination of immunomodulatory effects in these models will 
also contribute to a broader understanding of immune regulation in health & disease. 
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CHAPTER 2 
MATERIALS & METHODS 
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2.1 MATERIALS 
All chemicals used were from Sigma-Aldrich (Poole, Dorset, UK) unless otherwise 
stated.  Reagents/materials are described in Tables 2.1 – 2.6.  
 
2.2 CULTURE OF BORDETELLA PERTUSSIS 
A stock aliquot of B. pertussis was thawed at 37 °C and 100 µl was aseptically 
transferred to a plate of Bordet-Gengou agar.  The suspension was evenly spread across the 
plate using a sterile plate spreader and then sealed with parafilm (Pechiney Plastic Packaging 
Company, Chicago, IL).  The plate was inverted and incubated at 37 °C for 3 days.  After 72 
h, 1 ml of supplement was added to 100 ml of S&S medium (section 2.2.3) in a 250 ml 
Erlemeyer flask and incubated for 20min at 37 °C.   Using a sterile cell scraper, B. pertussis 
was harvested from the plate and transferred into the prepared flask.  Cultures were agitated 
at 37 °C for a further 2-3 days to obtain culture dividing at log – this was ascertained by 
measurement of optical density at 580 nm. 
 
2.3 ANIMAL STRAINS 
The following mouse strains were used: FVB.Cg-Tg(GFPU)5Nagy/J (Jackson Labs, 
Bar Harbour, Maine, USA), BALB/c, 129 Sv/Ev, C57BL/6 (Harlan, Bichester, Oxon, UK). 
All mice were housed according to Dept. of Health (Ireland) guidelines. 
 
2.4 ETHICAL APPROVAL   
All procedures involving animals were carried out by licensed personnel (License no. 
B100/3999).  Ethical approval was received from the ethics committee of NUI Maynooth. 
 
2.5 AEROSOL INFECTION 
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An aerosol chamber was used for whole body aerosol exposure.  Animals were placed 
in the chamber and a nebuliser for the bacterial suspension was attached to the chamber.  The 
challenge inoculum 2 x 10
10
 of B. pertussis (BPSM or BPZE1) was administered directly into 
the aerosol chamber containing no more than 10 mice over a period of 15 min.  Un-infected 
control mice were „sham‟ sensitised with PBS (Zachariadis, 2006).  
 
2.6 IMMUNISATION & AIRWAY DELIVERY OF OVA 
Ovalbumin (OVA) (grade V, Sigma) was mixed with alum for intra-peritoneal (i.p.) 
delivery (Imject Alum, ThermoScientific, Rockford, IL, USA).  Alum was mixed
 
at a 1:2 
ratio with a 100 μg/ml solution of OVA in sterile PBS, followed by vigorous shaking for at 
least 1h.  300 µl of this solution was administered per mouse using a 27 G needle on day 0, 7 
and 14.  On days 14, 25, 26 and 27, mice also received OVA by an intra-nasal route.  This 
was performed by first, anaesthetising the mouse with isofluorane and then placing 150 μl of 
50 μg/ml OVA diluted in sterile PBS on each nostril, allowing the solution to be inhaled.  
Control groups were sham sensitised with sterile PBS, i.p. and i.n. 
 
2.7 MEASUREMENT OF LUNG FUNCTION 
Unrestrained whole body plethysmography (WBP) was used to study the development 
of airway hyperresponsiveness after allergic sensitisation in mice.  Airway responsiveness 
was assessed by methacholine-induced airflow obstruction from conscious mice using the 
Buxco whole-body plethysmography chamber in conjunction with the BioSystem XA 
software (Buxco Electronics, USA).  Enhanced pause, or PenH, was used as a surrogate of 
airway responsiveness.  PenH is an index of respiratory signal created by calculating the sum 
of the nasal air flow, and flow due to changes in the thoracic volume.  Under normal 
conditions, these flows are out of phase and should largely cancel each other out, but 
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obstruction causes deviation in this signal.  The instrument was calibrated by forcing 1ml of 
air into the chamber using a syringe and adjusting amplifier readouts until the signal was in 
range of detection (5.0 V to –5.0 V). The mouse was then placed in the chamber which was 
attached to two pneumotachographs.  Baseline readings were collected upon aerosol delivery 
of PBS.  This was followed by four increasing dosages of methacholine (3.3, 10, 30 and 50 
mg/ml) each lasting 5 minutes.         
    
2.8 BRONCHOALVEOLAR LAVAGE FLUID (BALF) 
Mice were sacrificed by lethal injection sodium pentobarbitol to preserve the trachea, 
and the respiratory tract was exposed by dissection.  An incision was made near the top of the 
trachea with a scalpel and a 20-gauge needle was inserted and fixed with suture thread around 
the trachea.  BALF was obtained by flushing the lungs with 1.5 ml of cold PBS and 
withdrawing the fluid with a 3-way stop-cock syringe.  BAL fluid was passed though a 10 K 
membrane centrifugal filter (Amicon Ultra, Millipore, Billerica, MA, USA) to concentrate 
the lavaged cells.  Cells were recovered by centrifugation at 300 g for 5 min, and resuspended 
in PBS.  Supernatants were collected for cytokine analysis and stored at -80 ˚C until use.  100 
μl of BAL cells were cytospun at 10,000 rpm for 10 minutes and stained with Giemsa 
(Riedel-deHaen) according to manufacturer‟s instructions.  
 
2.9 ASSESSMENT OF NEUTROPHIL ACTIVITY (MPO ASSAY) 
BALF samples (30 µl) were added to 180 µl of PBS (pH 6.0) containing 0.167 mg/ml 
o-dianisidine dihydrochloride and 1 drop of hydrogen peroxidase.  The change in absorbance 
was measured every 2-3 minutes using a plate reader (Labsystems) at 450 nm.  
Myeloperoxidase (MPO) activity was expressed as ΔAbs/min/U.  A standard curve was 
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generated using serial dilutions of a human MPO standard with 5 U/ml as the highest 
concentration. 
 
2.10 TISSUE PREPARATION 
Lungs were processed for histology using an automated processor (Shandon 
Pathcentre, Runcorn, UK) which immerses the tissues in various fixative and dehydrating 
solutions: formalin, ethanol (x 6), xylene (x 3) (BDH AnalaR® Laboratory supplies, Poole, 
UK).  The samples were embedded in paraffin wax using a Shandon Histocentre 2 (Shandon) 
and left to set overnight.  4 µm sections were cut using a microtome (Shandon Finesse 325, 
Thermo-Shandon, Waltham, MA, USA).  The sections were placed in cold water containing 
ethanol followed by transfer to a hot water bath (42 °C) to smooth out folding.  Prior to 
staining, tissue sections were heated to 56 °C for a minimum of 1 h to aid clearance of wax.  
 
2.11 RESPIRATORY TRACT HISTOLOGY  
Mice were culled and the lungs were removed and fixed in 10 % formalin (Sigma-
Aldrich), embedded in paraffin, sectioned and stained with haematoxylin and eosin (H&E) 
for examination by light microscopy.  Histopathological changes were graded according to a 
semi-quantitative scoring system as mild, moderate or severe, using the scoring devised by 
Ennis et al (Ennis, 2004).   
  
2.11.1 HAEMATOXYLIN/EOSIN STAINING 
Slide sections were immersed in 2 changes of xylene, 10 minutes each, followed by 
rehydration in 3 concentrations of ethanol ranging from 100 % to 80 %.  The sections were 
then placed in 2 changes of water, followed by Harris Haematoxylin (Sigma) solution for 3 
min.  Slides were washed in water for 2 min, and then immersed in 1 % acid alcohol for 20 
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seconds, followed by another washing step.  Slide sections were counterstained in Eosin Y 
(Sigma) for 3 min and washed again.  Finally, the slides were put through a series of 
dehydration steps in ethanol concentrations ranging from 80 % to 100 % for 5 min each.  
Slides were mounted with DPX mountant (BDH) and examined under a light microscope.  
 
2.11.2 ALCIAN BLUE & PAS STAINING  
This is a combined method which uses both Alcian Blue and Periodic Acid-Schiff to 
demonstrate the full complement of tissue proteoglycans.  Lung tissue slide sections were 
dipped in distilled water and then stained with Alcian blue for 15 min.  Slides were washed in 
running tap water for 2 min, followed by brief washing in distilled water.  Slides were stained 
with periodic acid (0.5 % aq) for 5 min, followed by a washing step in distilled water.  Slides 
were then stained in Schiff reagent (Sigma) for 10 min and washed well in running tap water 
for 5 min.  Slides were immersed in Discombes eosin for 10 min, followed by a washing step.  
Nuclei were stained with haematoxylin for 1 min followed by washing in running tap water 
for 2 min.  Finally, the slides were washed in Scotts tap water, followed by a washing step in 
distilled water.  Slides were mounted with DPX mountant and examined under light 
microscopy. 
 
2.12 MEASUREMENT OF CYTOKINES   
Bead array technology is a method for quantifying multiple cytokines simultaneously 
in a single sample volume.  The technology is based on the same premise as enzyme-labelled 
immunosorbent assays (ELISA); however the bead array uses fluorescence, instead of 
colorimetric intensity for quantitation, and through the use of distinct beads labelled for 
different cytokines allows the simultaneous detection of multiple analytes from single small 
samples.  Analysis of cytokines from BALF and splenocyte supernatant was carried out using 
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a Th1/Th2 Flow Cytomix mouse bead array kit (BenderMedSystems) and was analysed on a 
FACSCaliber flow cytometer (Becton Dickinson, Franklin Lakes).  Standard curves and raw 
data were generated for each cytokine using FlowCytomix Pro 2.2 software 
(BenderMedSystems).  Cytokines were quantified as per manufacturers‟ instructions.  
Briefly, samples, standards and blanks were added to 4 ml polypropylene FACS tubes 
(Falcon, BD Biosciences).  Beads coated with primary antibodies for individual cytokines 
were mixed together and added to each tube.  The beads are internally dyed with varying 
intensities of fluorescent dye corresponding to specific cytokines allowing for differentiation 
by flow cytometry.  Biotin-conjugated secondary antibodies were added to all tubes and 
allowed to incubate for 2 h protected from light at room temperature.  Following incubation, 
1ml of FACS buffer was added to each tube and the tubes were centrifuged at 200 g for 5 
min.  Supernatant was discarded carefully and the wash step was repeated.  Streptavidin-PE 
was added to the tubes and allowed to incubate at room temperature for 1 h and protected 
from light.  This was followed by a wash step, which was repeated twice.  The supernatant 
was discarded and each tube was resuspended in 500 µl of assay buffer.  Cytokines were 
quantified based on the fluorescent intensity which was analysed on a flow cytometer.  
  
2.13 MEASUREMENT OF OVA-SPECIFIC IGE  
IgE was measured by ELISA.  Plates (Nunclon, ThermoScientific, Rochester, NY) 
were coated with OVA (5 µg/ml) in carbonate coating buffer and left overnight at 4°C.  The 
following day, plates were washed five times in PBS-Tween (0.05 %) and blocked with 10 % 
FCS in PBS.  After 2 h at room temperature, plates were washed 3 times, and serum samples 
were applied (50 µl/well).  Samples were left overnight at 4 °C or incubated at 37 °C for 1 
hour.  The plates were washed and biotinylated anti-IgE (2 µg/ml) was applied to each well.  
Following 2 h incubation at room temperature, the plates were washed and Streptavidin-
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horseradish peroxidise (BD Pharmingen) was applied according to manufacturer‟s 
instructions and left for 30 min.  The plates were washed again, and 100 µl of TMB was 
added to the wells.  Reactions were allowed to proceed for 20 min, and O.D. at 450 nm was 
measured (Multiskan RC, Labsystems, Thermo, Waltham, MA, USA). 
 
2.14 MEASUREMENT OF CELL VIABILITY (FLUORESCENT MICROSCOPY) 
A small sample of cells was suspended in medium and diluted 1/10 in ethidium 
bromide and acridine orange (EB/AO).  20 µl was pipetted to a haemocytometer and live 
cells were counted using an epi-fluorescent light microscope. 
 
2.15 MEASUREMENT OF CELL VIABILITY (FLOW CYTOMETRY) 
Propidium iodide staining was measured by flow cytometry to determine cell 
viability.  1 x 10
6
 cells were centrifuged at 600 g for 5min.  Supernatant was discarded, and 
the pellet was resuspended in 1 ml of phosphate-buffered saline (PBS) at room temperature.  
A 2 µg/ml concentration of propidium iodide was added to the cells, and allowed to incubate 
at room temperature for 15 min.  Analysis was carried out on a flow cytometer 
(FACSCalibur, California, USA).  
 
2.16 ISOLATION OF TOTAL LUNG CELLS 
Lungs were removed aseptically and transferred to a 15 ml tube containing complete 
RPMI.  Using sterile tweezers, the lungs were transferred to a Petri dish and sectioned into 
small pieces using anatomical scissors.  The small lung pieces were then digested in 10ml of 
collagenase digestion (500 U/ml) (Sigma) solution at 37 °C under constant horizontal shaking 
at 300 rpm.  Following 1 h digestion, the lung was passed through a 40 µm sieve into a 50 ml 
tube using a sterile syringe top.  5 ml of medium was added and the digested lung solution 
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was centrifuged at 300 g for 5min.  Supernatant was discarded and the pellet was resuspended 
in lysis buffer and incubated at room temperature for 5 min.  Following incubation, the 
solution was centrifuged at 300 g for 5 min and the pellet resuspended in PBS.  Lung cells 
were prepared for FACS analysis, as described in Section 2.20. 
 
2.17  PERIPHERAL BLOOD MONONUCLEAR CELL (PBMC) ISOLATION 
 
 Human PBMC were isolated from buffy coat packs by density centrifugation using 
Lymphoprep.  50 ml of the buffy coat blood were added to 5 ml sterile 5 % w/v aq EDTA 
solution and diluted to 200 ml with complete Hank‟s Balanced Salt Solution (HBSS) 
(Invitrogen-Gibco) (containing 1 % v/v hi FCS (Biosera, Essex, UK) and 1 mM HEPES 
(Invitrogen-Gibco)).  40 ml of diluted blood were overlayed onto 10 ml Lymphoprep (Axis-
Shield, Oslo, Norway) in a 50 ml tube ensuring no mixture of the solutions took place.  
Preparations were centrifuged at 400 x g for 25 min without acceleration or breaking.  20 ml 
of the resulting top layer of plasma were discarded from the tube, the remaining buffy layer 
was gently disturbed and the PBMC collected.  Care was taken to not disturb the underlying 
erythrocyte layer.  The collected PBMC were then centrifuged at 800 x g for 5 minutes.  The 
supernatant was decanted and the cell pellet washed in 10 ml cHBSS, repeating the previous 
centrifugation step.  Supernatant was again decanted and the cell pellet resuspended in 20 ml 
warm cRPMI (see Table 2.2).  The cell suspension was then filtered through a 40 m nylon 
mesh filter.  Cells were maintained on ice until required. 
 
2.18 CD4
+ 
T CELL ISOLATION 
CD4
+
 T cells were isolated from human PBMC using a MagCellect CD4
+
 T cell 
negative selection isolation kit (R & D Systems) according to manufacturer‟s instructions.  
This kit employs a high affinity negative selection whereby undesired cells are bound by 
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biotinylated antibody and then captured by Streptavidin-conjugated magnetic particles.  10 ml 
of 1x MagCellect buffer was added to 20 x 10
7 
cells.  200 µl of human CD4
+
 T cell 
biotinylated antibody cocktail was added, mixed and incubated at 4 °C for 15 min.  250 µl of 
streptavidin was added to the cell suspension and incubated for 15 min at 4 °C.  The volume 
was adjusted to 3 ml with buffer and mixed gently.  Undesired cells were isolated from the 
sample by negative selection using a MagCellect Magnet incubated for 6 min at room 
temperature.  Positive enrichment of the CD4
+
 T cell population was achieved by aspirating 
the sample solution and placing the supernatant in a fresh 5 ml tube.  Magnetic depletion was 
repeated and the purified cell population was prepared for flow cytometric analysis of CD4, 
CD3 and CD8 (Immunotools) expression. 
 
2.19 MIXED LYMPHOCYTE REACTION (MLR) 
Spleens were removed from mice aseptically into cRPMI.  Splenocytes were isolated 
by homogenising the spleens through a 70 µm filter followed by resuspension in 8 ml of 
cRPMI containing 0.1 % v/v beta-mercaptoethanol.  The homogenate was centrifuged at 
1200 rpm for 7 minutes and resuspended in 2 ml of red blood cell lysis buffer solution 
(BioLegend, San Diego, CA, USA) for 10 min at room temperature.  2 ml of medium was 
added to the suspension to neutralise the lysis solution which was then centrifuged at 600 g 
for 5 min.  Supernatant was removed and the cells were then resuspended in fresh cRPMI for 
counting using EB/AO.  Splenocytes were seeded at a density of 1 x 10
6
/ml and added to a 
96-well plate in a final volume of 225 µl.  For two-way mixed lymphocyte reactions, 
splenocytes from two MHC mismatched mice (typically BALB/C and C57/BL6) were co-
cultured.  The effect of MSC on lymphocyte proliferation was assessed by adding MSC to the 
MLR at a density of 1.5 x 10
5
 cells/ml in a total volume of 225 µl.  The cells were incubated 
at 37 °C for 72 h after which 100 µl of supernatant was carefully removed and stored at -20 
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°C for cytokine analysis.  Medium supplemented with 5 Ci/ml of [3H]-Thymidine 
(Amersham Biosciences, Buckinghamshire, England) replaced the removed supernatant and 
allowed to incubate for 6 h at 37 °C.  Cultures were harvested using an automatic cell 
harvester (Micro96 Harvester, Skatron Flow Laboratories, Oslo, Norway) onto glass filter 
mats.  The mats were dried and placed in plastic sample bags (Wallac– PerkinElmer, 
Waltham, MA, USA).  3 ml of β-scintillation fluid (Beta-Plate Scint, Wallac-PerkinElmer) 
was pipetted into the bag after which it was sealed and placed in a cassette.  [
3
H]-Thymidine 
incorporation was quantified by a β-scintillation counter (1450 MICROBETA Liquid 
Scintillation Counter; Wallac-Perkin Elmer) and results were expressed in counts per minute 
(cpm).   
  
2.20 OVA-SPECIFIC T-CELL PROLIFERATION ASSAY 
Splenocytes from mice were prepared as previously described (Section 2.17).  The 
cells were seeded at a density of 1 x 10
6
 cells/ml in a total volume of 225 µl.  Concanavalin A 
(ConA)(5 ug/ml) was used as a positive control and increasing concentrations of OVA (20, 
50 and 200 µg/ml) were added to selected cultures.   Medium alone was added to negative 
control wells.  Following incubation for 72 h, supernatants were removed and stored at -20 
°C for cytokine analysis, and cultures received fresh medium.  Cells were incubated for the 
final 6 h with 5 Ci/ml [3H]-thymidine and proliferation was measured as radioactivity 
incorporated by liquid scintillation as described in 2.17.  
 
2.21 ISOLATION AND CULTURE OF MURINE MESENCHYMAL STEM CELLS 
Female mice were sacrificed by cervical dislocation.  Femurs and tibias were removed 
under sterile conditions and stripped of connective tissue.  The ends of each bone were 
removed and the bone marrow flushed out using a 27 G needle and syringe filled with 
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isolation medium (Table 2.1, p.73).  Cells were then centrifuged at 600 g for 5 minutes, 
resuspended in complete isolation medium and plated in tissue culture flasks.  Cells were 
maintained for a period of four weeks with medium changes every 3-4 days at 37 C in 5 % 
CO2 incubator.  After this four-week period, cells were passaged (P1) and further cultured for 
two weeks at a low seeding density of 50 cells/cm
2
 in complete isolation medium (cα-MEM 
expansion medium, Table 2.1, p. 72).  The cells were then passaged and expanded twice (P2, 
P3) at a seeding density of 50 cells/cm
2
 before use in vitro or in vivo. 
 
2.22 CHARACTERISATION OF MSC BY FLOW CYTOMETRY  
 Cells were grown to 70-90 % confluence and split using 0.25 % trypsin/1 mM EDTA 
(Gibco, Carlsbad, CA) for 5 min at 37°C.  An equal volume of medium (cα-MEM) was 
added to cells to neutralise the trypsin/EDTA (Gibco).  Cells were centrifuged at 600 g for 5 
min and resuspended in FACS buffer (PBS containing 1% FCS) for counting.  Cells were 
resuspended in the appropriate volume of FACS buffer to yield a concentration of 1 x 10
5
 
cells/FACS tube in 50 µl.  Fluorochrome or unconjugated antibodies (see Table 2.5) were 
incubated with the cells for 15 min at 4 °C.  Cells were then washed in buffer and centrifuged 
at 300 g for 5 min.  Supernatant was discarded and the cells requiring secondary labelling 
were allowed to incubate with the appropriate secondary conjugated antibodies for 15 min at 
4 °C.  All cells were washed in 2 ml of buffer, followed by centrifugation at 300 g for 5 min 
followed by resuspension in 300 µl of cell fixative.  Cells were analysed for their cell surface 
expression of MHC class I, Sca-1, CD44, CD80, CD106, CD117, CD105, CD80, CD45 and 
CD90 by flow cytometry (FACSCalibur, California, USA) using CellQuest software (BD 
Biosciences, Oxford, UK).  
  
2.23 CHARACTERISATION OF MSC DIFFERENTIATION CAPACITY 
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2.23.1  OSTEOGENESIS 
MSC were seeded at a density of 1 x 10
3 
cell/cm
2 
in a 6-well plate in 2 ml cα-MEM.  
Once confluence had been reached (typically 7 days), cells were incubated in osteogenic 
differentiation medium (see Table 2.1).  Fresh medium was added every 3-4 days for 21 days.  
At day 21, the medium was removed and the cells were washed in PBS and then fixed in 10 
% (v/v) neutral buffered formalin for 20 min at room temperature.  Formalin was removed 
and cells were washed in 2 ml of PBS.  1 ml of Alizarin Red (see Table 2.1) was added to the 
fixed cells and allowed to stain for 20 min.  Excess stain was removed and the cells were 
washed with dH2O.  Finally, 1 ml of dH2O was added to each well and cells were examined 
under the microscope for red deposits indicating the presence of osteogenesis. 
 
2.23.2 CHARACTERISATION OF MSC ADIPOGENIC DIFFERENTIATION CAPACITY 
MSC were seeded at a density of 1 x 10
3 
cell/cm
2 
in a 6-well plate (BD Falcon) in 2 
ml cα-MEM.  Once confluence had been reached (typically 7 days), cells were incubated in 
adipogenic differentiation medium (see Table 2.1) and fresh medium was added every 3-4 
days for 21 days.  At day 21, the medium was removed and the cells were washed in PBS and 
then fixed in 10 % neutral buffered formalin for 20 min at room temperature.  Formalin was 
removed and cells were washed in 2 ml of PBS.  1 ml of Oil Red O (see Table 2.1) was added 
to the fixed cells and allowed to stain for 20 min.  Excess stain was removed and the cells 
were washed with PBS.  Finally, 1 ml of PBS was added to each well and cells were 
examined under the microscope for red fat globules indicating the presence of adipogenesis.   
 
2.23.2 CHARACTERISATION OF MSC CHONDROGENIC DIFFERENTIATION CAPACITY 
A pellet culture system was used for chondrogenesis differentiation. 2 x 10
5
 cells were 
centrifuged in a 15 ml polypropylene tube.  The pellet was cultured at 37 °C in 5 % CO2 in 
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500 µl of chondrogenic medium (see Table 2.1).  Fresh medium was added every 3-4 days 
for 21 days, after which the pellets were washed with Dulbecco‟s PBS.  Purification of total 
RNA from cell cultures was performed using the RNeasy® Plus Mini kit (Qiagen, Crawley, 
UK) according to manufacturer‟s instructions, reverse-transcribed to cDNA and analysed for 
the expression of chondrogenesis markers aggrecan and collagen II using hotstart RT–PCR 
reaction (Promega, Southampton, UK) (Section 2.34).  Glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) was detected as an internal control. 
 
2.24 DELIVERY OF MSC TO MICE 
Animals were held in conventional cages before and after procedure.  Before infusion, 
cells were washed three times with sterile PBS and resuspended at a concentration of 5 x 10
5 
cells/ml.  The cells were delivered to the tail vein using a 27 G needle and a 1 ml syringe.  
Animals were then returned to their cages where they were monitored closely for the first 
hour, and at regular intervals daily for signs of distress or ill health.  If distress or ill health 
was observed, animals were killed by cervical dislocation.  At appropriate time points 
following infusion of MSC, animals were killed by cervical dislocation.  Organs and serum 
were removed for analysis. 
 
2.25 DEPLETION OF REGULATORY T CELLS IN VIVO 
Mice were sensitised with 100 µg of OVA in alum on day 0, 7 and 14 according to the 
model described in Section 2.4.  A moderate dose of cyclophosphamide (CY) (Sigma) was 
used in this study (Yung-Chang, 2006).  Mice received 3 doses of 150 mg/kg CY 
intraperitoneally on day 8, 12 and 15.  One group received 2 intravenous infusions of MSC 
via the tail vein on day 7 and 14.  All groups were challenged with OVA (50 µg in 30 µl 
PBS) intranasally on day 25, 26 and day 27.  Mice were culled on day 28.   The effectiveness 
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of depletion was assessed by examination of regulatory T cell marker expression (CD25 and 
FoxP3) by flow cytometry. 
 
2.26 DETECTION OF MALE CELLS IN FEMALE MICE BY FLUORESCENT IN SITU 
HYBRIDISATION (FISH) 
FISH is a cytogenetic technique used to detect the presence or absence of DNA-
specific sequences on chromosomes.  A Y-chromosome-specific probe was used to detect 
male MSC transplanted into female recipients.  Using sex-mismatched transplantation, the Y-
chromosome of male donor MSC were detected with a Cy3 chromosome (Cambio 1200-
YMC 3.02) paint probe.  The probe hybridised with a prepared lung tissue section from 
recipient female mice.  Tissue sections were dewaxed with xylene and subsequently 
rehydrated in several graded alcohols to water.  The slides were incubated with sodium 
thiocyanate for 10 minutes at 80 ˚C and washed in PBS.  Incubation in a pepsin solution was 
crucial prior to quenching in a glycine solution.  Next, the tissue sections were fixed in 4 % 
paraformaldehyde for 2 min, washed with PBS and again dehydrated through graded 
alcohols.  13 μl of Cy3 Chromosome Y paint was dropped on the centre of the slide; a 
coverslip was mounted and sealed with rubber cement.  The section was denatured at 60 ˚C 
and placed in a humid chamber to hybridise overnight at 37 ˚C.  Slides were first washed in a 
formamide wash solution at 37 ˚C for 5 min three times, followed by a stringency wash 
solution at 37 ˚C for 15 min x 3, and finally in detergent wash solution at 37 ˚C for 10 min.  
Following 3 washes in PBS, the nuclei were counterstained with DAPI.  Sections from un-
transplanted females were used as negative controls for Y-chromosome staining. 
 
2.27 CRYOSECTION AND IMMUNOFLUORESCENCE 
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Mice were sacrificed and the respiratory tract was exposed by dissection.  A small 
incision was made in the trachea with a scalpel, and an 18 G needle inserted carefully to 
avoid damaging the trachea.  A 1 ml syringe was filled with a 1:1 OCT (optimal control 
temperature): sucrose (10 %) solution, and fitted to the syringe.  The lungs were slowly filled 
with OCT sucrose solution until they were expanded as much as possible.  The lungs were 
dissected; the lobes were separated and placed in a disposable mould.  The mould was filled 
with OCT (undiluted) until the lung lobes were fully covered, and snap frozen in liquid N2 
until OCT turned white in colour.  Tissues were sliced into 5 μm sections on a cryostat 
(Shandon Cryotome, ThermoShandon, Waltham, MA) and stored at 80 ˚C until ready to 
examine by fluorescent microscopy. 
 
2.28 RECOVERY OF CELLS FROM LIQUID NITROGEN 
Cells were quickly thawed to 70 % liquid at 37 °C and transferred to a 15 ml tube.  
8ml of warmed medium was added to the cells and centrifuged at 600 g for 5 min.  
Supernatant were discarded, and the pellet was resuspended in 2 ml of warmed medium for 
counting. 
 
2.29 PARAFORMALDEHYDE-FIXED MSC 
Cells were trypsinised and resuspended in 50 ml paraformaldehyde (0.5 % in PBS) for 
20 min at room temperature.  Cells were washed with 50 ml PBS three times and resuspended 
in PBS for counting using EB/AO. 
 
2.30 ASSESSMENT OF CELL CHEMOTAXIS  
Cell migration was examined using a 24-well Transwell culture chambers with 5.0 
μm pore polycarbonate membrane insert (Corning Costar, Massachusetts, USA). 
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Recombinant murine CCL11 (eotaxin) (Immunotools) or recombinant murine RANTES 
(Immunotools) were diluted to 100 µM in serum-free medium (RPMI containing 1 % L-
glutamine) and added to the lower chamber compartment in a final volume of 600 µl.  
Control wells contained medium alone.  The polycarbonate membranes inserts were placed in 
the wells using sterile forceps and allowed to equilibrate with the chemokine at 37 °C in 5 % 
CO2 for 10 min.  5 x 10
4
 eosinophils (cell line, EOL-1) in a final volume of 100 µl were 
pipetted into the upper chamber.  Following 4 h incubation, the membrane inserts were 
removed and cells that had migrated to the lower chamber were counted in five fields of view 
using a inverted microscope with a digital camera attached (Olympus, London, UK).  
Chemotactic index (CI) was calculated by normalising the cell migration in control wells to 1 
and expressing wells containing the chemokine as fold increases of the control CI.    
 
2.31 EXPRESSION OF EOSINOPHIL SURFACE MARKERS  
To assess the effect of MSC on the expression of eosinophil adhesion markers, human 
MSC and human eosinophil cell line (EOL-1) were co-cultured in a 6-well plate (Nunc, 
Roskilde, Denmark) at a density of 5 x 10
4
 and 3 x 10
5
, respectively, for 48 h at 37 °C in 5 % 
CO2.  Co-cultures were prepared at four ratios of eosinophils:MSC (10:1, 5:1, 3:1 and 1:1).  
Eosinophils were carefully aspirated, leaving adherent MSC on the plate.  The cells were 
centrifuged at 300 g for 5 min and resuspended in FACS buffer for viability counting (2.11).  
Cells were transferred to polypropylene tubes at a concentration of 5 x 10
4
/tube in 50 µl of 
cold FACS buffer for incubation with appropriate antibodies.  Cell surface expression of 
ICAM-1, ICAM-3, CD18 and L-selectin on eosinophils was examined by flow cytometry.  
 
2.32 DETECTION OF APOPTOTIC CELLS 
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Apoptosis was detected by binding of Annexin V/Propidium iodide staining according 
to manufacturer‟s instructions (BD Biosciences).  Cells were washed twice in PBS and 
resuspended in 1x binding buffer (BD Biosciences) at 1 x 10
5 
cells/50 l.  2.5 l of Annexin 
V (BD Biosciences, Oxford, UK) and/or 5 l of propidium iodide (BD Biosciences) were 
added to FACS tubes (Falcon, BD Biosciences) containing 50 l of cell suspension and 
incubated for 15 min at RT in the dark.  Cells were analysed for binding of Annexin V and/or 
propidium iodide by flow cytometry within 1 h.   
 
2.33 RNA ISOLATION 
Total RNA was extracted using TRIzol® Reagent (Invitrogen) according to the 
manufacturer‟s instructions.  Briefly, 106 cells were lysed in 1ml TRIzol at room temperature 
for 5 min.  100 l of RNA-grade chloroform (BDH) was added to the cells, mixed vigorously 
and incubated at room temperature for 5min.  Samples were centrifuged at 12,000 g for 15 
min at 4 °C.  Two distinct layers resulted with RNA remaining in the clear, aqueous upper 
layer.  350-400 µl of RNA was carefully removed, ensuring the lower white DNA layer was 
not disturbed, and precipitated with 500 l isopropanol (Riedel-de Haen).  The samples were 
incubated at room temperature for 10 min and followed by centrifugation for 10 min at 4 °C.  
The resulting RNA pellet was washed with 1 ml 75 % v/v ethanol and centrifuged at 7,500 g 
for 5 min at 4 
o
C.  The ethanol was aspirated and the RNA pellet was allowed to briefly air 
dry prior to resuspension in 30 l RNase-free water (Promega, Southhampton, UK).  The 
purity and concentration of RNA was determined using a spectrophotometer (Nanodrop 
2000, ThermoScientific, Wilmington, DE, USA) which calculated the ratio of absorbance at 
260 nm to 280 nm.  A ratio between 1.8 and 2.0 indicated sufficient purity of the RNA.   
Samples outside this range were discarded. 
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2.34 DNASE TREATMENT OF RNA 
RNA contaminated with genomic DNA was treated with DNase I (Invitrogen) as per 
manufacturer‟s instructions.  1 μl of DNase (Amplification grade) was added to 5 μl of RNA 
and incubated for 28 min at room temperature.  The mix was then incubated at 65 °C for 10 
min, followed by cooling on ice with 1 μl of 25 mM EDTA to inactivate the DNase.  RNA 
was then reverse transcribed as detailed below (Section 2.35). 
 
2.35 CDNA SYNTHESIS 
Total RNA was reverse transcribed using 25 U Superscript II (Invitrogen, Paisley, 
UK).  Each reaction contained a 1x GoTaq reaction buffer (Promega), 2.5 mM MgCl2 
(Promega), 1 mM dNTP mix (Promega), 50 U/ml of ribonuclease inhibitor (Invitrogen) and 
20 g/ml Oligo (dT) 12-18 primer (Invitrogen) diluted in nuclease-free water (Promega).  The 
conditions for cDNA synthesis were as follows: 25 
o
C for 10 min, 42 
o
C for 60 min, 95 
o
C for 
5 min and 4 
o
C for 10 min.  Quantification of cDNA was performed by measuring the 
absorbance value of the sample 260 nm.  Samples were stored -20 
o
C until required. 
 
2.36 POLYMERASE CHAIN REACTION (PCR)  
PCR was used to determine the presence of specific DNA sequences (or mRNA 
following reverse transcription) using primers summarised in Table 2.5.  Expression of the 
housekeeping gene, GAPDH, was used as a positive control.  PCR reactions contained 2.5 
mM MgCL
2+
, 1 mM dNTP, 1x GoTaq reaction buffer, 40 U/ml Taq polymerase (Promega) 
and 0.4 pM of the appropriate primer pairs.  The reaction mastermix was adjusted to a final 
volume of 24 µl with nuclease-free water.  The PCR conditions were as follows: denaturation 
at 95 °C for 45 sec (10 min for first cycle), annealing for 45 sec (optimal annealing 
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temperatures are summarised in Table 2.6) and extension for 1 min at 72 °C.  DNA products 
were resolved on a 1.3 % w/v agarose gel and detected by binding of ethidium bromide.     
  
2.37 COMPLIANCE WITH GMO AND SAFETY GUIDELINES 
All GMO/GMM work was performed according to approved standard operating 
procedures and recording protocols approved by the Environmental Protection Agency 
(Ireland).  Safe working practices were employed throughout this study as documented in the 
Biology Department Safety manual NUI Maynooth. 
 
2.38 STATISTICAL ANALYSIS 
Student‟s T-test was used to measure the significance between groups.  Probabilities 
less than 0.05 were considered significant.  Values for all measurements were expressed as 
the mean ± standard error of the mean (SEM). Statistical analysis was performed using 
GraphPad Prism software (GraphPad, San Diego, CA).  Comparison was made using the 
Kruskal Wallis test, or the Mann Whitney test as appropriate.  Significance was denoted by p 
value <0.05.  
 
 
 
 
 
 
 
 
73 
 
 
 
 
74 
 
 
 
 
75 
 
76 
 
77 
 
78 
 
79 
 
80 
 
81 
 
82 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
AN EXPLORATION OF THE “HYGIENE HYPOTHESIS” USING AN 
ATTENUATED STRAIN OF BORDETELLA PERTUSSIS 
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3.1 INTRODUCTION 
Since CD4
+
 Th2 cells represent a co-ordinating cell type in allergy, it has been 
suggested that the induction of counterbalancing responses might prevent the subsequent 
development of atopic disease (Strachan, 2000; Romagnani, 2004).  According to this 
modification of Strachan‟s hygiene hypothesis, microbial exposure activates innate immune 
pathways that alter Th1, Th2 and Treg responses (Romagnani, 2004) resulting in the 
suppression of Th2 cell expansion, and a consequent inhibition of isotype switching to IgE.  
Contrary to this hypothesis, several studies have suggested that viral and bacterial infections 
play a role in exacerbation of respiratory disease.  Virulent Bordetella pertussis infection can 
exacerbate airway pathology (Mills, 1998; Ennis, 2004; Harju, 2006) and stimulate IgE 
responses in a murine model of allergen driven-inflammation despite induction of Th1 
immunity (Nilsson, 1998; Ryan, 2000).  However, systemic immunisation with Th1-inducing 
whole-cell pertussis (Pw) vaccines inhibits allergic airway responsiveness (Ennis, 2005) 
indicating that protection from allergen-driven pathology is not simply modulation of 
Th1/Th2 responses, but may also be associated with the degree of airway damage at the time 
of priming, such that allergen priming in the mucosae during breakdown of the airway 
epithelial mesenchymal unit may be an equally important factor (Holgate, 2000).  A 
genetically-attenuated B. pertussis strain, BPZE1, has been developed as a live neonatal 
mucosal vaccine candidate against whooping cough (Mielcarek, 2006).  This strain induces 
strong local and systemic immune responses upon a single intranasal delivery.  This chapter 
explored the influence of the candidate vaccine on OVA-induced airway pathology in order 
to (1) test the hypothesis that priming during a period of respiratory damage is an important 
factor in the phenotypic shift from Th2 to Th1 allergen-specific responses and (2) ascertain 
the safety of this live vaccine candidate in a preclinical model. 
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3.2 STUDY DESIGN– A MODEL OF ALLERGIC AIRWAY INFLAMMATION 
The murine model of ovalbumin driven airway inflammation was used to elucidate 
the effect of an attenuated Bordetella pertussis strain, BPZE1, in vivo.  Systemic sensitisation 
to OVA followed by respiratory allergen exposure induces an acute allergic response in the 
airways and lungs.  This model has been used previously to uncover the influence of infection 
on allergen-driven inflammation (Ennis, 2005; Ennis, 2005).  This was probed using Th1-
inducing virulent (airway damaging) and attenuated (non-damaging) bacterial strains.  Mice 
were challenged with either virulent BPSM, or attenuated BPZE1, and sensitised to OVA at 
the peak of bacterial carriage (day 10) to investigate whether respiratory damage is an 
important factor in effecting a phenotypic shift from Th2 to Th1 allergen-specific responses.  
Section 3.3 summarises the experimental outline.   
Doses of allergen and bacterial challenge were based on the prior work of Ennis et al 
(Ennis, 2005).  A preliminary study was carried out in order to assess the efficacy of 
intranasal delivery of OVA with our without anaesthesia.  Fully conscious or anaesthetised 
mice were administered trypan blue dye (0.4 % in PBS) intranasally.  After 1h, the mice were 
culled.  The lungs were dissected and examined for the presence of blue stain within the 
trachea and lungs.  No stain was evident in the airways of non-anaesthetised mice, but 
deposited stain was seen in lungs of anaesthetised animals (Fig. 3.1).  This suggested that 
intra-nasal delivery without anaesthesia likely resulted in the bulk of material being 
misdirected to the oesophagus and subsequently the gastro-intestinal tract.  As a result, mice 
were routinely anaesthetised prior to intranasal delivery of OVA.  
 
3.3 EXPERIMENTAL OUTLINE 
Virulent B. pertussis (BPSM) or attenuated BPZE1, were cultured as described in 
Section 2.2 and delivered via aerosol to mice on day 0.  Ten days later, at the height of 
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bacterial infection (Mills, 1998), mice were sensitised with OVA by intraperitoneal injection 
(100 μg) and injected again on day 24.  On days 35, 36 and 37, mice were exposed to either 
saline or OVA via the intranasal (i.n.) route.  Un-sensitised control mice received either PBS, 
BPSM or BPZE1 alone (Fig. 3.2).  On day 38, airway hyperresponsiveness to a chemical 
irritant (methacholine) was assessed using whole-body plethysmography.  On day 39, mice 
were bled by facial bleed for subsequent serum analysis.  Mice were culled and BALF, spleen 
and lungs were sampled for subsequent analysis.  BALF supernatants were collected and 
cytokine profiles were examined.  Differential cell counts were performed to assess the extent 
of cellular infiltration.  Splenocytes were cultured in the presence of exogenous OVA and 
their ability to mount a recall response was measured.  Lungs were fixed in 10% formalin for 
histological analysis in order to examine the effect of an attenuated B. pertussis strain on 
OVA-induced airway pathology.         
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Figure 3.1 Anaesthesia during intranasal delivery of allergen is required for sufficient 
antigen delivery to the airways.  Fully conscious (A) or anaesthetised (B) mice were 
administered 0.4 % trypan blue dye by placing 50 µl solution of each nostril and allowing it 
to be inhaled.   
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Figure 3.2 Experimental design.  Groups of 6-8 week old female BALB/c mice (n=10) 
were challenged by aerosol with either an attenuated strain (BPZE1) or virulent (BPSM) B. 
pertussis on day 0.  Control mice were sham infected by aerosol exposure to physiological 
saline.  Mice were sensitised by intraperitoneal (i.p.) injection of either OVA or saline on 
days 10 and 24.  On days 35, 36 and 37, mice were exposed to either saline or OVA via 
intranasal (i.n.) administration.  Readouts were performed on day 39. 
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3.4 OPTIMISATIONS:  
3.4.1 OVA-SPECIFIC IGE ELISA 
Optimisation of an OVA-specific IgE assay was required in order to examine whether 
B. pertussis infection influenced IgE induction in a model of allergic airway inflammation.  
Three variables of the ELISA protocol were adjusted.  Initially, milk powder and fetal calf 
serum (FCS) were compared as blocking buffers.  Blocking with milk powder resulted in 
excessive background readings (Fig. 3.3A).  Therefore, FCS was used in future experiments.  
Varying dilutions of Tween were used in order to determine the optimum buffer for washing 
the plate after serum incubation.  The optimum was found to be 0.2 % Tween in PBS (Fig. 
3.3B).  Further, a 1/250 dilution of anti-mouse biotinylated IgE detection antibody and the 
use of a carbonate coating buffer instead of PBS proved most successful in this assay (Fig. 
3.3D).      
 
3.4.2 COMPARISON STUDY OF MULTIPLEX BEAD ARRAY AND ELISA FOR CYTOKINE 
DETECTION 
Due to the limited quantity of BALF supernatant resulting from the in vivo 
experiments, an alternative method for multiple cytokine quantitation was required in order to 
determine a broad cytokine profile from each sample.  A comparison study to examine the 
similarity of results between multiplex bead array analysis and ELISA was carried out.  Both 
ELISA and multiplex bead array assays were performed on supernatant samples from eight 
treatment groups resulting from a mixed lymphocyte reaction experiment.  The resulting data 
were compared for their reproducibility.  This study found a generally good agreement 
between the multiplex assay and ELISA.  Whilst the bead array and ELISA assays yielded 
different absolute concentrations of cytokines, the cytokine levels followed similar qualitative 
patterns (i.e. similar trend), with Pearson correlation coefficients consistently above 0.85 for 
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IL-10 and IFN-γ, and 0.7 for IL-5 (Table 3.1).  The interpretations of the degree of 
correlation (none, small, medium, large) are given in Table 3.2.  Results were 2 to 10-fold 
lower for multiplex analysis when compared to ELISA determinations and there was poorer 
sensitivity in the case of IL-5 when compared to ELISA.  Similar to other investigators 
(Chen, 1999; Khan, 2004; Young, 2008) multiplex bead array assays have demonstrated good 
correlations with ELISA, but poorer concurrence of quantitative values.  However, these data 
indicated that the multiplex assay could be used as a sufficiently sensitive method to detect 
cytokines in splenocyte supernatant.        
 
Table 3.1 Correlation between multiplex studies and ELISA of mouse cytokines.   
Cytokine
1
 Pearsons correlation coefficient 
2
IL-5 0.692332 
2
IL-10 0.849009 
3
IFN-γ 0.89259 
 
1 Splenocyte supernatant from eight treatment groups were analysed for IL-5, IL-10 and IFN-γ using both 
ELISA and multiplex bead array methods.  Each assay was performed according to the manufacturers‟ 
instructions.  Standard curves were generated using reference concentrations supplied by each manufacturer.  
Pearson correlation coefficient was calculated as a measure of the correlation between two variables (ELISA 
and multiplex bead array).  
2ELISA from R&D 
3ELISA from Peprotech 
 
Table 3.2 Summary of Pearson correlation coefficients 
Descriptor of Correlation Negative Positive 
None -0.09 to 0.0 0.0 to 0.09 
Small -0.3 to -0.1 0.1 to 0.3 
Medium -0.5 to -0.3 0.3 to 0.5 
Large -1.0 to -0.5 0.5 to 1.0 
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Figure 3.3 Optimisation of OVA-specific IgE assay.  The sensitivity of an assay is given by 
the r
2
 value of the standard curve.  The closer the r
2
 is to 1, the greater the sensitivity of the 
assay. (A) milk powder used as coating buffer, (B) low concentration of PBS-Tween wash 
buffer, (C) 1/200 dilution of biotinylated anti-IgE.  (D) Optimum conditions included the use 
of carbonate coating buffer, a greater concentration of washing buffer and 1/250 dilution of  
biotinylated anti-IgE.
A B 
C D 
pg/ml 
pg/ml pg/ml 
pg/ml 
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3.5 ATTENUATED B. PERTUSSIS PREVENTS OVA-DRIVEN ALLERGIC AIRWAY 
PATHOLOGY. 
Virulent B. pertussis can exaggerate unrelated allergen priming in animal models 
(Ennis, 2004) and has been associated with exacerbation of allergy in humans (Harju, 2006).  
To assess the influence of the candidate BPZE1 vaccine on OVA-induced airway pathology, 
mice were challenged with either virulent BPSM, or attenuated BPZE1, and sensitised to 
OVA at the peak of bacterial carriage.  As expected, non-sensitised groups exhibited no 
allergen-driven airway inflammation (Fig. 3.4).  In the absence of infection, OVA-sensitised 
mice exhibited typical peribronchial and perivascular inflammation at day 39, which was not 
observed in control mice (Fig 3.5 A&B).  At this time point, pathology due to virulent 
bacterial infection alone has resolved (Barnard, 1996; Skerry, 2009).  Priming at the peak of 
virulent B. pertussis infection resulted in a more severe pathology when compared to non-
infected sensitised mice, featuring strong perivascular inflammation and hypertrophied 
bronchiolar epithelium (Fig 3.5 C).  In contrast, prior challenge with attenuated BPZE1 
resulted in decreased peribronchial inflammation when compared to sensitised, BPSM-
infected mice (Fig 3.5 C&D).  Thus BPZE1 does not damage the airways, confirming earlier 
reports (Skerry, 2009), and thus differential challenge by BPSM or BPZE1 provides an 
opportunity to study priming in the presence or absence of airway damage.   
Excessive mucus secretion from goblet cells is a characteristic feature of the allergic 
airway.  An examination of lung tissues stained with PAS and Alcian blue demonstrated that 
prior immunisation with BPZE1 in OVA-sensitised mice reduced mucus secretion when 
compared to those sensitised to OVA alone (Fig. 3.6 G&H).  In contrast, virulent BPSM-
infection exacerbated goblet cell hyperplasia and mucus secretion in OVA-sensitised mice 
(Fig 3.6 D&E).  Taken together these data show that unlike infection with virulent B. 
pertussis, administration of attenuated B. pertussis BPZE1 did not enhance, but reduced the 
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pathology associated with allergen sensitisation.  
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Figure 3.4 Non-sensitised mice exhibit no allergen-driven airway inflammation.  
Representative morphological changes at day 39 in bronchiolar transverse sections of 
lungs from (A&B) non-sensitised after immunisation with BPZE1 (C&D) Non-sensitised 
and infected with B. pertussis.  All sections are representative of duplicate experiments; 
in each case at least five animals were assessed.  Original magnification A & C x100, B 
& D x400.  
 
A B 
C D 
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Figure 3.5 Attenuated B. pertussis BPZE1 reduces the severity of airway pathology 
induced by sensitising allergen.  Representative morphological changes at day 39 in 
bronchiolar transverse sections of lungs from (A) Non-sensitised, (B) OVA-sensitised, 
(C) OVA-sensitised following infection with virulent B. pertussis SM, (D) OVA-
sensitised following immunisation with BPZE1.  Airway inflammation was detected 
using haematoxylin and eosin (H&E) staining of fixed lung sections.  p and h indicate 
perivascular inflammation and bronchiolar epithelial hypertrophy, respectively.  All 
sections are representative of duplicate experiments; in each case at least five animals 
were assessed.  Original magnification A, B, C & D x400.  
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Figure 3.6 Attenuated B. pertussis BPZE1 reduces the severity of mucus 
hyperplasia to sensitising allergen.  Representative morphological changes at day 39 
in transverse sections of lungs (bronchiolar region) from (A & B) non-sensitised, (C & 
D) OVA-sensitised, (E & F) OVA-sensitised and infected with virulent B. pertussis, (G 
& H) OVA-sensitised and vaccinated with BPZE1. Airway inflammation was detected 
using combined Discombes/Alcian blue/PAS staining on lung sections.  g and m 
indicate goblet cell hyperplasia and mucus secretion, respectively.  All sections are 
representative of duplicate experiments; in each case at least five animals were assessed.  
Original magnification (A), (C), (E), (F) x100 and (B), (D), (F), (H) x400. 
G H 
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3.6 ATTENUATED B. PERTUSSIS BPZE1 PREVENTS OVA-DRIVEN ALLERGIC AIRWAY 
INFLAMMATION  
 Sensitisation and aerosol challenge of mice with ovalbumin
 
results in airway 
eosinophilia and extensive lung damage analogous to that
 
seen in asthma (Lukacs, 1994).  
Administration of live B. pertussis BPZE1 moderated the quality of the OVA-induced 
inflammatory influx to the respiratory tract.  Control mice showed minimal cellularity in 
bronchoalveolar lavage (Fig. 3.7A & 3.8A), whereas OVA sensitisation/challenge resulted in 
significant infiltration by inflammatory cells (>2 x 10
6
 cells, p<0.05) (Fig. 3.7B & 3.8B).  
The capacity for live attenuated B. pertussis BPZE1 to influence OVA-induced inflammatory 
influx to the respiratory tract was examined.  OVA sensitisation resulted in characteristic 
inflammation with eosinophils, neutrophils, macrophages and lymphocytes detected in 
BALF, which was not seen in control mice (Fig. 3.7 & 3.8).  Mice sensitised during virulent 
B. pertussis infection showed a similar pattern of inflammation.  However, in marked 
contrast, immunisation with live attenuated BPZE1 prior to OVA sensitisation resulted in 
significantly reduced inflammatory infiltration of the airways (p<0.05) for all cells examined.   
 A key feature of inflammation in this model is OVA-driven allergic airway 
eosinophilia (Lukacs, 1994).  However, immunisation with live attenuated BPZE1 prior to 
OVA sensitisation resulted in significant decrease in OVA-driven eosinophil infiltration of 
the airways (p<0.05) (Fig. 3.7D & 3.8D).  The number of lymphocytes in the BALF was 
reduced by BPZE1 administration prior to OVA sensitisation/challenge, when compared to 
OVA treatment alone, whereas, no significant decrease was observed as a result of BPSM 
infection (Fig. 3.7B).  Thus, a major finding of this study was that attenuated B. pertussis 
BPZE1 reduced the OVA-driven allergic airway inflammation typically seen in this model.   
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Figure 3.7 Attenuated B. pertussis BPZE1 reduces the cell infiltrate in BAL fluid.  Effect 
of virulent B. pertussis infection, attenuated BPZE1 challenge and/or OVA sensitisation on 
BAL composition 24h after final OVA exposure.  Negative controls were sham 
infected/sensitised with saline.  BAL fluid was examined for the total cell number (A), or the 
presence of lymphocytes (B), neutrophils (C), eosinophils (D), or macrophages (E).  The data 
are representative of two experiments; in each case, at least five animals were assessed. 
Results are expressed as mean ± S.E.M. of cell number. *p < 0.05. 
B 
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Figure 3.8   BALF was harvested on day 39 from (A) Non-sensitised (B) OVA-sensitised (C) 
OVA-sensitised and infected with B. pertussis, (D) OVA-sensitised and immunised with 
BPZE1, (E) Non-sensitised and immunised with BPZE1 and (F) Non-sensitised and infected 
with B. pertussis.  Cells were stained with Giemsa according to manufacturers‟ instructions 
and examined microscopically for the presence of a number of cell types.  e, m, n and l 
denote eosinophil, macrophage, neutrophil and lymphocyte, respectively.  Magnification x 
400. 
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3.7 ATTENUATED B. PERTUSSIS BPZE1 DOES NOT ENHANCE SERUM IgE RESPONSES 
TO SENSITISING ALLERGEN 
 OVA sensitisation in mice is known to induce IgE and a powerful specific Th2 
response, whereas B. pertussis infection induces a strong Th1 response (Mills, 1993; 
Hamelmann, 1999).  However, pertussis toxin alone can elevate IgE concentrations (Nilsson, 
1998; Ryan, 2000).  Therefore, it was important to explore whether BPZE1, producing a 
genetically inactivated pertussis toxin (Mielcarek, 2006), had an adjuvant effect or enhanced 
allergen-specific IgE.  The influence of BPZE1 on allergic sensitisation was examined by 
measuring the concentration of OVA-specific IgE in serum from mice sensitised to OVA, 
infected with BPSM or BPZE1, or receiving combinations of these treatments (Fig. 3.9).  
Unlike non-sensitised controls, OVA sensitisation induced significant levels of IgE as 
expected.  Allergen-specific IgE responses in mice exposed to attenuated BPZE1 prior to 
OVA sensitisation were not enhanced but were not significantly different to those receiving 
OVA alone.  However, compared to mice infected with virulent BPSM in combination with 
OVA sensitisation, attenuated BPZE1 immunised mice exhibited a reduction (p < 0.05) in 
OVA-induced IgE.  Therefore, unlike virulent B. pertussis SM, live attenuated B. pertussis 
BPZE1 delivered prior to allergen priming did not enhance or have an adjuvant effect upon 
the IgE response to allergen. 
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Figure 3.9 Attenuated B. pertussis BPZE1 does not enhance serum IgE responses to 
sensitising allergen.  OVA-specific IgE in serum elicited in response to OVA sensitisation.  
Sera were collected on day 39 and OVA-specific serum IgE levels were measured by ELISA.  
The data presented are representative of two experiments; in each case, at least five animals 
were assessed, and each individual assessment was performed independently in triplicate. 
Concentrations below 100 pg/ml were considered negative.  Results are expressed as mean 
antibody concentrations ± S.E.M. (*, p < 0.05, ***, p<0.01). 
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3.8 B. PERTUSSIS BPZE1 MODULATES RECALL CYTOKINE RESPONSES TO SENSITISING 
ALLERGEN 
Pathology in the OVA model is driven by Th2 cytokines, in particular IL-5 and IL-13.  
However, there are two components to this; the first is the induction of IgE (Hamelmann, 
1999; Sur, 1999) and classical atopic inflammation.  The second is Th2-driven 
fibrosis/remodelling (Richter, 2001), which can be driven by IL-13 or antagonised by IFN-γ 
(Cohn, 2001; Wen, 2002).  The observations here that allergen specific IgE was not 
significantly changed whilst pathology was reduced in mice immunised with BPZE1 prior to 
OVA sensitisation (Fig 3.5 & Fig 3.9) suggested that a mechanism of protection other than 
IgE reduction was involved here.  To further investigate this, the influence of bacterial 
exposure on the pattern of allergen-induced cellular immune responses was characterised.  
OVA-specific cytokine production in both spleen cell preparations and BALF was assessed in 
the groups described above, in order to evaluate the influence of BPZE1 on allergen-induced 
priming.  As expected, OVA sensitisation alone induced high levels of the Th2 cytokines IL-
4, IL-5 and IL-13 (Fig. 3.10).  Neither virulent BPSM nor attenuated BPZE1 alone induced 
any recall response to OVA.  Virulent BPSM challenge prior to sensitisation did not induce a 
significant reduction in OVA-specific IL-5 or IL-13 and did not increase IFN-γ significantly 
(Fig. 3.10 & 3.11).  However, a striking increase in IL-4 in BALF was observed when 
compared to those sensitised to OVA alone.  In contrast, BPZE1 polarised the allergen 
response away from Th2-type cytokine production.  Prior BPZE1 significantly reduced the 
levels of OVA-induced IL-5 (p<0.005), IL-13 (p< 0.05) and IL-4 (c<0.005).  This was an 
immunomodulatory effect because suppression was not global; BPZE1 significantly 
increased IFN-γ in BALF and from splenocytes re-stimulated with OVA (p< 0.05) (Fig. 3.10 
& 3.12).  In summary, BPZE1 did not promote Th2 cytokine induction to allergen, but rather 
redirected this to a Th1 like response.   This study demonstrated that BPZE1 shifted systemic 
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immune responses to OVA away from IL-4, IL-5 and IL-13 towards IFN-γ.  
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Figure 3.10 B. pertussis BPZE1 modulates recall cytokine responses to sensitising 
allergen in BALF.  Cell-mediated immune responses in BALF, elicited by OVA 
sensitisation 10 days following prior exposure to attenuated (BPZE1) or virulent (BPSM) B. 
pertussis infection.  BALF was harvested on day 39.  Negative symbols indicate sham 
sensitisation or challenge with PBS.  Cytokine responses from similar cultures are shown for 
(A) IL-5, (B) IL-4 (C) IL-13 and (D) IL-10.  Responses are representative of duplicate 
experiments, each of which were determined independently from at least nine mice per group  
and are expressed as means ± S.E.M. p < 0.05.  
A B 
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Figure 3.11 B. pertussis BPZE1 significantly increased IFN- production in BALF.  
BALF was harvested on day 39.  Negative symbols indicate sham sensitisation or challenge 
with PBS.  Responses are representative of duplicate experiments, each of which were 
determined independently from at least nine mice per group and are expressed as means ± 
S.E.M. p < 0.05.   
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Figure 3.12  B. pertussis BPZE1 significantly increased IFN- production from 
splenocytes re-stimulated with OVA.  Spleens were harvested on day 39 and processed as 
described in Section 2.13. Splenocytes were cultured in the presence of media alone (    ) or 
OVA (200µg/ml) (     ) for 72 h.  Negative symbols indicate sham sensitisation or challenge 
with PBS.  Responses are representative of duplicate experiments, each of which were 
determined independently from at least nine mice per group and are expressed as means ± 
S.E.M. p < 0.05.   
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Figure 3.13 B. pertussis BPZE1 modulates recall cytokine responses to sensitising 
allergen from splenocytes re-stimulated with OVA.  Cell-mediated immune responses 
from splenocytes restimulated with OVA elicited by OVA sensitisation 10 days following 
prior exposure to attenuated (BPZE1) or virulent (BPSM) B. pertussis infection.  Cytokine 
responses from similar cultures are shown for (A) IL-5, (B) IL-13 and (C) IL-10.  Spleens 
were harvested on day 39 and processed as described in Section 2.13. Splenocytes were 
cultured in the presence of media alone (     ) or OVA (200µg/ml) (     ) for 72 h.  Negative 
symbols indicate sham sensitisation or challenge with PBS.  Responses are representative of 
duplicate experiments, each of which were determined independently from at least nine mice 
per group and are expressed as means ± S.E.M.  
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3.9 ATTENUATED B. PERTUSSIS BPZE1 DOES NOT ENHANCE AIRWAY 
HYPERRESPONSIVENESS TO SENSITISING ALLERGEN 
In further support of these observations, the influence of BPZE1 immunisation on 
lung function was examined using unrestrained whole-body plethysmography to measure 
PenH, a surrogate of airway hyperresponsiveness, following exposure to methacholine.  As 
expected, sensitisation with OVA increased airway hyperresponsiveness (Fig. 3.14).  
Challenge with wildtype B. pertussis prior to OVA sensitisation demonstrated similar PenH 
values when compared to those sensitised to OVA alone.  However, prior immunisation with 
BPZE1 resulted in significantly reduced bronchial hyperreactivity compared to those infected 
with virulent B. pertussis.  PenH cannot assess direct pulmonary mechanics, but does reflect 
them (Lomask, 2006), therefore, the data needs to be interpreted with caution.  Nevertheless, 
when combined with the histological and cell infiltration studies, these data strongly suggest 
that a live attenuated B. pertussis vaccine did not exacerbate OVA driven allergic airway 
inflammation.   
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Figure 3.14 BPZE1 challenge prior to OVA sensitisation decreases airway 
hyperresponsiveness to sensitising allergen.  Airway responsiveness was assessed on day 
38 by methacholine induced airflow obstruction from conscious mice using whole-body 
plethysmography in conjunction with the BioSystem XA software (Buxco Electronics, USA) 
as described in Section 2.5.  (A) Non-sensitised ( ), OVA-sensitised ( ), BPSM infected + 
OVA sensitisation ( ) and BPZE1 challenge + OVA sensitisation ( ).  (B) Non-sensitised 
(Control ), OVA-sensitised ( ), non-sensitised BPSM infected ( ) and non-sensitised 
BPZE1 challenge ( ).  Results are expressed as mean enhanced pause (PenH) ± S.E.M.  
Where no error bars are visible, error bars are shorter than the size of the data point symbol. 
A 
B 
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3.10 ATTENUATED B. PERTUSSIS BPZE1 DOES NOT ENHANCE RECALL PROLIFERATIVE 
RESPONSES TO SENSITISING ALLERGEN 
It was clear that attenuated BPZE1 has a radically different effect on allergen driven 
airway pathology when compared to virulent B. pertussis.  The influence of bacterial 
exposure on the pattern of allergen induced modulation of the immune response was 
characterised.  In addition to allergen-specific cytokine induction, the effect of BPZE1 on 
recall proliferative responses to exogenous ovalbumin was examined ex vivo.  Splenocytes 
from OVA challenged but not saline challenged mice proliferated significantly in response to 
exogenously added antigen in a dose dependent manner (Fig. 3.15).  Likewise, virulent 
BPSM induced a strong proliferative response to OVA (p<0.001).  BPZE1 significantly 
reduced the levels of OVA specific proliferative responses when compared to OVA-
sensitised mice (p<0.05).  These data indicate that this attenuated B. pertussis strain did not 
have the adjuvant effect on recall OVA-specific proliferative responses, routinely associated 
with virulent B. pertussis (Ennis, 2004).  
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Figure 3.15 BPZE1 prevents recall proliferative response to exogenous allergen.  Cell-
mediated immune responses from splenocytes to OVA, elicited by OVA sensitisation 10 days 
following prior exposure to attenuated (BPZE1) or virulent (BPSM) B. pertussis infection.  
Spleens were harvested on day 39 and processed as described in Section 2.13. Splenocytes 
were cultured in the presence of medium alone (     ) or OVA (200 µg/ml) (     ) for 72 h.  
Subsequent proliferation was measured by 3H-thymidine incorporation (
**
, p<0.05).  
Negative symbols indicate sham sensitisation or challenge with PBS.  Responses are 
representative of duplicate experiments, each of which were determined independently from 
at least nine mice per group and are expressed as means ± S.E.M.   
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3.11 SUMMARY 
This chapter explored the influence of the candidate vaccine on OVA-induced airway 
pathology in order to (1) test the hypothesis that priming during a period of respiratory 
damage is an important factor in the phenotypic shift from Th2 to Th1 allergen-specific 
responses and (2) ascertain the safety of this live vaccine candidate in a preclinical model.  
An attenuated strain of B. pertussis, BPZE1, did not enhance but reduced allergen-driven 
airway pathology.  BPZE1 prevented OVA-driven inflammation of the airways, assessed by 
histological and qualitative analysis of mucus production.  Furthermore, BPZE1 diminished 
the severity of allergen-driven inflammation in the lungs.  Eosinophilic and neutrophilic 
infiltration was significantly reduced in BPZE1-immunized mice sensitised to OVA.  
Virulent BPSM enhanced IL-4 in BALF, whereas BPZE1 modulated allergen responses 
towards a Th1 phenotype, demonstrated by a marked increase in IFN-γ.  Likewise, analysis 
of recall responses to allergen showed that BPZE1 modulated responses away from IL-5 and 
IL-13 towards IFN-γ.  In contrast to virulent B. pertussis, BPZE1 demonstrated no adjuvant 
associated increase in allergen-specific IgE.   
The present study supports findings that suggest allergic asthma is linked not just to 
CD4
+
 T cell profile, but also to the degree of airway damage at the time of priming (Ryan, 
2000).  Here, we use virulent (airway damaging) and attenuated (non-damaging) bacterial 
strains to  show that  prior immunisation with BPZE1, that does not damage the airway 
epithelium (Skerry, 2009) results in a significant reduction in allergic pathology, compared to 
those mice sensitised whilst infected with virulent B. pertussis (Skerry, 2009).  Since 
attenuation of BPZE1 is based on the genetic removal or attenuation of three major toxins, 
pertussis toxin, tracheal cytotoxin and dermonecrotic toxin (Mielcarek, 2006), this study 
suggests that one, or a combination, of the attenuated virulence factors in BPZE1 plays a role 
in the adjuvant effect observed with virulent B. pertussis strains.  The key finding here is that 
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in contrast to virulent B. pertussis, attenuated BPZE1 did not exacerbate allergen-induced 
airway pathology in a murine model indicating that induction of a robust Th1 response in the 
absence of respiratory damage can counteract the pro-allergic responses of Th2 cells. 
The increase of allergic diseases in the industrialised world has often been explained 
by a decline in infections during childhood, suggesting that bacterial and viral infections 
during early life
 
direct the maturing immune system towards Th1, which acts to 
counterbalance
 
the pro-allergic responses of Th2 cells (Strachan, 2000; Romagnani, 2004).  
This results in the suppression of Th2 cell expansion, and a consequent inhibition of isotype 
switching to IgE.  Some versions of the hygiene hypothesis suggest that Th1-inducing 
infections may have an inhibitory effect on the development of atopy (Strachan, 2000).  
However, previous studies have demonstrated that the induction of Th1 immunity did not 
counterbalance Th2 driven allergy but rather altered the pathology (Hansen, 1999; Ennis, 
2004).  This has been clarified by work with microbial agents; for example virulent B. 
pertussis enhanced the severity of allergen driven airway pathology (Mills, 1998; Ennis, 
2004) despite induction of Th1 immunity.  In contrast, systemic immunisation with a Th1-
inducing whole cell pertussis (Pw) vaccine inhibited allergic airway responsiveness (Ennis,  
2005).  These seemingly counter-intuitive findings suggest that protection from allergen-
driven pathology is linked not just to CD4
+
 T cell profile, but also to the degree of airway 
damage at the time of priming.  This is more consistent with asthma models predicated on 
damage and the disruption of the epithelial mesenchymal unit (Holgate, 2000; Wark, 2005; 
Holgate, 2007; Swindle, 2009).  These observations have an important public health 
implication as the need to understand the role of immunisation and prevalence of asthma is 
necessary for reassuring populations recruited to mass vaccination programmes.   
Immunisation with Pw protects against B. pertussis-exacerbation of OVA-induced 
airway hyperresponsiveness in a murine model of allergic airway inflammation (Ennis 2005) 
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and there is no allergy-promoting effect in response to common childhood vaccines, 
including pertussis vaccines (Grüber, 2008).  However, much less is known about protective 
effects of childhood vaccines against allergic asthma. Other investigators have shown that 
live attenuated vaccines, such as oral poliomyelitis vaccine or Bacillus Calmette-Guérin, 
inhibited the development of asthma and allergic disease (Martignon, 2005).  The purpose of 
Chapter 3 was to test the hypothesis that priming during a period of respiratory damage is an 
important factor in the pathology of allergen-specific responses.  This was probed using 
virulent (airway damaging) and attenuated (non-damaging) bacterial strains and in particular 
BPZE1 a candidate for use as a live, intranasal, single-dose neonatal vaccine against 
whooping cough (Mielcarek, 2006).   
The present study supports findings showing that prior immunisation with BPZE1, 
which does not damage the airway epithelium (Skerry, 2009), results in significantly reduced 
allergic pathology, compared to those mice sensitised whilst infected with virulent B. 
pertussis.  BPZE1 prevented OVA-driven inflammation of the airways, diminished the 
severity of allergen-driven inflammation in the lungs and significantly reduced airway 
eosinophilia.  Unlike the virulent strains used in this study, BPZE1 modulated allergen 
responses away from Th2-like responses towards a Th1 phenotype, demonstrated by a 
marked increase in IFN-γ.  BPZE1 also demonstrated no adjuvant associated increase in 
allergen-specific IgE.  Taken together, these data demonstrate that attenuated BPZE1 acts as 
a powerful immunomodulator that suppresses allergen-driven pathology at both a local and 
systemic level, does not promote allergic sensitisation and may indeed be 
immunomodulatory. 
The mechanisms underlying the beneficial influence of attenuated BPZE1 on allergen-
driven pathology may be multiple and inter-linked.  In other models, immune interaction 
between infection and allergen sensitisation critically depends on timing of challenges 
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(Peebles, 2001).  Here, the challenge schedule was chosen to examine the effect of prior 
immunisation on allergen sensitisation and for consistency with previous reports (Ennis, 
2004; Ennis, 2005a; Ennis, 2005b).  However it will be important to examine the reverse 
scenario to assess the effect of immunisation on pre-existing allergen sensitivity, such as that 
seen using unmethylated CpG oligodeoxynucleotides which inhibited ragweed allergen-
induced lung inflammation in pre-sensitised animals (Sur, 1999).  As exposure to CpG 
oligodeoxynucleotides would be expected during challenge with BPZE1, the vaccine might 
also be predicted to inhibit pre-existing sensitivity. 
Pathology in the OVA model is driven by Th2 cytokines, in particular IL-5 and IL-13.  
However, there are two components to this; the first is the induction of IgE (Hamelmann, 
1999) and classical atopic inflammation.  The second is Th2-driven fibrosis/remodelling 
(Richter, 2001), which can be antagonised by IFN-γ (Cohn, 2001; Wen, 2002).  The 
observations here that allergen specific IgE was not significantly changed whilst pathology 
was reduced in mice immunised with BPZE1 prior to OVA sensitisation suggested that a 
mechanism of protection other than IgE reduction was involved here.  Infection with virulent 
B. pertussis exaggerates the OVA-induced inflammatory influx to the respiratory tract, with 
an increase in eosinophils, and an associated increase in the severity of airway pathology.  
Administration of attenuated BPZE1 prior to allergen sensitisation significantly reduced 
inflammatory infiltration (Fig. 3.1).  The inhibition of allergic airway pathology might be 
explained by the modulation of the key cytokines involved in remodelling.  For example, 
airway mucus hypersecretion is in part driven by IL-13 and is a major pathophysiological 
feature of both allergic asthma (Wills-Karp, 1998) and whooping cough (Heininger, 2001).  
Therefore, it is not surprising that mucus production mirrored IL-13 levels in this study and 
was significantly reduced in sensitised mice previously exposed to BPZE1.  This study 
demonstrated that BPZE1 shifted systemic immune responses to OVA away from IL-4, IL-5 
116 
 
and IL-13 towards IFN-γ (Fig. 3.12).  IL-4 and IL-5 contribute to tissue damage and 
remodelling due to their function as mediators of eosinophil recruitment (Brusselle, 1994; 
Gleich, 2000).  However, IFN-γ can directly suppress IL-4 gene expression through IRF-1 
and 2, which bind to three distinct IL-4 promoter sites and act as transcriptional repressors 
(Elser, 2002).  IFN-γ can also inhibit the expression of the eotaxin receptor (CCR3), an 
important inducer of eosinophil differentiation from hematopoietic progenitor cells 
(Lamkhioued, 2003).   
Taken together, these data suggest that immune modulation in this model has its 
greatest impact on mucus secretion and remodelling rather than IgE induction.  Since 
attenuation of BPZE1 is based on the genetic removal or attenuation of three major toxins, 
pertussis toxin, tracheal cytotoxin and dermonecrotic toxin (Mielcarek, 2006), this study 
suggests that one, or a combination, of the attenuated virulence factors in BPZE1 plays a role 
in the adjuvant effect observed with virulent B. pertussis strains.  The protection against 
allergen-driven pathology and the modulation of the allergic immune response by BPZE1 
seen here is consistent with some versions of the hygiene hypothesis.  It might be that the key 
beneficial feature of BPZE1 is the combination of a Th1 skewed response, combined with the 
absence of induced airway pathology.  This is supported by previous reports in which 
exacerbation of airway pathology to allergen was associated with allergen priming during a 
period of airway damage or remodelling (Gern, 2000; Ennis, 2004; Marsland, 2004).
  
Fig. 
3.16 illustrates the plausible mechanisms by which an attenuated B. pertussis strain, in the 
absence of damage, regulates the allergic inflammatory response via an IFN-γ-dependent 
pathway.      
In both systems OVA tends to induce Th2 responses and remodelling, whereas 
infection tends to support IFN-γ and Th1.  In the case of sensitisation during a Th1 infection 
but where no epithelial damage occurs (BPZE1), conventional immune modulation takes 
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place, thus BPZE1 reduces Th2 cytokine production, increases Th1 immunity, and inhibits 
IL-5 secretion and eosinophilia.  Furthermore IFN-γ directly effects remodelling.  In contrast 
when a breakdown in the mesenchymal-epithelial unit occurs (e.g. damage by virulent BPSM) 
in spite of IFN-γ production, there is an over-riding requirement to repair the airways.  The 
fibrotic/remodelling process is exacerbated by the active pertussis toxin adjuvant effect on 
OVA-induced IL-13 and IL-4 which in turn promotes fibrosis.  Thus there is an enhanced 
pathology despite induction of Th immunity.   
The data presented here support the use of BPZE1 as a candidate vaccine even for   
populations where exposure to allergens and atopy is prevalent.  Most current pertussis 
vaccination regimes require three doses, beginning at 2 months of age necessitating 6 months 
for optimal protection (Das, 2002).  Therefore, there is a need for vaccines that induce strong 
protection against B. pertussis in neonates.  BPZE1 has been developed as a candidate 
neonatal vaccine (Mielcarek, 2006) as it induces strong local and systemic immune responses 
upon intranasal delivery (Mielcarek, 2006).  Administration via the nasal route mimics natural 
infection and is expected to promote long-lasting immunity in children from 1 month of age 
(Mascart, 2003).  Live recombinant bacteria that have been adapted to the respiratory tract are 
attractive vehicles for the presentation of vaccine antigens to the respiratory mucosa.  As a 
result, B. pertussis has been used successfully as a live bacterial vector in mouse models 
(Mielcarek, 2001).  These combined benefits of BPZE1 as a potential protective agent against 
atopy makes it an attractive candidate as a neonatal vaccine against whooping cough and also 
a potential vehicle for vaccine delivery via the nasal route.     
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Figure 3.16 Schematic presentation of plausible mechanism by which attenuated B. pertussis, 
in the absence of damage, regulates the allergic inflammatory response via an IFN-γ-
dependent pathway.  In the absence of respiratory damage, BPZE1 increases Th1 immunity, 
reduces Th2 cytokine production and inhibits IL-5 secretion and eosinophilia which directly 
affects airway remodelling.  In contrast when a breakdown in the mesenchymal-epithelial unit 
occurs (e.g. damage by virulent BPSM) in spite of IFN-γ production, the fibrotic/remodelling 
process is exacerbated by the active pertussis toxin adjuvant effect on OVA-induced IL-13 
and IL-4 which in turn promotes fibrosis.   
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CHAPTER 4 
THE ISOLATION AND CHARACTERISATION OF ADULT  
MESENCHYMAL STEM CELLS  
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4.1 INTRODUCTION 
The overall goal of the work presented in this thesis was to investigate immune 
modulation with a particular focus on airway inflammation and allergic pathogenesis.  In 
Chapter 3, this was probed using virulent (airway damaging) and attenuated (non-damaging) 
bacterial strains to test the hypothesis that priming during a period of respiratory damage is 
an important factor in the phenotypic shift from Th2 to Th1 allergen-specific responses.  The 
immunomodulatory capacity of mesenchymal stem cells (MSC) suggests that they have a 
potential therapeutic value in a number of inflammatory and autoimmune diseases models 
(Lee, 2006; Bouchez, 2008).  MSC are a heterogenous subset of stromal stem cells that can 
differentiate into cells of mesodermal lineage, such as adipocytes, osteocytes and 
chondrocytes (Horwitz, 2005).  They possess potent anti-proliferative and anti-inflammatory 
effects supporting their possible use as a therapy for immune-mediated diseases (Krampera, 
2003; Barry, 2005).  The purpose of Chapter 4 was to determine the immunomodulatory 
effect of bone marrow-derived MSC with particular emphasis on the establishment of an 
experimental system.  This was broken down into three objectives: (1) to establish and verify 
that the protocol for MSC isolation from bone marrow delivers reliable and homogenous 
MSC populations for potential cell therapy (2) to investigate the effect of exogenous IFN-γ 
on MSC-mediated immunosuppression in vitro, and (3) to examine the immunosuppressive 
capacity of MSC isolated from IFN-γ-receptor knockout mice. 
 
4.2 ISOLATION OF ADULT MURINE MSC BY ADHERENCE TO PLASTIC 
As bone marrow contains both haematopoietic and mesenchymal cell types, it was 
important to determine the cell type(s) isolated and the purity of those cells.   Murine MSC 
were isolated from the femurs and tibiae of BALB/c female mice using plastic adherence and 
selective media, as described in Section 2.21.  MSC isolated by adherence to plastic were 
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examined microscopically at each passage for changes in morphology.  A homogeneous 
MSC population was evident at passage 3 with fibroblastoid spindle shaped morphology (Fig. 
4.1).  There was no evidence of spontaneous differentiation in these cultures.  Subsequent 
passages were characterised by flow cytometry for expression of surface markers.  Bone 
marrow-derived adherent cell layers comprise many different cell types including fibroblasts, 
hematopoietic progenitor cells, macrophages, endothelial cells, and adipocytes (Tavassoli, 
1982; Zuckerman, 1983; Phinney, 1999).  Typically, MSC isolated by other groups expressed 
CD9, CD29 and CD81 and variable levels of Sca-1, CD106 and CD44 but not CD11b, CD31, 
CD34, CD45, CD48, CD90, CD117 or CD135 (Baddoo, 2003).  Although no specific marker 
has been reported for murine MSC, the expression of Sca-1 and CD44 and the lack of 
expression of CD45 and CD11b are typically used for the identification of MSC (Peister, 
2004).  Primary cultured cells from mouse bone marrow were immunophenotyped for 
expression of various cell surface antigens.  CD44 and Sca-1 expression and absence of 
CD11b and CD45 was observed on the populations selected.  Flow cytometric analysis 
demonstrated that the MSC population lacked detectable expression of MHC II.  They were 
also negative for the haematopoietic markers CD45, CD11b and CD34 and the 
haematopoietic progenitor cell marker CD117.  Passage 3 murine MSC expressed low levels 
of CD106 and CD80 (Fig. 4.2).  The cells were also positive for CD105.  The stability of 
expression was measured over passages 4-8 for all cell types.  MSC characterised at each 
subsequent passage possessed a similar phenotype to that seen at passage 3.  Thus the cells 
isolated were devoid of contaminating haematopoietic cells but showed stable expression of 
typical MSC markers (Fig. 4.1 and Table 4.1) (Baddoo, 2003; Peister, 2004).   
MSC were also isolated from two other mouse strains (FV/BN and IFN-γR-/-), these 
had the same appearance and expression characteristics as the MSC described above (Fig. 
4.2).  A limited number of adult human MSC were also required.  Human MSC were isolated 
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and expanded from aspirates of bone marrow from three different donors provided by 
collaborators at the National University of Ireland Galway (NUIG) and validated by flow 
cytometry (Table 4.2).     
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Figure 4.1 MSC exhibit a homogeneous morphology typical of stromal cells.  Plastic 
adherent MSC were grown to near confluence and examined using phase contrast microscopy 
for morphological appearance at passage 3.  Magnification x100. 
 
Table 4.1 Summary of surface marker expression of mouse mesenchymal stem cells 
 
Marker Expression 
MHC I + 
MHC II - 
Sca-I + 
CD11b - 
CD34 - 
CD44 + 
CD45 - 
CD80 + 
CD90 - 
CD105 + 
CD106 + 
CD117 - 
 
Table 4.2 Summary of surface marker expression of human mesenchymal stem cells 
Marker Expression 
CD29 - 
CD34 - 
CD44 + 
CD45 - 
CD105 + 
CD106 + 
CD90 + 
HLA-ABC + 
HLA-DR - 
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Figure 4.2 MSC isolated by adherence to plastic from FV/BN mice expressed MHC class 
I, Sca-1, CD44, CD80 and CD106 but not CD117, CD105, CD80, CD45 and CD90 at 
passage 3.  MSC were characterised by flow cytometry for expression of a panel of markers 
(black) and corresponding isotype controls (dotted line) at passage 4. A minimum of 10,000 
events were acquired for each marker.  
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Figure 4.3 MSC isolated by adherence to plastic from IFN-γR-/- mice at passage 3 
expressed MHC class I, Sca-1, CD44, CD90 and CD105 but not MHC class II, CD11b, 
CD34, CD45, CD117 or CD80.  Plastic adherent MSC were characterised for expression of 
a number of markers (black) and corresponding isotype controls (dotted line) at passage 4.  A 
minimum of 10,000 events were acquired for each marker.  
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Figure 4.3 MSC isolated by adherence to plastic from human MSC at passage 3 
expressed CD44, CD105, CD44, CD106, CD90 and HLA-ABC but not CD29, 
CDCD34, CD45 or HLA-DR.  Plastic adherent MSC were characterised for expression of 
a number of markers (black) and corresponding isotype controls (dotted line) at passage 4.  
A minimum of 10,000 events were acquired for each marker.  
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4.3 DIFFERENTIATION CAPACITY OF MSC 
An important characteristic of MSC is the ability to differentiate into multiple cell 
types, including cartilage, fatty tissue and bone.  In order to investigate the stemness or 
differentiation potential of the isolated MSC, their ability to differentiate into adipocytes, 
chondocytes and osteoblasts was examined (Fig. 4.5).   In addition, MSC were cultured for 
the same period without differentiation components and examined for the appearance of 
spontaneous differentiation.  Adipocytes were visualised by staining with Oil Red O, 
osteoblasts by staining with Alizarin Red S and chondrocytes by Alcian blue staining.  
Control cells were stained with the corresponding dyes.   Cells differentiated into adipocytes 
were identifiable by large lipid filled vacuoles.  Adipocytes, chondocytes or osteoblasts were 
not observed in control cultures, indicating the absence of spontaneous differentiation (Fig. 
4.5).  These cells maintained their differentiation capacity through each passage.  These data 
confirm the multilineage potential associated with MSC and their capacity to retain this 
function through each generation.  The ability to attach to tissue culture plastic, their potential 
to differentiate along mesenchymal lineages, fibroblastic morphology, and the pattern of cell 
surface markers support the method of isolation used here as sufficient to obtain a pure and 
stable population of MSC for further study. 
 
4.4 IMMUNOMODULATORY CAPABILITY OF MSC 
MSC inhibit the proliferation of T cells induced by non-specific mitogens (Nicola, 
2002; Ryan, 2007).  Therefore, it was important to test for the presence of this characteristic 
feature prior to using the cells therapeutically.  The immunosuppressive ability of MSC was 
assessed by carrying out mitogen driven proliferation assays.  Splenocytes were cultured in 
the presence of the mitogen ConA in the presence or absence of MSC.  The level of 
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proliferation was measured using 
3
H thymidine incorporation. As expected, ConA stimulation 
induced significant splenocyte proliferation (Fig. 4.6), however, MSC significantly inhibited 
this (*, p<0.05).  ConA stimulation is a powerful T cell mitogen, so this result indicated that 
MSC were capable of potent immunosuppression of lymphocyte activity.   
MSC also possess the ability to suppress alloreactivity (Djouad, 2003; Krampera, 
2003; Augello, 2005).  This function was assessed by carrying out a two way murine mixed 
lymphocyte reaction (MLR). Splenocytes from two MHC-mismatched mice (D1 and D2 
isolated from BALB/C and C57/BL6 mice, respectively) were co-cultured.  The effect of 
MSC on lymphocyte proliferation was assessed by adding allogeneic MSC isolated from 
FV/BN mice to the MLR.  The co-culture of allogeneic splenocytes (D1 & D2) induced 
significant proliferation; however, MSC effectively inhibited the proliferation of mismatched 
splenocyte T cells (Fig. 4.7).  This capacity was retained over subsequent passages (4-7). 
These data suggested that the MSC populations used here were capable of 
significantly reducing both alloantigen-driven and mitogen-driven proliferation in mixed 
lymphocyte reactions supporting their use as a therapeutic modality in vivo. 
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Figure 4.5 MSC differentiated along the chondrocytic, adipogenic and osteogenic 
lineages.  MSC were seeded at a density of 1 x 10
3
cells/cm
2 
and cultured in normal media 
(A & C), osteogenic induction media (B) adipogenic induction media (D) or chondrogenic 
induction media (F) for 21 days.  Adipogenesis was visualised by staining cells with Oil 
Red O.  Osteogenesis was assessed using Alizarin Red S.  MSC did not spontaneously 
differentiate into adipogenic (A) osteogenic cells (C) or chondrogenic cells (E) (when 
cultured for 21 days in normal expansion media without differentiation components.  
Magnification x 100.   
A B 
C D 
E F 
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Figure 4.6 Allogeneic MSC inhibit mitogen driven proliferation.  FV/BN MSC (1.5 x 10
4 
/ml) were examined for their capacity to inhibit mitogen (ConA) driven proliferation of 
BALB/c (D1) splenocytes at passage 3.  MSC significantly inhibited mitogen driven 
proliferation (*, p<0.05).  Results are representative of three experiments, each performed in 
triplicate.  
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Figure 4.7 Allogeneic MSC inhibit allo-driven proliferation.  MSC were examined for 
their capacity to inhibit allogeneic-driven proliferation of splenocytes in a two-way mixed 
lymphocyte reaction.  FV/BN MSC (1.5 x 10
4
) were co-cultured with splenocytes (2 x 10
5
) 
from MHC-mismatched mice (BALB/c (D1) and C57BL/6 (D2) respectively). MSC 
significantly inhibited alloantigen driven proliferation (*p<0.0005). Results are representative 
of three experiments, each performed in triplicate.  
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4.5 IFN-GAMMA ENHANCES MSC-MEDIATED IMMUNOSUPPRESSION 
In vitro studies have shown that MSC can suppress T lymphocyte proliferation more 
efficiently when triggered by cellular stimuli, non-specific mitogenic stimuli or antigen 
(Sheng, 2008, Phinney, 2006, Corcione, 2006).   Therefore, pre-stimulation or “licensing” of 
MSC prior to in vivo administration could potentiate its‟ putative protective effect (Ryan, 
2007; Polchert, 2008).  Interferon-gamma (IFN-γ) is a major pro-inflammatory cytokine 
secreted by activated T cells (Krampera, 2006) and can strongly up-regulate co-stimulatory 
molecules (Cheng, 2007).  The effect of pre-incubation with IFN-γ on MSC was examined in 
terms of enhancement of immunosuppressive ability.  Allogeneic MSC (FV/BN) were 
cultured in the presence of recombinant mouse IFN-γ.  The cells were washed and 
subsequently cultured in the presence of MHC-mismatched (BALB/c and C57/BL/6) 
splenocytes or mitogenic stimulus (ConA).  IFN-γ enhanced the inhibitory effect of MSC 
compared to non-stimulated cells.  This was the case in both mitogen-driven (Fig. 4.8 A) and 
allo-driven (Fig. 4.8 B) reactions.  These data indicated that the immunosuppressive effect of 
MSC could be enhanced by pre-stimulation of MSC and supported previous findings that 
IFN-γ licensed MSC for novel functions.  These data also supported the use of these licensed 
cells in in vivo models of disease. 
 
4.6 IFN- GAMMA-SPECIFIC SIGNALING IS REQUIRED FOR IMMUNOSUPPRESSION BY MSC 
To confirm that IFN-γ-specific signaling played a role in triggering the enhancement 
of immunosuppressive function of MSC, MSC isolated from IFN-γ receptor knockout mice 
(IFNγR-/-) were used in a co-culture with allogeneic splenocytes or ConA mitogen.  Co-
culture of mismatched splenocytes with IFNγR-/- MSC failed to inhibit suppression (Fig. 4.9).  
Thus, lack of the IFN-γ receptor impairs the normal functionality of MSC to inhibit 
proliferation supporting a critical role for this cytokine in immune suppression.  Interestingly, 
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IFNγR-/- MSC were capable of effective suppression of mitogen-driven T cell proliferation 
indicating that IFN-γ is not essential for inhibition of proliferation to occur (Fig. 4.10).  To 
further investigate the role of IFN-γ in mitogen-driven proliferation, a more physiologically 
relevant approach which uses beads coated with anti-CD3 and anti-CD28 to stimulate T cells 
in a manner that partially mimics antigen specific stimulation by antigen-presenting cells was 
employed (Fig. 4.11).  Here, MSC lacking IFN-γ receptor expression were not capable of 
effective suppression of mitogenic proliferation demonstrating the critical role of IFN-γ 
signalling in MSC-mediated inhibition of  cognate allogeneic T cell responses.    
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Figure 4.8 “Licensed” MSC enhance the immunosuppressive ability of MSC in allo- and 
mitogen-driven reactions. MSC cultured in the presence of 500U/ml of recombinant IFN-γ 
were added to an MLR at a density of 1.5 x 10
4
/ml.  The effect of prior stimulation on (A) 
allo-driven and (B) mitogen-driven proliferation was assessed by 
3
H thymidine incorporation. 
Results are representative of three experiments, each performed in triplicate. (* p<0.05, ** 
p<0.005, *** p<0.0005).  
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Figure 4.9 IFN-y receptor KO MSC fail to suppress allo-driven T cell proliferation.  
MSC isolated from IFN-γ receptor knockout mice were examined for their capacity to inhibit 
allogeneic-driven proliferation of splenocytes in a two-way mixed lymphocyte reaction.  
MSC (1.5 x10
4
/well) were co-cultured with splenocytes (2 x 10
5
/well) from MHC-
mismatched mice (BALB/c (D1) and C57BL/6 (D2) respectively).  MSC lacking the IFN-γ 
receptor did not retain the capacity to suppress allo-driven proliferation.  Results are 
representative of three experiments, each performed in triplicate. ** p<0.005 
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Figure 4.10 MSC retain the capacity to inhibit mitogen-driven proliferation in the 
absence of the IFN-γ receptor.  MSC lacking the IFN-γ receptor (1.5 x 104/ml) were 
examined for their capacity to inhibit mitogen (ConA) driven proliferation of BALB/c 
splenocytes.  Results are representative of three experiments, each performed in triplicate. * 
p<0.05 
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Figure 4.11.  IFN-y receptor KO MSC fail to suppress anti-CD3 T cell proliferation.  
MSC isolated from IFN-γ receptor knockout mice were examined for their capacity to inhibit 
αCD3/CD28-driven proliferation of splenocytes.  FV/BN MSC (1.5 x104) or IFN-γR-/- MSC 
were co-cultured with CD3/CD28.  MSC lacking the IFN-γ receptor did not retain the 
capacity to suppress proliferation.  Results are representative of three experiments, each 
performed in triplicate.  
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4.7 VIABILITY OF MSC IS NOT AFFECTED BY SHEARING FORCE 
Prior to in vivo studies, it was important to ascertain whether the structural integrity 
and viability of MSC was affected by intravenous injection.  The mechanical responses of 
mesenchymal stem cells to deformation were investigated to determine the effect of different 
gauge needles on cell viability.  This study was carried out to demonstrate that shearing force 
was not a confounding factor.  MSC (1 x 10
5
) were passed through four needle sizes (23 G, 
25 G, 27 G and 30 G) via syringe and viability assessed pre and post passage.  Viability was 
assessed by viable cell counting (Chapter 2.14).  The cells were then transferred to individual 
tissue culture flasks and incubated for 48 h in order to assess whether the cells retained their 
capacity to adhere to plastic.  In addition, the effect on MSC structure and size was assessed 
by flow cytometry, where forward and side scatter identified any change in size or uniformity 
(Fig. 4.9).  No significant effect was identified as a result of passing MSC through any size 
needle in this study.   
 
 
Fig. 4.12 Viability of MSC was not significantly affected by passing through needle.  
MSC retained their capacity to adhere to plastic following passage through needle (A).  No 
significant loss of viable cells was observed (B).  Viability was assessed by counting with 
EB/AO before and after passage through needle.    
MSC passage 
through needle of  
gauge 
% Loss of MSC 
viability  
23G                                        
25G               
27G 
30G 
0.9
1.5 
0.9 
1.3 
A B 
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Figure 4.13 The physical characteristics of MSC are not affected by shearing force.  
MSC (1 x 10
6
) were forced through four needle sizes (23 G, 25 G, 27 G, 30 G).  The effect on 
MSC structure and size was assessed on a flow cytometer, plotting forward versus side 
scatter.  Results are representative of three experiments.  
   
  No needle                     23G       25G                          
325.09                               361.15                                 341.28 
   27G       30G     
342.86                       376.20 
Treatment:          
MFI: 
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4.8 SUMMARY 
In Chapter 4, functional assays were carried out in order to address quality-control 
issues that might arise as a result of systemic delivery of MSC in vivo.  These studies 
established the homogeneity of an MSC cell population with a hypo-immunogenic phenotype.  
Their “stemness” was defined by their ability to differentiate into adipocytes, osteoblasts and 
chondrocyte-like cells and by the surface marker phenotype of CD34
-
CD11b
-
CD45
-
MHC class 
II
-
CD44
+
Sca-1
+
MHC class I low following isolation from adult mouse bone marrow.  Cells 
retained multi-lineage potential through each subsequent generation.   
The immunosuppressive properties of MSC were confirmed by carrying out T-cell 
proliferation assays using a variety of stimuli including mitogens, anti-CD3, and allo-
antigens.  These demonstrated the ability of MSC to inhibit proliferation irrespective of the 
donor source.  The method of delivery in vivo via intravenous injection was also examined to 
ensure that the structural integrity of the cells would not be compromised by shearing force 
through the needle.  No significant effect on viability was identified as a result of passing the 
MSC through various needle gauges, suggesting that MSC will survive the processes needed 
for intravenous administration.  The effect of exogenous IFN-γ on MSC-mediated 
immunosuppression in vitro was also investigated, demonstrating an enhancement of 
immunosuppressive function in both mitogen-driven and allo-driven reactions as a result of 
prior stimulation.  These data verified the results of others (Polchert,  2008) by demonstrating 
the enhancing effect of pre-stimulation of MSC and indicated the importance of the inclusion 
of these licensed cells in further studies.  A comprehensive analysis of this study can be 
found within the discussion section at the end of Chapter 6.   
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CHAPTER 5 
THE INFLUENCE OF MSC ON ALLERGIC LUNG INFLAMMATION 
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5.1 INTRODUCTION 
The current treatments for allergic asthma require suppression of immune effector 
mechanisms to alleviate symptoms.  A fundamental intervention against the cause of asthma 
would require immune reprogramming of the response to innocuous environmental allergens.  
The immunomodulatory capacity of multipotent mesenchymal stem cells (MSC) suggests 
that they have a potential therapeutic value in asthma and other hypersensitive or 
autoimmune diseases.  The ability of MSC to be readily isolated and expanded ex vivo 
(Chapter 4) makes them promising candidates for cellular immunotherapy.  Extensive in vitro 
studies have demonstrated that, unlike other stem cell types, MSC can not only evade 
alloreactivity, but can also actively suppress broader immune responses (Bartholomew, 2004; 
Aggarwal, 2005; Barry, 2005).  Preclinical models of autoimmune/inflammatory conditions 
such as transplant rejection (Le Blanc, 2004), rheumatoid arthritis (Augello, 2007), and 
multiple sclerosis (Constantin, 2009), have demonstrated a functional role for MSC in vivo.   
It should also be noted that MSC are not a panacea, and have been unsuccessful as a 
cell therapy in some models (Nauta, 2006; Sudres, 2006).  The reasons for such failures are 
not clear; however it may be that MSC were not sufficiently “primed” or “licensed” for their 
biological role and thus lacking appropriate surface markers for homing or secretion of 
soluble effector molecules.   IFN-γ is a major pro-inflammatory cytokine produced by 
activated T-cells and plays an important role in priming the immunosuppressive property of 
MSC (Sheng, 2008).  Chapter 4 alluded to a critical role for IFN-γ in MSC-mediated 
immunosuppression, thus it was possible that IFN-γ pre-stimulation of MSC would result in 
an improved cell therapy. 
This study addressed the hypothesis that adult bone marrow derived-MSC would 
prevent the pathology associated with allergen-driven airway inflammation.  This was tested 
using a combination of a well established model of OVA driven inflammation and a cell 
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therapy based on allogeneic MSC alone or pre-stimulated with IFN-γ.  This chapter examined 
the influence of MSC delivered therapeutically on the key aspects of allergen driven 
inflammation including IgE induction, influx of inflammatory cells, modulation of cytokine 
profile and the effect on allergic airway pathology.   
 
5.2 STUDY DESIGN - OVA MODEL OF ALLERGIC AIRWAY INFLAMMATION 
   The murine model of ovalbumin driven airway inflammation was used again to 
elucidate the possible immunosuppressive effects of MSC cell therapy in vivo.   Allogeneic 
MSC from FVBN mice were isolated, cultured and characterised as described in Section 
2.21.  An additional group included IFN-γ-licensed MSC where cells were stimulated with 
500U/ml murine recombinant IFN-γ 48h prior to intra-venous infusion.  Mice were sensitised 
to OVA and received two intravenous treatments with allogeneic MSC.  The first was 
administered on day 7 after initial allergen challenge (Fig. 5.1 and Chapter 3.3), and again on 
day 14, 6h after the initial respiratory challenge with OVA.  The time-points for delivery of 
cells were chosen to mimic as much as possible other studies where delivery of MSC was 
carried out immediately after, or on the same day as disease induction.  Additional control 
groups included (1) paraformaldehyde-fixed MSC and (2) interferon-γ “licensed” MSC, 
delivered to OVA-sensitised and non-sensitised groups.  On day 28, mice were bled by facial 
bleed for subsequent serum analysis.  Mice were culled and BALF, spleen and lungs were 
sampled for subsequent analysis.  BALF supernatants were collected and cytokine profiles 
were examined.  Differential cell counts were performed to assess the extent of cellular 
infiltration.  Splenocytes were cultured in the presence of exogenous OVA and their ability to 
mount a recall response was measured.  Lungs were fixed for histological analysis in order to 
examine the effect of MSC delivery on OVA-induced airway pathology.            
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Initially, a preliminary study was carried out in order to assess the efficacy of 
systemic intravenous delivery of MSC.  Donor cell tracing was necessary to test whether 
transplanted donor cells were present in the lung following systemic delivery.  Female mice 
were administered GFP-expressing transgenic MSC from male donors intravenously, via the 
tail vein.  After 6,h, mice were culled.  The lungs were dissected and snap frozen for 
subsequent sectioning (Chapter 2.27).  Lung tissue sections were examined for GFP 
fluorescence.  Although fluorescence was detectable (Fig 5.2) this was difficult to detect 
against background fluorescence.  Therefore a fluorescent in situ hybridisation technique 
(FISH) was used for lung sections where female mice had received intravenous infusion of 
male MSC.  A Y-chromosome-specific probe was used to detect male MSC transplanted into 
female recipients in mice (Chapter 2.26).  Using gender-mismatched transplantation, the Y-
chromosome of male donor MSC was detected with a paint probe.  The probe hybridised with 
a prepared lung tissue section from the recipient female mice (Figure 5.2B).  Sections from 
mice receiving female MSC were used as negative controls for Y-chromosome staining.  
Results from this study indicated that MSC were present in the lung 6 h after intravenous 
injection and confirmed that the techniques for use in this model resulted in at least some 
MSC locating to the site of pathology. 
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Figure 5.1.  Groups of 6-8 week old female BALB/c mice (n=8) were sensitised by 
intraperitoneal (i.p.) injection of either OVA or saline on day 0, 7 and 14.  On days 25, 26 and 
27, mice were exposed to either saline or OVA via intranasal (i.n.) administration.  
Unsensitised controls received PBS.  Mice received allogeneic MSC (5x10
6 
/ml) by 
intravenous injection on day 7 and 14, 6 h after OVA i.p. /i.n.  Readouts were performed on 
day 28.  BALF, spleens and lungs were harvested for subsequent analysis.  Mice were bled  
by facial bleed for serum analysis.
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Figure 5.2.  MSC are present in the lung following systemic intravenous delivery via 
the tail vein.  (A) GFP-expressing transgenic MSC were delivered intravenously via the 
tail vein into BALB/c mice. (B) Donor cell tracing using FISH technology was carried 
out on lung tissue sections following intravenous delivery of male MSC into female 
recipients.  After 6 h, mice were culled.  The lungs were fixed for subsequent analysis 
and examination.  No GFP-expressing cells or Y-chromosome staining was evident in 
controls (C) and (D) respectively.  Magnification x 100. 
A B 
C D 
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  5.3 ALLOGENEIC MSC REDUCE OVA-DRIVEN AIRWAY PATHOLOGY 
Previous studies have demonstrated a role for MSC in effective intervention in 
lung diseases (Zhao, 2008; Cho, 2009; Lee, 2009).  To assess the influence of MSC on 
OVA-induced airway pathology, histological analysis of lung tissue sections were 
carried out.  As expected, non-sensitised groups exhibited no allergen-driven airway 
inflammation (Figure 5.3).  No inflammation resulted from live allogeneic cell delivery; 
however inflammation was observed in those mice receiving fixed MSC (Fig. 5.4).  In 
the absence of MSC treatment, OVA-sensitised mice exhibited typical peribronchial and 
perivascular inflammation at day 28, which was not observed in control mice (Fig 5.3 A 
& B).  Delivery of PFA-fixed MSC resulted in a more severe pathology when compared 
to OVA-sensitised mice, displaying strong perivascular inflammation and bronchiolar 
epithelial hypertrophy (Fig 5.3 C).  This phenomenon may be due to the fixed cells‟ 
inability to produce the soluble factors which would otherwise protect them from allo-
rejection, suppress T-cell proliferation or, in this case, attenuate the allergic airway 
response.  In contrast, live MSC treatment resulted in decreased peribronchial 
inflammation when compared to sensitised mice (Fig 5.3 C & D).  It is important to note 
that this protective effect was more apparent in those mice that received MSC pre-treated 
with IFN-γ, suggesting that in vitro stimulation of allogeneic MSC can improve their 
ability to reduce pathology.  This was most evident in the histopathological analysis of 
the lung tissues where mucus hypersecretion and peribronchial inflammation was 
significantly reduced (Fig. 5.4).    
A consistent feature of asthma is the production of excess mucus, causing blockage of 
the peripheral airways (Young, 2006).  In order to assess the effect of MSC on mucus 
hypersecretion, lungs were sectioned and stained with combined Discombes/Alcian blue and 
periodic acid-Schiff stain.  MSC delivery reduced mucus metaplasia in allergen-sensitised 
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mice, consistent with the findings above (Fig. 5.5).  In contrast, PFA-fixed MSC exacerbated 
goblet cell hyperplasia and mucus secretion in OVA-sensitised mice (Fig 5.4 D & E).  Mucus 
secretion and goblet cell hyperplasia were greatly reduced in sensitised mice treated with 
IFN-γ pre-treated MSC, but were exacerbated in mice receiving fixed MSC (Fig 5.5).  These 
data show that MSC treatment attenuated the pathology associated with allergen sensitisation 
and that prior activation of MSC enhanced this effect.  Evidence is also provided for the 
importance of soluble-factor mediated protection by MSC as delivery of fixed MSC 
exacerbated allergic airway pathology in this model.   
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Figure 5.3  MSC reduce the severity of airway pathology induced by sensitising 
allergen.  Representative morphological changes at day 28 in bronchiolar transverse sections 
of lungs from (A) Non-sensitised, (B) OVA-sensitised, (C) OVA-sensitised, MSC treated, 
(D) OVA-sensitised, IFN-γ-stimulated MSC treated, (E) OVA-sensitised, PFA-fixed MSC 
treated.  Airway inflammation was detected using haematoxylin and eosin (H&E) staining of 
fixed lung sections.  p and h indicate perivascular inflammation and bronchiolar epithelial 
hypertrophy, respectively.  All sections are representative of duplicate experiments; in each 
case at least five animals were assessed.  Original magnification A, B, C, D & E x100. 
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Figure 5.4 Non-sensitised groups do not display allergen-driven airway inflammation 
following delivery of live, but not fixed, MSC.  Representative morphological changes at 
day 28 in bronchiolar transverse sections of lungs from (A) Non-sensitised, MSC treated (B) 
Non-sensitised, IFN-γ-stimulated MSC treated and (C) Non-sensitised, PFA-fixed MSC 
treated.  All sections are representative of duplicate experiments; in each case at least five 
animals were assessed.  Original magnification x100. 
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Figure 5.5 MSC reduce the severity of mucus hyperplasia to sensitising allergen.  
Representative morphological changes at day 28 in transverse sections of bronchioles 
from (A&B) non-sensitised, (C&D) OVA-sensitised, (E&F) OVA-sensitised, MSC 
infused, (G&H) OVA-sensitised, infused with IFN-γ-stimulated MSC, (I&J) OVA-
sensitised, infused with PFA-fixed MSC.  Airway inflammation was detected using 
combined Discombes/Alcian blue/PAS staining on lung sections.  g and m indicate goblet 
cell hyperplasia and mucus secretion, respectively.  All sections are representative of 
duplicate experiments; in each case at least five animals were assessed.  Original 
magnification (A), (C), (E), (G) & (I) x100 and (B), (D), (F), (H) & (I) x400. 
H G 
 I  J 
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5.4 ALLOGENEIC MSC MODULATE THE INNATE RESPONSE 
 Extensive in vitro studies have shown that MSC can exert profound 
immunosuppressive effects via modulation of both cellular and innate immune pathways 
(Tse, 2003; Jiang, 2005; Spaggiari, 2006).  For clarity, therefore, MSC therapy in this model 
was investigated in terms of the effect on (1) innate effector cells, (2) humoral immunity, (3) 
local cell-mediated immunity and (4) systemic cell-mediated immune responses.  
 
5.4.1 MSC REDUCE THE CELL INFILTRATE IN BAL FLUID 
A cardinal feature of allergen driven airway inflammation is the elevated number of 
inflammatory cells, particularly eosinophils (Varney, 1992).  Therefore, the influence of 
MSC cell therapy on the quantity and quality of cellular infiltration in allergen sensitised 
airways was examined.  Control mice showed minimal cellularity in bronchoalveolar lavage 
(Fig. 5.6 & 5.8A), whereas OVA sensitisation resulted in significant infiltration by 
inflammatory cells (> 6 x 10
5
 cells per lung) (p<0.05).  Total cellular infiltration was 
decreased in OVA-sensitised mice that received MSC, whereas it remained high in sensitised 
animals treated with PFA-fixed MSC.  BALF from control mice showed minimal cellularity 
(Fig. 5.6 & 5.7), whereas OVA sensitisation/challenge resulted in significant infiltration by 
inflammatory cells including eosinophils.  However, airway eosinophilia was significantly 
reduced in OVA sensitised mice treated following MSC delivery (p<0.05).  This effect was 
only evident upon delivery of live, but not fixed cells, as OVA-sensitised, PFA-fixed MSC 
treated groups exhibited a considerable increase in airway eosinophilia when compared to 
OVA sensitised mice (Fig. 5.6 B & 5.7 E).  Similarly, delivery of MSC in sensitised mice 
resulted in a significant reduction in lymphocytes and macrophages.  There were few 
remarkable differences in the numbers of neutrophils among the different groups (Fig. 5.6 C).  
Infiltration of neutrophils in combined MSC-treated/OVA sensitised mice was typically 
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lower than OVA alone (Fig. 5.6 C).  However, this did not achieve statistical significance in 
this study.  Few differences were observed in those mice receiving activated MSC, when 
compared to those without prior IFN-γ stimulation with regard to infiltration of eosinophils, 
lymphocytes and neutrophils.  However, the numbers of macrophages in this group were not 
unlike those seen in the OVA-sensitised alone group.  These findings demonstrate that 
allogeneic MSC have wide ranging therapeutic influence on allergen driven airway 
inflammation, but this influence is attributable to living MSC and cannot be replaced by fixed 
cells.   
 
 
 
 
 
 
 
 
Figure 5.6 (See below).  MSC reduce the cell infiltrate in BAL fluid.  Effect of MSC 
infusion and/or OVA sensitisation on BAL composition 24 h after final (i.e. day 29) OVA 
exposure.  Negative controls were sham infected/sensitised with saline.  BAL fluid was 
examined for the total cell number (A), or the presence of eosinophils (B), neutrophils (C) 
macrophages (D) or lymphocytes (E).  The data are representative of two experiments; in 
each case, at least five animals were assessed. Results are expressed as mean ± S.E.M. of cell 
number. (*, p < 0.05, **, p<0.01).  
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Figure 5.7 MSC reduced the numbers of cells in the airways of OVA sensitised 
mice.  BALF was sampled on day 28 from (A) Non-sensitised (B) OVA-sensitised 
(C) OVA-sensitised, MSC infused, (D) OVA-sensitised, infused with IFN-γ-
stimulated MSC, (E) OVA-sensitised, infused with PFA-fixed MSC.  Cells were 
stained with Giemsa and examined microscopically for the presence of a number of 
cell types.  Magnification x400.  
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Figure 5.8 Non-sensitised mice exhibited no allergen-driven airway 
inflammation.  Representative morphological changes at day 28 in bronchiolar 
transverse sections of lungs from (A) Non-sensitised and infused with MSC (B) 
Non-sensitised and infused with IFN-γ-stimulated MSC and (C) Non-sensitised and 
infused with PFA-fixed MSC.  All sections are representative of duplicate 
experiments; in each case at least five animals were assessed.  Original 
magnification x400.  
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5.4.2 MSC REDUCE MYELOPEROXIDASE ACTIVITY IN LUNGS OF OVA- SENSITISED 
MICE 
Migration and accumulation of neutrophils is a characteristic feature of the host 
response to injury (Menezes GB 2008).  Neutrophils release inflammatory mediators, 
including myeloperoxidase (MPO).  Therefore the production of MPO is an indicator of local 
neutrophil activity.  BALF was harvested from mice on day 28 (Fig. 5.9), and the cell free 
supernatants were analysed for the presence of MPO, as described in Section 2.9.  The levels 
of MPO (Fig. 5.9) reflected the numbers of neutrophils observed in differential cell counts 
(Fig. 5.6).  Lungs from non-sensitised control mice contained no, or baseline concentrations 
of MPO, whilst a considerable increase was demonstrated in OVA-sensitised BALF.  MSC 
delivery resulted in a significant decrease in neutrophilic activity.  Activation of MSC with 
IFN-γ prior to delivery in OVA-sensitised mice indicated a trend towards increased MPO 
activity; however this did not reach significance in either supernatant analysis or differential 
cell counts in BALF (Fig. 5.9 & 5.6 C).            
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Figure 5.9 Live, but not PFA fixed MSC significantly reduced (MPO) activity in murine 
BALF.  BALF on day 28 was analysed for MPO activity as described in section 2.9.  The 
change in absorbance was measured at 450nm.  MPO activity was calculated using a standard 
curve generated from human MPO.  Results are expressed as the change in OD (absorbance) 
(∆Abs/min/U protein).  Responses are representative of duplicate experiments, each of which 
were determined independently from at least four mice per group and are expressed as means 
± S.E.M. p < 0.05.   
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5.5 ALLOGENEIC MSC PREVENT ALLERGEN-DRIVEN INDUCTION OF IgE 
IgE induction is a key feature of allergen driven pathologies and OVA sensitisation in 
mice is known to induce elevated levels of IgE combined with a powerful allergen-specific 
Th2 response (Hamelmann, 1999).  MSC can inhibit B-cell proliferation and differentiation 
in vitro (Corcione, 2006).  Therefore, their effect on the production of serum OVA-specific 
IgE was investigated here. Previous studies have investigated the modulatory effects of 
human MSC on the alloantigen-specific humoral response and shown that they are capable of 
suppressing allo-specific antibody production in vitro (Comoli, 2008).  Therefore, the 
capacity for adult allogeneic bone marrow-derived MSC to influence IgE induction in this 
model was examined by measuring the concentration of OVA-specific IgE in serum from 
OVA-sensitised mice in which MSC were used therapeutically.  Non-sensitised, MSC-treated 
mice demonstrated negligible levels of IgE, comparable with control groups.  As expected, 
elevated serum levels of OVA-specific IgE were observed in those mice sensitised to OVA.  
Sensitised mice that received fixed MSC showed similar levels of OVA specific IgE.  
However, this effect was inhibited in OVA sensitised, MSC-treated mice (p<0.05) (Fig 5.10).  
Similar to histological data, the protective effect of MSC delivery was enhanced upon 
treatment with IFN-γ activated MSC (p< 0.001).  These data demonstrate that cell therapy 
based on allogeneic MSC can suppress the induction of allergen-specific IgE detectable in 
serum. 
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Figure 5.10 MSC reduce serum IgE responses to sensitising allergen.  OVA-specific IgE 
in serum elicited in response to OVA sensitisation.  Sera were collected on day 28 and OVA-
specific serum IgE levels were measured by ELISA.  The data presented are representative of 
two experiments; in each case, at least five animals were assessed, and each individual 
assessment was performed independently in triplicate. Concentrations below 20 pg/ml were 
considered negative.  Results are expressed as mean antibody concentrations ± S.E.M. (**, p 
< 0.01, ***, p<0.001). 
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5.6 ALLO-MSC MODULATE LOCAL CELL-MEDIATED RESPONSES 
The phenomena described above are interesting but might be explained by MSC 
mediated global, non-antigen specific, immune suppression or by MSC interference in 
immune induction.  Therefore, the effect of allogeneic MSC on T cell mediated immunity 
was examined in this model.  Particular attention was given to IL-4, IL-5 and IL-13 induction 
as these play well defined roles in allergen driven pathology.   
 
5.6.1 ALLO-MSC MODULATE LOCAL CYTOKINE RESPONSES IN VIVO 
 The cytokine profile in the BALF from the mice described above was investigated.  
As expected, IL-4, IL-5 and IL-13 in both BALF and splenocyte supernatants were 
significantly higher in the OVA sensitised group when compared to those sham sensitised 
with PBS (p < 0.05).  However, levels of IL-5 were significantly increased (p < 0.05) in 
the sensitised, MSC-treated group.  The increase in IL-5 was surprising given the 
considerable decrease in eosinophilic lung infiltration and improvement in airway 
pathology.  The typical damaging effects of IL-5 in acute lung inflammation may have 
been in part offset by the significant increase in IL-10 (Fig. 5.11 D) (p<0.05) and also the 
marked reduction in IL-4 (Fig. 5.11A) (p<0.05).  IL-4 plays an important role in sustaining 
established IgE responses (Del Prete, 1988); therefore a decrease in its secretion can 
moderate the induction of IgE.  Despite reducing circulating and sputum eosinophil 
numbers, systemic administration of anti-IL-5 antibody only partially reduces airway 
tissue eosinophils in asthmatic patients (Flood-Page, 2003), possibly because eosinophils 
lose IL-5 receptor from the cell surface as they enter the airways from circulation, and lose 
their dependence on IL-5 for survival (Liu, 2002).   Several studies have also demonstrated 
a role for IL-10 in modulating the allergic immune response (Prigione, 2009).  IL-10 plays 
a direct regulatory role in controlling the accumulation of eosinophils at inflammatory sites 
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by accelerating their apoptosis (Takanaski, 1994) but can also participate in the induction 
of regulatory T cells which in turn inhibit allergic airway inflammation (Grindbacke, 
2004).   
 IL-13 was reduced in sensitised groups following delivery of MSC and “licensed” 
MSC (Fig. 5.11 B).  This effect was offset upon delivery of fixed cells, indicating a crucial 
role for soluble factor secretion in MSC-mediated protection in this model.  An increase in 
IL-5 was also observed in those mice treated with “licensed” MSC; however this was 
significantly less than those levels observed in groups treated with MSC without prior 
stimulation.  Similarly, an increase in IL-10 was demonstrated in sensitised, IFN-γ licensed 
MSC treated mice, however this was also reduced when compared to “unlicensed” MSC-
treated groups.    
 
5.6.2 ALLOGENEIC MSC MODULATE LOCAL RECALL PROLIFERATIVE RESPONSES TO 
OVA 
The influence on recall proliferative response to exogenous OVA was examined ex 
vivo.  Mediastinal lymph nodes (MLN) from OVA challenged, but not saline challenged mice 
proliferated significantly in response to OVA, as expected (Fig. 5.12).  MSC delivery in 
sensitised mice resulted in an increase in proliferation in response to OVA when compared to 
those sensitised to OVA alone.  However, this effect was counteracted when MSC were 
activated prior to delivery.  As MLN are the draining lymph nodes for the upper airways, the 
increase in BALF IL-5 and IL-10 in MSC-treated mice may explain the enhanced T cell 
response in these groups.  Prior activation of cells does not cause an equivalent increase in 
these cytokines which is reflected in the absence of proliferative response in the MLN.  
Delivery of PFA-fixed MSC to OVA challenged mice prevented the inhibition of 
proliferation observed when live cells were delivered.  Cytokine profile analysis of this group 
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adds further credence to this hypothesis as dramatic increases in IL-13 and IL-4 production 
was evident in BALF which again mirrored T cell proliferative responses to OVA in vitro.     
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Figure 5.11 MSC modulate cytokine responses in BALF.  Cytokines in BALF, 
elicited by OVA sensitisation following infusion with MSC.  BALF was harvested on 
day 28.  Negative symbols indicate sham sensitisation or challenge with PBS.  Cytokine 
responses from similar cultures are shown for (A) IL-4, (B) IL-13 (C) IL-5 & (D) IL-10.  
Responses are representative of duplicate experiments, each of which were determined 
independently from at least nine mice per group and are expressed as means ± S.E.M. (*, 
p < 0.05). 
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Figure 5.12 MSC modulate recall responses to sensitising allergen in local lymph nodes 
re-stimulated with OVA.  Cell-mediated immune responses from mediastinal lymph nodes 
(MLN) to OVA elicited by OVA sensitisation.  Lymph nodes were harvested on day 28 and 
processed as described in Section 2.17. Cells were cultured in the presence of media alone     
(    ) or OVA (200µg/ml) (    ) for 72h.  Subsequent proliferation was measured by 3H-
thymidine incorporation (
*
, p<0.05).  No proliferation was detected from sham sensitised 
mice in MLN.  Negative symbols indicate sham sensitisation or challenge with PBS.  
Responses are representative of duplicate experiments, each of which were determined 
independently from at least three mice per group and are expressed as means ± S.E.M.  
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5.7 ALLO-MSC MODULATE SYSTEMIC CELL-MEDIATED RESPONSES 
In order to determine whether MSC were affecting local suppression at the site of 
injury only, systemic in vivo responses to MSC delivery were also investigated using 
supernatants from splenocyte preparations stimulated with OVA.  Both cytokine profiles and 
proliferative responses were assessed.  IL-4, IL-5 and IL-13 levels in splenocyte supernatants 
were significantly higher in the OVA sensitised group when compared to those sham 
sensitised with PBS.  Unlike the increase in IL-5 seen in the BALF, MSC treatment did not 
significantly change the splenic IL-5 compared response to the OVA-sensitised group.  
Likewise, cytokine data did not concur between splenocyte preparations and BALF with 
regard to IL-4.  A decrease in IL-4 production in the MSC-treated/OVA sensitised group 
(when compared to the OVA sensitised group) was observed in BALF, whereas an increase 
was demonstrated in splenocyte supernatant (Fig. 5.13 A).  This effect was offset when MSC 
were activated prior to delivery.  Fixed cells initiated a significant increase in the production 
of IL-4 when compared to those sensitised to OVA alone.  As expected, an increase in IL-13 
was demonstrated in OVA-sensitised mice when compared to those sham sensitised with 
PBS, however, no remarkable differences were observed upon MSC delivery.  IL-10 
production was markedly increased in both BALF and splenocyte supernatant (Fig. 5.11 D & 
5.13 D).  No significant induction/suppression of Th2-type cytokine responses were observed 
in sensitised, IFN-γ-stimulated MSC treated mice.  These data suggest that MSC may be 
having a different effect locally (at the site of damage) when compared to the systemic 
response in the spleen.  
The influence on recall proliferative response to exogenous OVA was examined ex 
vivo.  Splenocytes from OVA challenged, but not saline challenged mice proliferated 
significantly in response to OVA, as expected.  In contrast to T cell responses in MLN, 
proliferative responses from sensitised, MSC-treated mice were not significantly greater than 
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those seen in OVA-sensitised mice.  However, no significant inhibitory effect on proliferation 
was observed in these groups.  “Licensed” MSC prevented recall proliferative responses (Fig 
5.14), whilst delivery of PFA-fixed MSC cells to OVA challenged mice prevented the 
inhibition of proliferation observed when stimulated cells were delivered.  
These data have two implications.  Firstly, figures 5.11 C & 5.13 A demonstrate that 
MSC-mediated immune suppression was not a global phenomenon as both BALF and OVA-
driven recall cytokine responses were elevated by MSC in some instances.  In addition, these 
data suggests the existence of one, or a combination of, functionally distinct pathways 
exploited by MSC to inhibit allergic airway inflammation, including possible 
immunomodulation via cytokine (IL-10) induction/suppression directly affecting immune cell 
infiltration and/or induction of regulatory T cells.    
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Figure 5.13 MSC modulate recall cytokine responses to sensitising allergen from 
murine splenocytes re-stimulated with OVA.  Spleens were harvested on day 28 and 
processed as described in Section 2.19.  Splenocytes were cultured in the presence of 
media alone (    ) or OVA (200µg/ml) (    ) for 72h. Negative symbols indicate sham 
sensitisation or challenge with PBS.  Cytokine responses from similar cultures are shown 
for (A) IL-4, (B) IL-5 (C) IL-13 and (D) IL-10.  Responses are representative of 
duplicate experiments, each of which were determined independently from at least nine 
mice per group and are expressed as means ± S.E.M. (*, p < 0.05). 
A B 
C D 
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Figure 5.14 MSC modulate recall responses to sensitising allergen from splenocytes re-
stimulated with OVA.  Cell-mediated immune responses from splenocytes to OVA elicited 
by OVA sensitisation.  Cytokine responses from similar cultures are shown for IL-5, IL-4, 
IL-13 and IL-10 in Figure 5.12.  Spleens and lymph nodes were harvested on day 28 and 
processed as described in Section 2.19. Cells were cultured in the presence of media alone     
(    ) or OVA (200µg/ml) (     ) for 72 h.  Subsequent proliferation was measured by 3H-
thymidine incorporation (
*
, p<0.05).  Negative symbols indicate sham sensitisation or 
challenge with PBS.  Responses are representative of duplicate experiments, each of which 
were determined independently from at least nine mice per group and are expressed as means 
± S.E.M.  
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5.8  PRE-STIMULATION OF MSC WITH IFN-GAMMA INDUCES HIGH LEVELS OF HGF 
MSC express the immunosuppressive cytokines hepatocyte growth factor (HGF) and 
TGF-β at concentrations that can suppress allogeneic responses in vitro (Rehman, 2004; 
Barry, 2005).  Moreover, co-culture with IFN-γ significantly increases the expression of these 
suppressive mediators (Ryan, 2007) supporting a role for IFN-γ in potentiating the 
immunosuppressive activities of MSC.  HGF has recently been shown to negatively regulate 
allergic airway inflammation and hyperresponsiveness in a murine model (Ito, 2007) via 
direct attenuation of eosinophil chemotactic function.  This led to the hypothesis that perhaps 
an increase in HGF production by “licensed” MSC effects an enhancement of protective 
function in this group.  Therefore, the effect of prior stimulation of MSC on the secretion of 
HGF was investigated here.  These data demonstrated a dramatic increase in the level of HGF 
in the conditioned media of MSC co-cultured with IFN-γ for 48h.  This is an important 
finding as it supports the data observed in Chapter 4 which showed that “licensed” MSC 
exhibited a significant enhancement of protective function when compared to those without 
stimulation prior to delivery.  Collectively, these data strongly indicate that enhanced 
production of HGF in “licensed” cells may contribute to their ability to inhibit allergic airway 
pathology when compared to un-stimulated cells.      
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Fig. 5.15 Pre-stimulation with IFN-γ induces high levels of HGF secretion by MSC.   5 x 
10
4  
human MSC or IFN-γ-stimulated MSC were co-cultured with 3 x 105 human eosinophils 
(cell line, EOL-1) in the presence or absence of CD4
+
 T cells for 48 h.  Supernatants were 
analysed by ELISA for the presence of HGF.  
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5.9 SUMMARY  
This study demonstrated that adult bone marrow derived allogeneic MSC actively 
prevent the induction of allergen driven pathology in a murine model and suggested a novel 
cell therapy for allergic human disease.  Systemic administration of MSC protected the 
airways from OVA-induced pathology demonstrated by the reduction in BAL infiltration, 
airway pathology and OVA-specific IgE.  MSC modulated cell-mediated responses at both a 
local and systemic level.  Notable observations included a significant decrease in IL-4 
combined with an increase in IL-10 in BALF and splenocyte preparations.  Taken together, 
these findings demonstrate that MSC can reduce the intensity of the allergic airway 
inflammatory response through interactions with both innate and adaptive immunity.  
However, this inhibitory effect on airway inflammation is not mediated by global suppression 
as demonstrated by the increase in IL-5 in both the lung and spleen following MSC delivery. 
Prior stimulation of MSC with IFN-γ increased their protective effect in this model.  This was 
most evident in the histopathological analysis of the lung tissues where mucus hypersecretion 
and peribronchial inflammation was significantly reduced.  These data suggested that IFN-γ 
stimulation plays an important role in enhancing the efficacy of MSC in modulating the 
immune response in allergic airway inflammation.  The significant increase in HGF, an 
established inhibitor of allergic airway inflammation, in the conditioned medium of IFN-γ-
stimulated MSC suggests a role for this important cytokine in their protective effect.  
Current data suggest that Th2 responses to allergens are suppressed by IL-10-
producing regulatory T cells (Cottrez, 2000; Akdis, 2006; Meiler, 2008).  However, the 
absence of IL-10 induction in IFN-γ-stimulated MSC-treated groups in BALF and splenocyte 
supernatant suggests an alternative mechanism of protection against allergic airway 
inflammation that is independent of IL-10 in this particular group.  The induction of IL-10 
seen here as a result of MSC delivery suggested a role for MSC in Treg induction prompting 
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further investigation.  A comprehensive analysis of this study can be found within the 
discussion section at the end of Chapter 6.  Chapter 6 elucidates the mechanisms involved in 
the reduction of allergic airway pathology by MSC. 
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CHAPTER 6 
MSC–MEDIATED PROTECTION AGAINST ALLERGEN DRIVEN AIRWAY 
PATHOLOGY REQUIRES REGULATORY T CELL POPULATIONS 
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6.1 INTRODUCTION 
In Chapter 5, it was reported that the delivery of MSC reduced the pathology 
associated with allergic airway inflammation.  As both global suppression and blocking of 
immune induction have been eliminated as potential mechanisms underlying this observation, 
three processes could explain these data (1) MSC induce regulatory T cells (Treg) which 
suppress immunopathology; (2) MSC repair or regenerate the damaged airways ; (3) MSC 
prevent eosinophilia and thus prevent eosinophil mediated pathology.  In Chapter 5, an 
increase in IL-10 was detected in bronchoalveolar lavage fluid and also spleen cell 
preparations of mice that received MSC (with OVA sensitisation/challenge) (Fig. 5.10 & 
5.12), supporting the hypothesis that MSC induce the proliferation/differentiation of Treg 
which in turn regulate inflammation through the production of IL-10.  CD4
+
CD25
+
FoxP3
+
 
Treg are critical for control of antigen-specific inflammation and their recruitment into the 
airways and can suppress allergic airway inflammation (Strickland, 2006).   This chapter 
probed the mechanism of therapeutic efficacy of MSC.  A set of experiments were designed 
to discriminate between these alternative hypotheses.  This was structured in three parts; (1) 
by ascertaining whether there was an expansion of regulatory T cells upon MSC delivery, (2) 
establishing whether depletion of these suppressor cells would result in negation of the 
protective effect of MSC, (3) investigating whether MSC could directly inhibit eosinophil 
migration.   
 
6.2 MSC CELL THERAPY INDUCES DEFINED REGULATORY T CELL SUBSETS IN VIVO 
Cytokines produced by antigen-presenting cells (APC) and other cells play a critical 
role in the differentiation of regulatory T cells.  APC are an important source of IL-10, and 
priming of naive T cells in the presence of this cytokine results in the differentiation of Treg.  
An important finding of Chapter 5 was the significant induction of IL-10 as a result of MSC 
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delivery in both the spleen and lungs which warranted further investigation, as these data 
alluded to an alternative or additional mechanism to direct inhibition of allergic pathology via 
soluble factor secretion by MSC.  Several regulatory T cell subsets exist; however two major 
subsets of Treg, CD4
+
CD25
hi
 Foxp3
+
 Treg and CD8
+γδ T cells have demonstrated protection in 
models of allergic airway inflammation (Lahn, 1999; Grindbacke, 2004; Ling, 2004; Isogai, 
2007).  This made a compelling case for examining MSC as cellular inducers of these 
regulatory T cells.  First, it was necessary to investigate whether MSC could expand Treg 
subsets implicated in regulating the allergic airway response.  This was investigated by 
identifying T cell populations generated in response to MSC delivery in a model of allergic 
airway inflammation.  Mice were sensitised with OVA on day 0, 7 and 14.  Intravenous 
delivery of MSC was carried out on days 7 and 14, and respiratory challenge with OVA was 
performed on day 14.  Spleens and lungs were harvested from mice 5 days after the last 
treatment with MSC (day 19).  The generation and expansion of Treg subsets was assessed in 
the lungs and spleens of OVA sensitised mice, and from those mice that also received MSC. 
MSC therapy induced or expanded two populations of regulatory cells.  A significant 
increase in CD8
+γδ T cells was observed in lung and spleen preparations from MSC treated at 
day 19 when compared to non-treated, OVA-sensitised sensitised mice (Fig. 6.1).  MSC also 
increase γ/δ CD8- cells in the lungs and in the spleen, most cells were either γ/δ- CD8+ or γ/δ+ 
CD8
-
 (Fig. 6.1).  Furthermore, MSC induced or expanded a CD4
+
FoxP3
+
 population in both 
the lungs and spleen from sensitised, MSC-treated mice (Fig. 6.2 & 6.3).  Intracellular Foxp3 
expression was measured on a gated, viable, population.  An increase in FoxP3 expression (p 
< 0.05) was observed in CD4
+
 T cells from sensitised, MSC-treated mice.  These data provide 
evidence that MSC induce distinct Treg populations implicated in the suppression of the 
allergic airway inflammatory response.     
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Figure 6.1 MSC cell therapy induced a population of CD8
+ γδ T cells. A population of 
viable lymphocytes was gated on and the percentage of cells expressing the γδTCR and CD8 
on their surface was assessed in lungs and spleen of naïve, OVA-sensitised and OVA-
sensitised, MSC-treated mice at day 19.  Plots are representative of experiments performed at 
least three times. 
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Figure 6.2 MSC cell therapy induced a population of CD4
+
 FoxP3
+
 T cells in the lungs 
of OVA primed mice.  The OVA BALB/c allergic asthma model was used +/- MSC cell 
therapy (OVA MSC) on day 7 & 14. On d19, lungs were harvested and digested with 
collagenase/ DNase I for 1 h followed by intra/extracellular staining with PE-conjugated anti-
FoxP3 and Cy5-conjugated anti-CD4.   
 
 
 
 
 
 
 
                              
G 
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Figure 6.3 A population expressing CD4
+
FoxP3
+
 is increased in spleen following MSC 
delivery.  Expression of CD4
 
and
 
FoxP3 in splenocyte preparations isolated from OVA 
sensitised (OVA) or OVA-sensitised MSC treated (OVA MSC) mice at day 19.  Spleens 
were harvested and cells were lysed and stained with PE-conjugated anti-FoxP3 and Cy5-
conjugated anti-CD4 as above.   
 
Isotype control 
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Naive 0.0% 
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6.3 A LOW DOSE CYCLOPHOSPHAMIDE REGIMEN DEPLETES TREG CELLS IN THE 
MURINE OVA MODEL 
The data in Chapter 5 demonstrated that MSC are of therapeutic benefit in an OVA 
model of allergic airway inflammation.  In Section 6.2, it was shown that MSC induce 
regulatory T cell populations not seen in non-treated mice.   Therefore it was possible that the 
protective effect of MSC demonstrated in this model was due to Treg induction.  A 
reductionist approach was therefore employed to see if MSC could support the beneficial 
effect in the absence of Treg.  In the absence of a knockout mouse, cyclophosphamide was 
used to deplete these suppressor cells in vivo.  A monoclonal anti-CD25 antibody has been 
routinely used for depleting Treg in vivo (Van Meirvenne, 2005; Boudousquie, 2009).  
However, due to the expression of CD25 on activated effector T cells, this approach could 
not be used as such cells would be potential targets for depletion by anti-CD25 mAB also.  
Consequently, the use of an anti-CD25 antibody to examine the role of Treg mediated 
inhibition of airway inflammation by MSC was avoided and instead substituted with a model 
which depletes Treg using cyclophosphamide.  Cyclophosphamide (CY) is a cytotoxic, 
alkylating agent widely used as a chemotherapeutic agent (Aschan, 1999) that  has a direct 
inhibitory effect on CD4
+
CD25
+
 FoxP3
+
 Treg by impairing the functionality of these cells, as 
well as depleting this population in vivo (Lutziak C 2005).  It has been used in studies to 
examine the effect of Treg depletion in various disease models (Uchida, 1994; Aschan, 1999; 
Yung-Chang, 2006).  Absolute numbers of Treg typically return to baseline levels 
approximately 10 days after CY administration in these models.   
To validate this approach it was important to establish that CY could effectively 
deplete Treg and determine for how long this could be achieved in vivo.  Thus, the effect of 
CY treatment on the number and percentage of T-cell subsets in mice was examined in order 
to determine the optimum time points for CY administration in the OVA model and to test 
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the “leakiness” of the model.  One group (Group A) received 1 i.p. injection of CY (150 
mg/kg) and a second group received 2 i.p. administrations of CY (150 mg/kg) over a 10 day 
period.  Both groups were first sensitised to OVA via intraperitoneal injection on day -4.  
Four days later (day 0), during T cell expansion (Lin C-H 2003), CY was delivered by i.p. to 
Group A and Group B.  Group B received a second CY dose on day 6.  At each time point 
(i.e. days 0, 4, 6 and 10) splenocytes were harvested and the effect of cyclophosphamide on 
the kinetics of regulatory T cell marker expression was examined.  Expression of CD4, CD8, 
CD25 and FoxP3 was assessed by flow cytometry.  The experimental outline is summarised 
in Fig. 6.4.   
CY decreased the total number of splenocytes by ~50% at day 4 following treatment 
(Fig. 6.5).  The decrease was maximal on day 4 and persisted for at least 2 days.  Cell 
numbers returned to normal levels 10 days following CY administration.  However, a decline 
in CD4
+
CD25
+
 and CD4
+
FoxP3 expression was more profound (~85% decrease) and 
recovered more slowly than total splenocytes and CD4
+
 cells (Fig. 6.5 & 6.6 A).  Four days 
following CY treatment, the percentage of CD4
+
CD25
+
 and CD4
+
FoxP3
+
 in the spleen 
decreased dramatically and were only partially restored between days 6 and 10 (Fig. 6.6 C & 
6.6 D).  The decrease in CD8
+
 T cell expression was not significantly reduced 4 days 
following CY treatment.  The decrease in the numbers of CD4
+
 cells was maximal on day 4 
but began to increase thereafter; by day 10 after CY treatment, expression had returned to 
pre-treatment levels (Fig. 6.6 A).  These data were similar to other studies suggesting that 
cyclophosphamide affects all CD4
+
 T cells; however this affect was not sufficient to reduce 
allergic airway inflammation (Yung-Chang, 2006) and Fig. 6.9.   
These data indicated that Treg would not be depleted for a sufficient period over the 
course of the proposed experiment.  Therefore an additional CY treatment was incorporated 
into the regimen.  To assess that multiple doses of CY would repeatedly achieve depletion 
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one group of mice received a second intraperitoneal injection of CY on day 10.  Analysis of 
this group demonstrated a significant reduction in CD4
+
CD25
+ 
and CD4
+
FoxP3 (p < 0.05) at 
day 4 (Table 6.1).  These data highlighted the requirement for multiple administrations of CY 
in order to deplete Treg cells for the duration of allergen sensitisation and challenge (i.e. 28 
days) and informed the experimental outline in Section 6.5 below.  This was consistent with 
previous studies showing the effect of CY treatment on regulatory T cell populations in vivo 
(Ikezawa, 2005; Lutziak, 2005).  It showed that Treg could be effectively eliminated from this 
model for the critical period between days 7 and 28 when cell therapy was considered to be 
having an effect.  Thus a protocol was devised in which MSC could be delivered without 
allowing the induction of Treg and provided sufficient information to determine suitable time-
points for depleting Treg in an OVA sensitisation model where therapeutic stem cells could be 
delivered.   
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Figure. 6.4 Optimisation of cyclophosphamide-depletion of Treg.  Mice were sensitised 
with OVA via intraperitoneal (i.p.) injection on day 0.  On day 4, cyclophosphamide was 
administered at a dose of 150 mg/kg i.p (n=4).  Spleens were harvested on days 0, 4, 6 and 
10.  An additional group received a second dose of cyclophosphamide (150 mg/kg) on day 6. 
Spleens were harvested from this group on day 10.  Expression of CD4, CD8, CD25 and 
FoxP3 on splenocytes was assessed by flow cytometry.  
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Figure 6.5 CY treatment reduced the number of spleen cells at day 4.  Mice were 
sensitised with OVA i.p. (day -4) and then given 150 mg/kg of CY intraperitoneally at day 0. 
The effect on total cell number was assessed 4, 6 and 10 days following CY administration.  
Results are expressed as mean values ± S.D. obtained from groups of at least three mice and 
are representative of two experiments. *p < 0.05; **p < 0.005. 
 
Table 6.1 CY decreases CD4
+
, CD4
+
CD25
+
 and CD4
+
FoxP3 expression in the spleen 
(Summary) 
Marker                                                                   % Gated*  
                              d0                         d4                          d6                         d10                       d10 (2 CY)+ 
CD4                51.9 ± 2.61          20.9 ± 2.22           16.9 ± 7.55             46.2 ± 3.78               19.25 ± 4.62 
CD8               12.8 ± 1.22           13.6 ± 1.88            8.9 ± 3.06              10.3 ± 0.69               11.65 ± 2.91 
CD4FoxP3   3.03 ± 0.04            0.56 ± 0.01           0.83 ± 0.02              5.13 ± 0.12              0.22 ± 0.98 
CD4CD25    4.72 ± 0.22            0.00 ± 0.03           0.56 ± 0.89              2.36 ± 1.67               0.87 ± 0.03 
*Cells were gated on FSC and SSC to eliminate debris and dead cells.  The % of cells gated expressing CD4, 
CD8, CD25 and FoxP3 were recorded.  Results are expressed as mean values ± S.D. obtained from groups of at 
least three mice and are representative of two independent experiments. + indicates % at day 10 following a 
second administration of CY at day 6. 
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Figure 6.6 CY treatment reduced CD4
+
 cells and depleted CD4
+
CD25
+
/ CD4
+
FoxP3
+
 
cells in the spleen at day 4.  The effect of CY treatment on (A) CD4, (B) CD8, (C) 
CD4
+
FoxP3
+ 
& (D) CD4
+
CD25
+
.  Mice were given 150 mg/kg of CY intraperitoneally at day 
0. Spleen cells were isolated and stained with Cy5-conjugated anti-CD4mAb and APC-
conjugated anti-CD8mAb and analysed by flow cytometry.  Results are expressed as mean 
values ± S.D. obtained from groups of at least three mice and are representative of two 
independent experiments. *p < 0.05; **p < 0.005. 
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6.4 CY TREATMENT DID NOT AFFECT THE IMMUNOSUPPRESSIVE FUNCTION OF MSC 
Adult stem cells, including MSC, express high levels of aldehyde dehydrogenase 
(ALDH) (Gentry, 2007).  ALDH activity is important for multiple biological activities 
including drug-resistance to cytostatic agents including CY.  However, it was important to 
investigate the potential cytotoxic effects of CY on MSC to exclude the possibility that CY 
was inducing apoptosis (or similar) and, as a result, negating the protective effect of the stem 
cells in this model.  In order to examine the effect of CY treatment on MSC, a dose-response 
study was carried out where MSC were incubated with varying concentrations of CY in a 6-
well plate for 48h.  The ratios of MSC: CY were chosen to include the maximum exposure of 
MSC to CY that may occur in vivo (i.e. 0.5 x 10
6
 MSC exposed to 150 mg/kg CY).   The 
retention of immunosuppressive function was assessed by examining the ability of MSC to 
inhibit proliferation between MHC-mismatched splenocytes in a two-way mixed lymphocyte 
reaction.  MSC retained their ability to inhibit proliferation in this assay at all ratios CY: 
MSC (Fig. 6.12). This study revealed that CY treatment exerted no detectable effect on the 
immunosuppressive capacity of MSC and supported previous findings (Gentry, 2007).   
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Figure 6.7 Cyclophosphamide does not affect the immunosuppressive function of 
MSC. MSC were co-cultured with three different concentrations of CY (18, 0.18 and 0.018 
mg/ml) for 24 h in a 6-well plate.  MSC were harvested from the plate and washed twice.  
For two-way mixed lymphocyte reactions, splenocytes from two MHC mismatched mice 
(D1 and D2, BALB/C and C57/BL6, respectively) were co-cultured.  The effect of MSC on 
lymphocyte proliferation was assessed by adding MSC to the MLR at a density of 1.5 x 10
5
 
cells/ml.  This experiment was only performed once.  Results represent the mean (+/- SEM) 
of triplicate determinations. 
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Figure 6.8 Treg depletion in allergic airway inflammation model.  Groups of 6-8 week old 
female BALB/c mice (n=8) were sensitised by i.p. injection with OVA (100 µg) on days 0, 7 
and 14.  On days 25, 26 and 27, mice were exposed to OVA (50 µg) via intranasal (i.n.) 
administration.  Non-sensitised controls received PBS.  Mice received allogeneic MSC 
(FV/BN) (5 x 10
6
/ml) via intravenous injection on day 7 and 14, 6 h after OVA i.p./i.n.  CY 
(150 mg/kg) was delivered via i.p. injection on day 8, 12 and 15.  Readouts were performed 
on day 28.  BALF, spleens and lungs were harvested for subsequent analysis.  Mice were 
bled by facial bleed for serum analysis. 
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6.5 REGULATORY T CELLS PLAY ARE REQUIRED FOR MSC MEDIATED INHIBITION OF 
ALLERGIC AIRWAY INFLAMMATION  
To investigate the hypothesis that MSC exert their immunosuppressive function via 
induction of Treg, these suppressor cells were depleted using the protocol optimised above, in 
an ovalbumin-induced model of allergic airway inflammation (used previously in Chapter 3 
& 5), and the effect of MSC delivery on airway pathology was examined.  This approach 
would allow discrimination between two major mechanistic possibilities outlined in Section 
6.1, because Treg depletion should not interfere with potential repair function by MSC.   
Allergen sensitisation and MSC delivery was performed as described in Chapter 5.  Briefly, 
mice were sensitised to OVA on days 0, 7 and 14 via i.p. injection, followed by intranasal 
challenge on day 14, 25, 26 and 27.  Mice received MSC, or vehicle alone, intravenously on 
days 7 and 14.  In addition, mice received three i.p. injections of CY on days 8, 12 and 15 
(see experimental outline, Fig. 6.8) equivalent to the depletion timings optimised in Section 
6.3.  On day 28, mice were culled and the effect of MSC delivery on OVA-induced airway 
pathology in a Treg-depleted model determined as previously described in Chapter 5.            
Contrary to findings in Chapter 5 which demonstrated a significant protective effect 
by MSC, here, MSC could not alleviate pathology in Treg depleted mice.  Lung histology was 
assessed 24h after the last allergen challenge. In the absence of MSC treatment, OVA-
sensitised mice (ovalbumin group), had significant cellular infiltration including perivascular 
and peribronchial inflammation (Fig. 6.9)  demonstrating that the partial loss of CD4
+
 cells 
(described in Section 6.3) does not impair induction of Th2-associated allergic airway 
pathology.  The decrease in FoxP3 expression seen previously was consistent with the 
possibility that selective depletion of regulatory T cells contributes to the increase in the 
inflammatory response in CY treated mice.  Sensitised, CY-treated mice that received MSC 
had a cellular infiltrate in the perivascular and peribronchial areas (Fig. 6.9).  In periodic 
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acid-Schiff–stained sections, the CY/OVA group displayed mucus production but notably, 
delivery of MSC to Treg depleted mice resulted in more pronounced levels of mucus 
production that partially plugged some airway lumina entirely (Fig. 6.10).   
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Figure 6.9 Transverse sections of lungs from OVA-sensitised, Treg depleted mice 
(A&B), OVA-sensitised MSC treated/ Treg depleted mice (C& D).  Airway 
inflammation was detected using H&E staining on lung sections.  p and h indicate 
perivascular inflammation and bronchiolar epithelial hypertrophy, respectively.  All 
sections are representative at least three animals.  Original magnification A and C 
x100; B and D x400.  
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Figure 6.10 Representative morphological changes at 28 days in bronchiolar 
transverse sections of lungs from OVA sensitised-Treg depleted mice without cell 
therapy (A&B), or with cell therapy (C&D).  Airway inflammation was detected 
using combined Discombes/Alcian blue/PAS staining on lung sections.  g and m 
indicate goblet cell hyperplasia and mucus secretion, respectively.  All sections are 
representative of at least three animals.  Original magnification A and C x100; B 
and D x400.  
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6.6 GENERATION OF TREG BY MSC ARE REQUIRED FOR INHIBITION OF OVA-SPECIFIC 
IGE 
Previously, a significant reduction in allergen-driven IgE was observed in mice 
receiving MSC following allergen sensitisation (Fig. 5.10).  However, when mice were 
depleted of Treg by cyclophosphamide, there was no observable difference in IgE in those that 
received MSC when compared to those that did not (Fig. 6.11).  Consistent with previous 
studies (Su, 2006), CY treatment increased IgE production in OVA-sensitised mice (Fig. 
6.11) compared to the levels seen in non CY treated (Fig. 5.10).  Typical values in sensitised 
mice with no CY treatment were ~80 pg/ml; however, CY significantly increased OVA-
specific IgE production to approximately 150 pg/ml.  As CY selectively depletes Treg, this 
suggests that IgE mediated allergy (atopic) conditions are moderated in vivo by the 
suppressive influence of constitutive Treg in the OVA model and that Treg are required for the 
MSC mediated reduction of IgE. 
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Figure 6.11 OVA-specific IgE in serum elicited in response to OVA sensitisation in Treg 
depleted mice.  Sera were collected on day 28 and OVA-specific serum IgE levels were 
measured by ELISA.  The data presented are representative at least four animals, and each 
individual assessment was performed independently in triplicate. Results are expressed as 
mean antibody concentrations ± S.E.M.  
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6.7 MSC MEDIATE AIRWAY EOSINOPHILIA VIA A TREG-INDEPENDENT PATHWAY 
In Chapter 5, a reduction in BALF cellular infiltration was observed in those mice 
receiving MSC.  This was evident in all cell types examined, including neutrophils, 
lymphocytes, macrophages and eosinophils (Fig. 5.6).  In contrast, there was no significant 
differences in the immune cell types in the airways of allergen sensitised Treg depleted mice in 
the presence or absence of MSC cell therapy, with one exception.  A reduction in eosinophils 
was observed (Fig. 6.12 B).  The degree of airway eosinophilia was significantly higher (>80 
x 10
3 
/lung) in all groups treated with CY when compared to those seen previously in OVA-
sensitised groups with no CY treatment (>40 x 10
3 
/lung) (see Chapter 5).  This is consistent 
with studies that demonstrated a worsening of allergic airway pathology.  However MSC 
treatment specifically reduced eosinophilia even in the absence of Treg (Fig. 6.12 B).  This 
observation was interesting as it indicated an alternative mechanism employed by MSC 
which directly inhibits airway eosinophilia, however its‟ main significance was that it 
allowed elimination of a hypothetical mechanism of MSC action.  As a reduction in 
eosinophilia is retained in this model whilst the pathology is impaired it implies that reduced 
eosinophilia cannot account for the MSC mediated effects, and that these are linked to Treg 
induction.  
 
6.8 TREG ARE REQUIRED FOR MSC MODULATION OF LOCAL AND SYSTEMIC CYTOKINE 
INDUCTION 
In Chapter 5, MSC were shown to reduce local IL-4 and IL-13 in allergen primed 
mice, however, an increase in IL-5 production was observed.  Examination of the cytokine 
profile of BALF from CY-treated, OVA-sensitised mice revealed no significant differences in 
IL-5, 13 or IL-4 between those receiving MSC, and those that did not (Fig. 6.13).  A 
significant increase in IL-10 in MSC-treated mice was reported in Chapter 5 (Fig. 5.11 D & 
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5.12 D); however, when mice were depleted of Treg using CY the opposite was true.  There 
was a decrease in IL-10 in CY-OVA-MSC as a result of CY administration (Fig. 6.13 C).  
These data support the hypothesis that MSC generate regulatory T cells that suppress allergic 
airway responses in vivo.        
As expected, incubation of splenocyte preparations from sensitised mice with 
exogenous OVA demonstrated a significant increase in proliferation (Fig. 6.14).  This was 
also the case for sensitised mice receiving MSC, however the stimulation was significantly 
lower when compared to OVA-sensitised groups, suggesting that MSC mediated suppression 
may utilise additional (non Treg) mechanisms which reduce proliferation but which are not 
sufficient to reduce pathology.   
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Figure 6.12 Depletion of Treg does not affect MSC-mediated suppression of airway 
eosinophilia.  Cellular composition of BAL from Treg-depleted (CY-treated (150 mg/kg)) 
mice 24 h after final OVA exposure.  Negative controls were sham infected/sensitised with 
saline.  Lavages were examined for the total cell number (A), or the presence of eosinophils 
(B), neutrophils (C) lymphocytes (D) or macrophages (E).  The data are representative of at 
least three animals. Results are expressed as mean ± S.E.M. of cell number. *p < 0.05.  
A 
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Figure 6.13 Depletion of Treg resulted in a decrease in IL-10 production in sensitised, 
MSC-treated mice.  Cytokine profile of BALF elicited by OVA sensitisation.  Cytokine 
responses from similar cultures are shown for (A) IL-5, (B) IL-4, (C) IL-10 and (D) IL-13.  
Results are representative of responses determined independently from at least four mice per 
group and are expressed as means ± S.E.M. *p < 0.05.   
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Figure 6.14 Treg depletion impairs the inhibitory effect of MSC on T cell proliferation.  
Cells were cultured in the presence of media alone (    ) or OVA (200 µg/ml) (     ) for 72 h.  
Subsequent proliferation was measured by 3H-thymidine incorporation (
*
, p<0.05). The data 
presented are representative at least four animals per group and are expressed as means ± 
S.E.M. *p < 0.05.  
B A 
C D 
  OVA 
OVA MSC 
199 
 
6.9 MSC DIRECTLY ALTER EXPRESSION OF ADHESION FACTORS ON EOSINOPHILS 
In Section 6.8, MSC were shown to have a Treg-independent effect on eosinophil 
recruitment to the airways.  Despite a significant increase in IL-5, a reduction in airway 
eosinophilia was observed in mice receiving MSC in the absence of Treg (Fig. 6.12).  
Therefore the ability of MSC to directly affect the function of eosinophils upon entering the 
airways was investigated.  In this study, the functional effects of MSC on eosinophils were 
investigated in vitro in terms of modulating the chemotactic migration and expression of 
adhesion molecules, including intracellular adhesion molecule (ICAM-1), ICAM-3, L-
selectin and leukocyte function-associated antigen-1 (CD11a/CD18).   
Here, human MSC (hMSC) were used to investigate the putative direct affect on 
eosinophil function, as reagents for murine eosinophilia were not available.  Human 
eosinophils (cell line EOL-1) were cultured in the presence of hMSC for 48h.  This resulted 
in an inhibition of eosinophil expression of the adhesion molecules ICAM-1, ICAM-3, CD18 
and L-selectin (Fig. 6.15 & 6.16).  The experiment was carried out in a dose-dependent 
manner where four ratios of eosinophil to hMSC were used; 10:1, 5:1, 3:1 and 1:1.  The 
percentage of ICAM-1 expressing human eosinophils decreased from 99.6% to 1%, and the 
mean fluorescent intensity (MFI) of the positive population decreased (59% to 17%) (Fig. 
6.15 B).  Likewise, the addition of hMSC strongly inhibited the expression of ICAM-3 and 
CD18 on eosinophils (Fig. 6.15 D & 6.16 B).  A lesser but similar effect on L-selectin 
expression was observed, (Fig. 6.16 D).  Inhibition of surface marker expression was only 
evident at high (1:1 eosinophil:MSC)  ratios.  Although this seemed non-physiologically 
relevant, the number of eosinophils in BALF following OVA sensitisation and challenge was 
approximately 0.5 x 10
5
/lung.  Since mice each received 0.5 x 10
6
 MSC, the potential for 
MSC to come into contact with eosinophils in the lung is not impossible, however a soluble 
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effector seemed a more likely cause.  As a consequence of these data, the ability of MSC to 
affect chemotactic migration of eosinophils in vitro was investigated.       
 
6.10 MSC PREVENT EOTAXIN AND RANTES –INDUCED CHEMOTAXIS OF EOSINOPHILS 
 The potential of hMSC to regulate soluble factor-induced chemotaxis of eosinophils 
was investigated.  Eotaxin has been implicated in many manifestations of allergic 
inflammation including airway eosinophilic infiltration (Conroy, 1997).  Similarly, RANTES 
is a potent chemoattractant and activation factor for eosinophils (Russell, 1994).  Eotaxin and 
RANTES-induced chemotaxis was measured using Transwell chamber plates, as described in 
Chapter 2.30.  Human eosinophils (cell line, EOL-1) (5 x 10
4
) were cultured with or without 
allogeneic hMSC (5 x 10
4
) for 48 h.  Human CD4
+
 T cells were also included as an additional 
group where they were co-cultured with MSC and/or eosinophils, separated by a Transwell 
membrane, to investigate whether T cells were required for MSC to exert their inhibitory 
effects on eosinophil chemotaxis.  Non-adherent eosinophils were aspirated from the wells 
leaving adherent MSC on the bottom.  As expected, when compared with control groups 
(vehicle only), both eotaxin and RANTES induced eosinophil migration (Fig. 6.17 A & B).  
However, pre-incubation with MSC prevented migration of eosinophils in response to both 
chemokines.  This effect was not seen when eosinophils were pre-incubated with CD4
+
 T 
cells alone.  Thus MSC blocking of eosinophil chemotaxis does not require CD4
+
 cells.           
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Figure 6.15 MSC directly inhibit the expression of ICAM-1 and ICAM-3 on eosinophils.  
Surface expression of (A&B) ICAM-1, (C&D) ICAM-3 on eosinophils (cell line, EOL-1) 
was determined by flow cytometry following co-incubation with hMSC (1:1) for 48 h.  Non-
adherent eosinophils were aspirated from the wells leaving adherent MSC.  Expression was 
reduced when cells had been cultured in the presence of MSC (B) and (D).  Plots are 
representative of experiments performed in triplicate.  M line indicates the percentage of cells 
within that population. 
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Figure 6.16 MSC reduce the expression of CD18 and L-selectin on eosinophils.  Surface 
expression of (A&B) CD18, (C&D) L-selectin on eosinophils was determined by flow 
cytometry following co-incubation with hMSC (1:1) for 48 h.  Expression was reduced when 
cells were cultured in the presence of MSC (B) and (D).  Plots are representative of 
experiments performed in triplicate.  M line indicates the percentage of positive cells within 
that population. 
 
99.87%
% 
80.52%
% 
99.70%
% 
99.64%
% 
Fluorescent intensity 
A 
D 
B 
Number 
C 
203 
 
   
0 1 2 3 4 5
EOL+MSC+CD4
EOL+MSC
EOL+CD4
EOL
**
Chemotactic index
 
 
  
0 1 2 3 4 5
EOL+MSC+CD4
EOL+MSC
EOL+CD4
EOL
Chemotactic index
***
 
Figure 6.17 The effect of MSC on eosinophil chemotactic activity. Human eosinophils (5 
x 10
4
) (cell line, EOL-1) were pre-incubated with hMSC (1:1) for 48 h before isolation and 
addition of eosinophils to chemotaxis chambers.  Chemotactic migration in response to (A) 
RANTES (100 µM) and (B) eotaxin (100 µM) is shown above.  Data are expressed as a 
chemotactic index, calculated as the number of cells migrating in response to stimulus 
divided by the number of cells migrating in response to medium. 
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6.11 SUMMARY 
Here the mechanism of action of an MSC-mediated cell therapy was determined.  
MSC cell therapy leads to the generation of peripheral CD8
+γ/δ and CD+FoxP3 Treg.  Several 
mechanisms have been proposed for MSC-elicited immunosuppression including immune 
deviation, induction of anergy and suppression by Treg (Maccario, 2005; English, 2008).  In 
an experimental asthma model, where mice are devoid of naturally occurring Treg, delivery of 
MSC fail to influence the development of allergic airway pathology and class switching to 
IgE.  As neither eosinophilia nor other MSC functions are impaired in this model, the MSC 
effect can be attributed to Treg induction.  In summary, the work presented here developed 
models to address the three hypotheses defined at the beginning of this chapter and explained 
the protective effect seen in this model. Furthermore, the experiments herein identified a 
novel influence of human MSC on eosinophil function which although not wholly 
responsible for the cell therapeutic effect described in Chapter 5, nevertheless merits future 
exploration.  
The capacity to therapeutically manipulate the immune response to allergens in order to 
restore or regulate normal immunity was examined further in subsequent chapters.  
Mesenchymal stem cells (MSC) are a heterogeneous subset of stromal stem cells that possess 
potent anti-proliferative and anti-inflammatory effects (Aggarwal, 2005; Barry, 2005; Uccelli, 
2006; Comoli, 2008), data which support their possible use as a therapy for immune-mediated 
diseases.  MSC can exert profound immunosuppressive effects via modulation of both cellular 
and innate immune pathways (Krampera, 2006).  The present study addressed the hypothesis 
that adult bone marrow derived-MSC would prevent the pathology associated with allergen-
driven airway inflammation.  In Chapter 4, functional in vitro assays were carried out in order 
to address quality-control issues linked to systemic delivery of MSC in vivo.  The capacity to 
actively inhibit immune responses is a characteristic feature of MSC.  Data in Chapter 4 
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demonstrated the ability of MSC to inhibit allo-proliferation irrespective of the donor 
haplotype.  This was important as functionally immunosuppressive MSC were central to the 
hypothesis that the pathology associated with allergen-driven airway inflammation could be 
prevented by cell therapy.   
Several studies have provided evidence in support of the plasticity and 
immunomodulatory properties of MSC, as well as their ability to be recruited to sites of 
injury, where they can contribute to tissue repair.  Selective localisation of systemically 
delivered MSC has been demonstrated in models of kidney failure (Ezquer, 2008), 
myocardial infarction (Quevedo, 2009), and neurological injury (Bouchez, 2008).  Extensive 
in vitro studies have demonstrated that, unlike other stem cell types, MSC can not only evade 
alloreactivity, but also mediate active suppression of immune responses (Bartholomew, 2004; 
Ryan, 2007; English, 2008).  Preclinical models of autoimmune/inflammatory conditions 
such as transplant rejection (Le Blanc, 2004), rheumatoid arthritis (Augello, 2007), and 
multiple sclerosis (Constantin, 2009), have demonstrated a functional role for MSC.  Several 
studies have also demonstrated a functional protective effect of MSC in models of acute lung 
injury, including pulmonary fibrosis (Ortiz, 2003; Xu, 2007) and very recently allergic 
rhinitis (Cho, 2009).  However, little was known about the mechanism of MSC-mediated 
immunomodulation and their clinical relevance in a model of allergic airway inflammation.  
Chapter 5 specifically addressed the hypothesis that adult bone marrow derived-MSC would 
prevent the pathology associated with allergen-driven airway inflammation.  This was tested 
using a combination of the OVA-driven model of inflammation utilised in Chapter 3 and a 
cell therapy based on allogeneic MSC.  This study demonstrated that adult bone marrow 
derived allogeneic MSC actively prevent the induction of allergen driven pathology in a 
murine model and suggests a novel cell therapy for allergic human disease.  Systemic 
administration of MSC protected the airways from OVA-induced pathology, airway 
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eosinophilia and broader cellular inflammation.  This effect was only evident upon delivery 
of live, but not fixed cells.  A consistent feature of asthma is the production of excess mucus, 
causing blockage of the peripheral airways (Young, 2006).  MSC delivery reduced mucus 
metaplasia in allergen-sensitised mice, consistent with the findings above.  In contrast, PFA-
fixed MSC exacerbated goblet cell hyperplasia and mucus secretion in OVA-sensitised mice 
airway pathology and OVA-specific IgE.   
Previous studies have observed an increase in the efficacy of MSC 
immunosuppression in vivo when they are activated prior to delivery, a process termed 
“licensing” (Ryan, 2007; Polchert, 2008).  This phenomenon was also investigated in Chapter 
4 by examining the effect of exogenous IFN-γ on MSC-mediated immunosuppression in 
vitro.  Stimulated MSC enhanced the inhibitory effect seen previously with un-stimulated 
MSC in both mitogen-driven and allo-driven reactions (Fig. 4.8).  Furthermore, the inability 
of MSC isolated from IFN-γ-receptor knockout mice to suppress T-cell proliferation in a two-
way mixed lymphocyte reaction demonstrated the importance of this cytokine in conferring 
immunosuppressive function to MSC (Fig, 4.9).  These data verified the results of others 
(Ryan, 2007; Polchert, 2008) by demonstrating the enhancing effect of pre-stimulated MSC 
and indicated the importance of the inclusion of these licensed cells in further studies.  In 
Chapter 5, prior stimulation of MSC with IFN-γ increased their protective effect.  This was 
most evident in the histopathological analysis of the lung tissues where mucus hypersecretion 
and peribronchial inflammation was significantly reduced.  These data suggest that IFN-γ 
stimulation can enhance the efficacy of live MSC in modulating the immune response in 
allergic airway inflammation.  However, the reduction in pathology in those sensitised groups 
receiving non-stimulated MSC indicated that prior activation is not essential.  Interestingly, 
the inhibitory effect of IFN-γ triggered by BPZE1 immunisation in Chapter 3 supports the 
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importance of this key cytokine in suppression of the allergic inflammatory response through 
either direct or indirect interactions.  
The phenomena described above were interesting but could be explained by MSC-
mediated global, non-specific immune suppression or by MSC interference in immune 
induction.  Therefore, the effect of allogeneic MSC on T cell mediated immunity was 
examined in this model.  Particular attention was given to IL-4, IL-5 and IL-13 induction as 
these play well defined roles in allergen driven pathology as evidenced by data from Chapter 
3.  OVA-sensitised mice exhibited a typical increase in BALF IL-5.  However, levels of IL-5 
were significantly increased in the sensitised, MSC-treated group in BALF when compared to 
OVA alone.  This was surprising given the considerable decrease in eosinophilic lung 
infiltration and improvement in airway pathology (Fig. 5.3 & 5.6).  The first conclusion from 
this was that MSC did not mediate global suppression or suppress antigen specific immune 
induction.  The typical damaging effects of IL-5 in acute lung inflammation may have been 
countered in this instance by the significant increase in BALF IL-10 and also the marked 
reduction in IL-4.  Several studies have demonstrated a role for IL-10 in modulating the 
allergic immune response (Prigione, 2009).  IL-10 can inhibit critical steps in the initiation of 
the clinical manifestations of allergic airway inflammation, namely IgE dependent activation 
of mast cells and survival of eosinophils and can regulate the production of eosinophilotactic 
cytokines (Li, 2010).  However, it has also been shown to play a direct regulatory role in 
controlling the accumulation of excessive eosinophils at inflammatory sites by accelerating 
their apoptosis (Takanaski, 1994).  Furthermore, IL-10 can inhibit CCR5 (Patterson, 1999) on 
T cells, macrophages and dendritic cells, whose ligand is, amongst others, RANTES, and is a 
major eosinophil chemoattractant in the asthmatic lung (Venge, 1994).  Despite reducing 
circulating and sputum eosinophil numbers, systemic administration of an anti-IL-5 antibody 
only partially reduces airway tissue eosinophils in asthmatic patients (Flood-Page, 2003).  
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This incomplete response may be because eosinophils lose their IL-5 receptor from the cell 
surface as they enter the airways from circulation, and, as a result, their dependence on IL-5 
for survival (Liu, 2002).  Therefore, in spite of the increase in IL-5 observed in MSC-treated 
group which may have initiated differentiation and migration of eosinophils, according to 
previous reports, this alone is not be sufficient to mobilise their accumulation in the lung.  IL-
4 plays an important role in sustaining established IgE responses (Del Prete, 1988); therefore 
a decrease in its secretion can lead to a reduction in IgE synthesis.  IL-4 is required for 
adherence and activation of eosinophils in the lung and since IL-4 was significantly reduced 
in MSC-treated mice, this may have prevented the otherwise damaging pathology associated 
with OVA-driven inflammation.   
Chapter 5 demonstrated that adult bone marrow-derived allogeneic MSC actively 
prevent the induction of allergen driven pathology in a murine model and suggested a novel 
cell therapy for allergic human disease and prompted further investigation of the 
mechanism/s employed by MSC in suppressing the allergen-driven response.  MSC may 
exploit one, or a combination of, functionally distinct pathways to inhibit allergic airway 
inflammation, including (1) repair of damaged tissue, (2) induction of regulatory T cells or 
(3) immunomodulation via cytokine induction/suppression directly affecting immune cell 
infiltration.   The third hypothesis is not consistent with the elevated IL-5 seen (Fig. 5.11 C) 
and therefore cannot pertain and so will not be discussed further.  The possibility of a repair 
mechanism employed by MSC is not viable as the sole contributor to the MSC-mediated 
protective effect in this model since no inhibition of allergic airway pathology was 
demonstrated upon depletion of regulatory T cells in Chapter 6.  .     
The role of regulatory cells in MSC-mediated immunosuppression has been suggested 
by the expansion of CD4
+
CD25
+
 cells in vitro when cultured with MSC (Maccario, 2005; 
Prevosto, 2007; English, 2008; Wang, 2009).  This created a compelling case for further 
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pursuing MSC as cellular tolerogens.  First, it was necessary to confirm that MSC could 
feasibly mediate the expansion or proliferation of Treg subsets that are important in regulating 
the allergic airway response.  Several regulatory T cell subsets exist, including (1) 
CD4
+
CD25
+
, (2) CD8
+
CD28
-
, (3) CD8
+TCRγ/δ+, (4) CD4-CD8-TCRα/β+.  There is evidence 
that the numbers or functions of these subsets are deficient in patients with atopic allergic 
disease (Grindbacke, 2004; Ling, 2004; Isogai, 2007).  MSC induced CD8
+TCRγ/δ cells in 
the lung and spleen.  CD8
+
 T cells play important roles, either as effector or regulatory T 
cells, in several immunopathologic manifestations such as autoimmune diseases (Najafian, 
2003; Brimnes, 2005), transplantation (Kato, 2010) and protection of the host against 
infectious diseases and cancer (Palmer, 2004; Nakamura, 2007; Gil, 2009).  CD8
+
 regulatory 
cells act through the production of suppressor cytokines (TGF-β or IL-10) or by inactivating 
dendritic cells (Rich, 1995; Gilliet, 2002).  A growing body of evidence now exists 
suggesting that CD8
+γ/δ T cells are influential in CD8+ T cell-mediated regulation of airway 
inflammation.  A deficiency in this distinct subset is associated with a reduction in 
inflammation within the lungs (Lahn, 1999).  Recent studies have also shown that γ/δ CD8+ T 
cells adoptively transferred into sensitised rats reduced airway eosinophilia and 
hyperresponsiveness (Isogai, 2003; Isogai, 2007).  The considerable increase in this distinct T 
cell subset upon MSC delivery is a novel finding and could, in part, explain the improvement 
in allergic airway pathology.  However, as no induction of this distinct CD8
+
 population was 
observed in OVA-sensitised mice, it could not be established that they were specifically 
depleted during CY treatment.  Nevertheless, as CY can target proliferating T cells, it could 
be predicted that γ/δ CD8+ Treg were indeed inhibited following MSC delivery, thus 
suggesting their important protective effect in this model.  
CD4
+
CD25
+
FoxP3-expressing Treg suppress effector T cells both directly and via 
interactions with antigen-presenting cells, such as dendritic cells (Oderup, 2006).  Recently, 
210 
 
using a FoxP3-specific conditional knockout of the IL-10 allele, it was demonstrated that IL-
10 production by Treg was required to control immune responses in the lung (Rubtsov, 2008).  
The current study revealed an increase in CD4
+
FoxP3
+
cells in the lungs of MSC-treated 
mice, prompting further investigation of these phenomena. Treg were depleted using 
cyclophosphamide in the ovalbumin-induced model of allergic airway inflammation, and the 
effect of MSC delivery on airway pathology was examined.  It was decided not to include a 
CY-treated, IFN-γ-stimulated MSC group here for clarity.  There are limitations to the use 
cyclophosphamide over denileukin diftitox or an anti-CD25 monoclonal antibody to deplete 
Treg.  A monoclonal anti-CD25 antibody has been routinely used for depleting Treg in vivo 
(McHugh, 2002; Van Meirvenne, 2005; Boudousquie, 2009).  However, due to the 
expression of CD25 on activated effector T cells, they are thus potential targets for depletion 
by anti-CD25 mAB also.  CY is widely used as an immunosuppressive drug and is reported 
to down-regulate T-cell derived IL-10 and TGF-β (Matar, 2001) and affect the functionality 
of Treg (Lutziak, 2005).  It has been used in studies to examine the effect of Treg depletion in 
various disease models (Aschan, 1999; Itescu, 2002; Ghiringhelli, 2004).   
No significant differences in pathology were observed in MSC-treated mice depleted 
of Treg when compared with those sensitised with OVA alone.  Likewise, the reduction in 
OVA-specific IgE seen previously with MSC-treatment was not observed here, suggesting 
the role of suppressor cells in MSC-mediated immunosuppression in this model.  In spite of 
the inhibition of Treg, a significant reduction in airway eosinophilia persisted in those treated 
with MSC.  This is an important finding as it eliminates an eosinophil mediated effect on the 
MSC suppression of pathology.  Thus these data suggest the existence of multiple 
mechanisms where the combination of T-cell-dependent and modes of protection are 
employed.  Figure 6.18 outlines the putative mechanism involved in MSC-mediated 
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protection in allergic airway inflammation and illustrates the interplay between multiple 
mechanisms. 
 
 
 
 
Figure 6.18 Schematic presentation of plausible mechanisms by which MSC regulates 
the allergen-driven response. (1) MSC can secrete a variety of soluble factors including 
TGF-β and PGE-2.  Through a soluble factor or contact-dependent mechanism, MSC initiates 
the expansion of regulatory T-cells directly or indirectly via IL-10 secretion with a 
subsequent inhibition of the otherwise damaging effect of allergen sensitisation and 
respiratory challenge. (2) MSC directly inhibits airway eosinophilia through the secretion of 
HGF which can exerts a direct regulatory role on the function of eosinophils by inhibiting 
their chemotaxis. 
 
1. 
2. 
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This chapter also revealed a Treg independent MSC-mediated effect on eosinophils that was 
not sufficient to alleviate airway pathology. In light of the reduction in airway eosinophilia in 
the presence of higher IL-5 secretion in MSC-treated mice, the possibility that MSC were 
exerting direct inhibitory effects on eosinophils and thus preventing their transmigration into 
the lung was investigated.  The critical observation here was that MSC can efficiently inhibit 
or down-regulate key adhesion molecules on eosinophils, hindering their chemotactic ability 
(Fig. 6.17).  Co-culture of T-cells with MSC and eosinophils was not essential for this to 
occur; demonstrating that indirect stimulation of T cells by MSC was not essential (e.g. IL-5, 
IL-4 are not involved).  These data provide an explanation as to why eosinophilia could be 
reduced when IL-5 was elevated.  Eosinophils express the integrin adhesion molecules 
CD11/18 complex which interacts with intercellular adhesion molecule-1 (ICAM-1) and 
vascular cell adhesion molecule-1 (VCAM-1), respectively (Burke-Gaffney, 1998).  However 
in Chapter 6 it was shown that human MSC interfered with expression of these adhesion 
molecules on human eosinophils (Fig. 6.16).  Hepatocyte-growth factor (HGF) is a 
homeostatic mediator associated with the direct attenuation of allergic airway inflammation 
(Okunishi, 2009).  It has recently been shown to exert a direct regulatory role on the function 
of eosinophils by inhibiting their chemotaxis (Ito, 2007).   Since HGF is one of a variety of 
cytokines secreted by MSC (Ryan, 2007) it is reasonable to suggest that it plays a role here.  
Interestingly, co-culture with IFN-γ significantly increases the expression of these 
suppressive mediators (Ryan, 2007) supporting a role for IFN-γ in potentiating the 
immunosuppressive activities of MSC.  HGF was significantly higher in conditioned media 
of pre-stimulated MSC when compared with MSC with no prior activation.  The effect of 
IFN-γ in this model may therefore be related to its‟ ability to stimulate an increase in the 
production of HGF (Ryan, 2007).  This may explain why the reduction in airway pathology 
was more evident in those sensitised mice receiving stimulated MSC when compared to those 
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treated with MSC in the absence of prior activation.  This novel finding provides further 
insights into the mechanisms of MSC-mediated immune modulation in vivo and indicates that 
viable allogeneic MSC could be a therapeutic modality against allergen driven airway 
disease.  It also suggests a role for IFN-γ- stimulated MSC whereby their efficacy is enhanced 
for use in a range of therapeutic treatments in human clinical trials.     
The immunological properties associated with MSC would appear to target critical 
pathogenic features for the development of allergic asthma.  A combination of T cell 
dysregulation, as well as the presence of inflammatory cytokine milieu in a coordinated 
fashion, leads to this failure to maintain tolerance to innocuous environmental allergens. 
MSC possess specific immunomodulatory properties that appear capable of protecting against 
this airway hyperresponsiveness through immune modulation and Treg induction.  Here, the 
immunoregulatory properties of MSC interfered effectively with the immune 
hyperresponsiveness in the course of allergen sensitisation, inhibiting the otherwise damaging 
effect of allergen sensitisation and respiratory challenge.  The protective effect as a result of 
MSC therapy may have more far-reaching clinical implications in humans.  For example, in 
atopic individuals with a genetic susceptibility for asthma or in patients who are unresponsive 
to current therapies, the use of stem cells may have more influential and sustained effects.  
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Asthma is a chronic inflammatory disorder of the airways whose prevalence is 
steadily increasing in developed societies (Galli, 2008).  New and improved anti-
inflammatory drugs, particularly inhaled corticosteroids have improved the quality of life of 
patients, however, even the long-term usage of pharmacotherapies does not appear to induce 
fundamental changes in the immune responsiveness or alter the natural history of the disease 
(Bisgaard, 2006; Guilbert, 2006).  Therefore, the need to develop strategies to permanently 
reverse immunologic reactivity and chronic airway inflammation has become recognised. 
Th2 cytokines, particularly IL-4, IL-5 and IL-13 initiate and potentiate the immune response 
in asthmatics (Kay, 2001).  In allergen specific immunotherapy, it was first believed that Th1 
cells such as IFN-γ played a beneficial role by down-regulating the Th2 response 
(Romagnani, 2004).  However, further investigation has demonstrated that allergic airway 
inflammation is not simply a balance between Th1 and Th2 responses (Hansen, 1999).  
Regulatory T cells have emerged as key players in controlling the development of 
inflammation (Akbari, 2002; Kearly, 2008) and an improved understanding of these cells has 
led to the emergence of new therapeutic modalities that may provide a more long-term 
inhibition of immune hyperresponsiveness (Akdis, 2001; Jutel, 2003).  This study examined 
therapeutic approaches to immune modulation, including the use of modified respiratory 
pathogens and stem cells, to define the mechanisms of action and to explore new ways to 
beneficially manipulate the immune response to aeroallergens.  
Asthma is a multi-factorial disease which encompasses numerous manifestations 
including inflammation, repair and remodelling.  Intriguingly, in both systems studied in this 
thesis, remodelling seemed to be more central to pathology than atopic inflammation.  The 
observation that allergen-specific IgE was not significantly changed whilst pathology was 
reduced in mice immunised with BPZE1 demonstrates that the protective effect of immune 
modulation seen here had its greatest impact on mucus secretion and remodelling rather than  
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a reduction in IgE.  Similarly, in the Treg-depleted OVA model, a reduction in airway 
eosinophilia inhibition as a result of MSC therapy was not sufficient to modulate pathology. 
Such a finding is also consistent with human clinical studies in which reduced airway 
eosinophilia was achieved but this had little impact on pathology (Flood-Page, 2007).  The 
implication of an alternative mechanism of action is that the biological therapies explored in 
this thesis could target complex multi-factorial diseases that involve both fibrotic and 
inflammatory processes or Treg dependent and independent aspects, for example chronic 
GvHD.  It may also provide novel approaches to treat currently intractable conditions where 
fibrosis is a major component such as scleroderma (Abraham, 2005) and idiopathic 
pulmonary fibrosis.  
Many questions remain unanswered with regard to a biological therapy based on 
bacterial immunomodulation.  For example, studies examining the protective role of 
mycobacteria and their components (e.g. Bacillus–Calmette–Guerin (BCG) immunisation) 
against the development of allergic diseases have demonstrated conflicting results (Krishna, 
2002).  Animal and experimental models have shown that exposure to Mycobacteria or 
mycobacterial proteins leads to a reduction in various allergic manifestations and although 
there are several epidemiological studies in support of this, they have not always been 
consistent.  Nevertheless, intriguing evidence suggests that microbial immunomodulation 
does occur.  Vaccination with whole-cell pertussis vaccine has been reported to protect 
against B. pertussis exacerbation of OVA-induced airway hyperresponsiveness in a murine 
model of allergic airway inflammation (Ennis, 2005b), however much less is known about 
protective effects of childhood vaccines against atopy.  It might be that the key beneficial 
feature of BPZE1 is the combination of a Th1 skewed response, combined with the absence 
of induced airway pathology.  This combined benefit makes BPZE1 an attractive candidate as 
a neonatal vaccine against whooping cough.  
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MSC also pose questions for cell therapy, however this has not impeded the more 
than 100 reported clinical trials currently using these cells.  Foremost amongst these 
questions concerns the mechanism of therapeutic action.  MSC are proposed to have 
beneficial function in numerous conditions, however it is rarely clear how the cells are 
functioning to achieve the benefit observed.  This study is one of very few to actually 
demonstrate how MSC function in vivo.  It is interesting to note that therapeutic improvement 
was linked not to a regenerative capacity (i.e. MSC did not seem to persist and differentiate 
into lung tissue) but rather it was through Treg induction.  Thus, the original claims by Caplan 
(Caplan 2006) and Phinney (Phinney 2007) that trophic influences are the major therapeutic 
mode of action is borne out by this study.  A second problem arises from this lack of 
understanding; if the mode of action is not characterised, clinical release criteria and 
decisions around expansion and manufacturing quality cannot be based on rational or 
measurable indices (linked to efficacy) but rather these become a mere quality assurance 
exercise linked to whatever parameters are measurable.  Therefore, it is not surprising that the 
recent Osiris trial using MSC (Prochymal III) against acute graft v Host disease was a failure 
(or partial in benefit).  The cells used in that study were well characterised with regard to 
surface markers and differentiation capacity, but as the correlates of efficacy were unknown, 
these criteria were largely irrelevant.  The approach adopted in this study, to examine and 
define the mechanism of action, is an essential step in the rational introduction of new stem 
cell therapies.  In the absence of this approach, clinical trials will continue to encounter the 
failures seen with Prochymal.  
The future for BPZE1 is promising, and the vaccine commences phase I human 
clinical trial in late 2010.  Likewise MSC show a remarkable ability to improve currently 
intractable diseases, at least in model systems.  The next key step for both approaches will 
rely on definition of their activities in scientific studies.  Many asthmatics are refractory to 
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single or combined chemotherapies targeting single or at best a small number of 
inflammatory mediators.  This work has shown that “biological” approaches based on cell 
therapies or attenuated microbes are effective modulators of the allergic response, providing a 
proof of principle in support for the eventual translation of novel biological cell therapies to 
humans. 
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Table 2.1  Summary of media for cultured cells 
Media Culture media Supplier 
Isolation of murine MSC RPMI 1640 
100 U/ml penicillin 
100µg/ml streptomycin  
2mM L-glutamine 
10% (v/v) horse serum  
10% (v/v) heat inactivated low-endotoxin foetal calf serum (FCS) 
Invitrogen-Gibco 
Invitrogen-Gibco 
Invitrogen-Gibco 
Invitrogen-Gibco 
Hyclone 
Hyclone 
 
Expansion of murine MSC 
 
Minimum Essential Medium (MEM
10% (v/v) heat inactivated low endotoxin FCS  
10% (v/v) horse serum  
100 U/ml penicillin 
100µg/ml streptomycin  
2mM L-glutamine 
Invitrogen-Gibco 
Hyclone 
Hyclone 
Invitrogen-Gibco 
Invitrogen-Gibco 
Invitrogen-Gibco 
 
Expansion of murine transgenic GFP MSC 
 
Mesencult Basal Medium  
10% murine mesencult supplement  
1% (v/v) penicillin/streptomycin 
Stem Cell Technologies 
Stem Cell Technologies 
Invitrogen-Gibco 
 
   
Osteoblast Differentiation 
 
Minimum Essential Medium alpha (MEM
1mM dexamethasone,                        
20mM β-glycerolphosphate,  
50µM L-ascorbic acid-2-phosphate,  
50ng/ml L-thyroxine sodium pentahydrate.   
Invitrogen-Gibco 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
   
 
 
Table 2.1 Summary of media of cultured cells continued 
Media Culture media Supplier 
Adipocyte Differentiation 
 
 
 
 
 
Chondrogenic Medium 
 
 
 
 
 
 
 
 
Human MSC culture 
Minimum Essential Medium alpha (MEM
5.0µg/ml insulin in 0.1N acetic acid 
50µM indomethacin 
1µM dexamethasone 
0.5µM 3-isobutyl-1-methylxanthine (IBMx) in methanol 
 
Dulbecco’s Modified Eagle’s Media (DMEM) containing 100 mg/ml glucose
100nM dexamethasone 
50μg/ml ascorbic-acid-2-phosphate 
40μg/ml proline 
1mM sodium pyruvate 
(1:99) ITS + supplement 
10ng/ml TGF-β3 
 
 
Dulbecco’s Modified Eagle’s Media (DMEM) containing 100 mg/ml glucose
10% hi FCS 
100 U/ml penicillin 
100g/ml streptomycin  
Invitrogen-Gibco 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
 
 
Invitrogen-Gibco 
Hyclone 
Invitrogen-Gibco 
Invitrogen-Gibco 
 
 
Human Eosinophil Cell Line (EOL-1) RPMI 1640  
15% fetal bovine serum (FBS) 
1% L-glutamine  
Invitrogen-Gibco 
Hyclone 
Invitrogen-Gibco 
 
Table 2.2  Summary of media for bacterial growth 
Strain Culture medium Components Concentration Supplier 
Bordetella pertussis 
(BPSM) 
Bordet Gengou agar 
 
Bordet Gengou Agar 
Glycerol 
Sterile defibrinated horse blood 
dH2O 
 
30g/L 
2.5ml/L 
50ml/L 
BD-Difco 
Sigma-Aldrich 
Unitech, Dublin, Ireland 
 Stainer & Scholte (S&S) 
liquid medium 
L-Glutamic acid,  
L-Proline,  
Sodium chloride  
Potassium dihydrogen phosphate 
Potassium chloride  
Magnesium chloride,  
Calcium Chloride  
Tris Base  
dH2O 
pH adjusted to 7.4   
 
10.72g/L 
20mg/L 
2.5g/L 
0.5g/L 
0.2g/L 
0.1g/L 
20mg/L 
1.525g/L 
 
Sigma-Aldrich 
Sigma-Aldrich 
BDH 
Merck 
Merck 
Merck 
BDH 
Sigma-Aldrich 
 
 
 S&S supplement L-cystine 
HCl 
Iron sulphate  
Ascorbic acid 
Nicotinic acid  
Glutathione (reduced) 
dH2O 
0.4g/L 
1.0ml/L 
0.1g/L 
0.2g/L 
40,g/L 
1.0g/L 
Sigma-Aldrich 
Merck 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
 
Bordetella pertussis 
(BPZE1) 
As above (BPSM)    
 
Table 2.3  Summary of buffer components and concentrations 
Application Buffer Components Concentration Supplier 
ELISA Phosphate Buffered Saline 
(PBS) (10x) 
 
Sodium chloride 
Potassium chloride 
di-Sodium orthophosphate 
Potassium dihydrogen orthophosphate 
dH2O   
pH was adjusted to 7.0  
 
1.37M 
27mM 
200mM 
20mM 
 
BDH 
Merck 
BDH 
Riedel-deHaen 
 
 
ELISA Wash  
 
Tween 20   
PBS 
pH adjusted to pH 7.4  
 
0.05% (v/v) Sigma-Aldrich 
ELISA Carbonate coating  Sodium carbonate  
Sodium bicarbonate 
dH2O  
pH was adjusted to 9.6  
 
100mM 
100mM 
Sigma-Aldrich 
Sigma-Aldrich 
ELISA Blocking 
 
Milk powder 
PBS 
 
10% (w/v) Marvel, Chivers Ireland 
Ltd, Dublin 
ELISA Diethanolamine Buffer 
 
Magnesium chloride   
Sodium azide  
Diethanolamine 
pH was adjusted to 9.8 dH2O 
 
9.52M 
0.5mM 
9.7% (v/v) 
Merck 
Merck 
Sigma-Aldrich 
 
ELISA Stop solution 
 
1M Sulphuric acid  Sigma-Aldrich 
 
Table 2.3  Summary of buffer components and concentrations continued 
Application Buffer Components Concentration Supplier 
FISH Sodium thiocyanate 
 
Sodium thiocyanate 
dH2O 
 
8% (w/v) Sigma-Aldrich 
FISH Digestion Pepsin in  
0.1M HCl  
 
0.4% (w/v) Sigma-Aldrich 
Merck 
FISH Quenching Glycine  
PBS  
 
0.2% (w/v) BDH 
FISH Sodium Saline Citrate 
(4XSSC) 
Sodium saline citrate 
dH2O 
 
1% (w/v) Sigma-Aldrich 
FISH Stringency wash solution 
2XSSC 
diluted from stock SSC   
 
 
0.5% (w/v)  
FISH Detergent wash solution 
 
10% Tween 20  
4X Sodium saline citrate. 
0.05% (w/v) Sigma-Aldrich 
Sigma-Aldrich 
 
Table 2.4  Summary of staining solutions 
Stain Components Concentration Supplier 
H&E Eosin Y   
Potassium dichromate  
dH2O 
1% (w/v) 
1.6% (w/v) 
Sigma-Aldrich 
 Hydrochloric acid 
2-Propanol  
dH2O 
 
1% (v/v) 
69.3% (v/v) 
 
BDH 
Riedel-deHaen 
Combined stain Alcian blue  
Acetone   
 
0.5% (w/v) 
3% (v/v) 
Sigma-Aldrich 
Discombes eosin Eosin  
Acetone  
 
0.05% aq (w/v) 
5% Acetone 
Sigma-Aldrich 
Sigma-Aldrich 
Scotts tap water Sodium bicarbonate 
Magnesium sulphate 
dH2O 
 
0.2% (w/v) 
1% (w/v) 
Sigma-Adrich 
Sigma-Adrich 
Fat differentiation  Oil Red O  
Isopropanol  
Working solution: 
0.5% Oil Red O stock  
PBS 
 
0.5% (w/v) 
 
 
30mls  
20mls 
Sigma-Aldrich 
Bone differentiation Alizarin Red S stain  
dH2O 
pH adjusted to between 4.1-4.3 using 0.1% 
ammonium hydroxide.   
1% (w/v) Sigma-Aldrich 
 
Table 2.5  Summary of antibodies and concentrations of use 
Application Name Concentration Supplier 
Flow cytometry Anti-mouse CD4 Cy5 
Anti-mouse CD8 APC 
Anti-mouse CD25 FITC 
Anti-mouse CD28 PE 
Anti-mouse TCRα/β FITC 
Anti-mouse TCRγ/δ FITC 
Anti-mouse CD16,CD56 NK PE 
Anti-mouse FoxP3 PE 
Anti-mouse CTLA4 PE 
Anti-mouse GITR PE 
Anti-mouse CD105 Biotin 
Anti-mouse CD106 FITC 
Anti-mouse CD44 PE 
Anti-mouse CD45 FITC 
Anti-mouse Sca-1 PE 
Anti-mouse CD117 PE 
Anti-human ICAM-1 PE 
Anti-human ICAM-3 PE 
Anti-mouse MHC Class I PE 
Anti-mouse MHC Class II PE 
Anti-mouse CD80 PE 
Anti-mouse CD86 PE 
Anti-mouse CD11b FITC 
Anti-mouse CD34 Biotin 
Anti-human CCR3 PE 
Anti-mouse NK cells 
2µl/ml 
2µl/ml 
2µl 
2µl/ml 
2µl 
2µl 
2µl 
2µl/ml 
2µl/ml 
2µl/ml 
5µl/ml 
5µg/ml 
2µg/ml 
5µg/ml 
2µg/ml 
2µl 
5µg/ml 
5µg/ml 
2µg/ml 
1µg/ml 
2µg/ml 
2µg/ml 
2µl 
5 g/ml 
5µg/ml 
2µl 
eBiosciences 
eBiosciences 
Immunotools, Friesoythe, Germany 
eBiosciences 
Immunotools 
Immunotools 
Immunotools 
eBiosciences 
eBiosciences 
eBiosciences 
eBiosciences 
eBiosciences 
eBiosciences 
Immunotools 
eBiosciences 
Immunotools 
eBiosciences 
eBiosciences 
eBiosciences 
eBiosciences 
BD Pharmingen 
eBiosciences 
Immunotools 
BD Biosciences 
R&D Systems 
Immunotools 
 
Table 2.6  Primer sequences 
 
Primer Forward 5’-3’ Reverse 3’-5’ Product Size 
(bp) 
Annealing 
temp (°C) 
MgCl2+ 
IL-10 AGGTGCGTTCCTC AAAGCCAACCAA 241 55 2.5 mM 
HGF CATTCAAGGCCAAGGAGAAG AACTCGGATGTTTGGGTCAG 208 53.5 2.5 mM 
GAPDH GGTGAAGGTCGGAGTCAACG AAAGTTGTCATGGATGACC 540 55 2.5 mM 
TGF-β TGACGTCACTGGAGTTGTACGG GGTTCATGTCATGGATGGTGC 170 60 2.5 mM 
 
